var title_f13_40_13952="Esophageal acid clearance";
var content_f13_40_13952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal acid clearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of an acid clearance test performed with radiolabeled 0.1 N HCl. The calculation of bolus volume within the esophagus is derived from scintiscanning over the chest. DS denotes dry swallows. Although all but about 1 mL of the infused fluid is cleared from the esophagus by the first peristaltic contraction, the distal esophageal pH initially is still reduced. Stepwise increases in distal esophageal pH occur with subsequent swallows due in part to the delivery of salivary secretions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Helm JF, Dodds WJ, Pelc LR, et al. N Engl J Med 1984; 310:284.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13952=[""].join("\n");
var outline_f13_40_13952=null;
var title_f13_40_13953="Retrograde urethrogram with short stricture";
var content_f13_40_13953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Retrograde urethrogram with short stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13953=[""].join("\n");
var outline_f13_40_13953=null;
var title_f13_40_13954="Patient information: Parkinson disease (The Basics)";
var content_f13_40_13954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15524\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/19/43312\">",
"         Dementia caused by changes in the brain",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/8/34947\">",
"         Patient information: Medicines for Parkinson disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/4/5188\">",
"         Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/50/28449\">",
"         Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/63/30708\">",
"         Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Parkinson disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/parkinson-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H196544163\">",
"      <span class=\"h1\">",
"       What is Parkinson disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Parkinson disease is a brain disorder that affects movement. It gets worse over time and can affect other brain functions, too, such as learning and memory (",
"      <a class=\"graphic graphic_figure graphicRef51927 \" href=\"UTD.htm?42/19/43312\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196544170\">",
"      <span class=\"h1\">",
"       What are the symptoms of Parkinson disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At first, Parkinson disease often causes only mild symptoms. As it gets worse, the symptoms can affect a person&rsquo;s ability to work or do everyday activities. When it becomes even more severe, people with the disease sometimes need help taking care of themselves.",
"     </p>",
"     <p>",
"      At first, Parkinson disease can make people:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Shake (doctors call this &ldquo;tremor&rdquo;)",
"       </li>",
"       <li>",
"        Move slowly",
"       </li>",
"       <li>",
"        Become stiff or rigid",
"       </li>",
"       <li>",
"        Lose their balance or have a hard time walking",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Later, Parkinson disease can also make people:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lose some of their memory",
"       </li>",
"       <li>",
"        Lose touch with reality or see things that aren't there (these are called &ldquo;hallucinations&rdquo;)",
"       </li>",
"       <li>",
"        Feel depressed, anxious, or less interested in everyday life",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The disease can even cause problems with vision, sleeping, swallowing, and a lot of other important functions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196544177\">",
"      <span class=\"h1\">",
"       Is there a test for Parkinson disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. But doctors can usually tell if a person has Parkinson disease based on his or her symptoms. Sometimes doctors use tests to make sure that the symptoms are not caused by something else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196544184\">",
"      <span class=\"h1\">",
"       How is Parkinson disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are several medicines that can improve the symptoms of Parkinson disease. Researchers are also studying drugs that might help keep Parkinson disease from getting worse. But for now, no treatment can cure the disease.",
"     </p>",
"     <p>",
"      The medicines used to treat Parkinson disease symptoms can sometimes cause serious side effects. For this reason, people often start taking them only after their symptoms start to really bother them.",
"     </p>",
"     <p>",
"      If you are thinking about treatment, ask your doctor or nurse to help you understand the risks and benefits of the medicines you might take. Here are some questions to ask your doctor that might help you decide what to do about treatment:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Which medicines would you suggest I take?",
"       </li>",
"       <li>",
"        What are their side effects?",
"       </li>",
"       <li>",
"        How much are my symptoms likely to improve with each medicine?",
"       </li>",
"       <li>",
"        What happens if I do not take the medicine?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196544191\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Exercise or do physical therapy, so that your body is less affected by stiffness and other symptoms",
"       </li>",
"       <li>",
"        Join social support groups, where you can talk to other people who understand your situation",
"       </li>",
"       <li>",
"        Make your home safer, so that you are less likely to fall. For example, get rid of loose rugs and clutter, and make sure all electrical cords are neatly tucked away.",
"       </li>",
"       <li>",
"        If you still drive, have yourself tested to make sure it is safe for you to keep driving",
"       </li>",
"       <li>",
"        Learn about Parkinson disease and its treatment. That way you can be actively involved in your care.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196544198\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/8/34947?source=see_link\">",
"       Patient information: Medicines for Parkinson disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"       Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28449?source=see_link\">",
"       Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/63/30708?source=see_link\">",
"       Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/40/13954?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15524 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13954=[""].join("\n");
var outline_f13_40_13954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196544163\">",
"      What is Parkinson disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196544170\">",
"      What are the symptoms of Parkinson disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196544177\">",
"      Is there a test for Parkinson disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196544184\">",
"      How is Parkinson disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196544191\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196544198\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/19/43312\">",
"      Dementia caused by changes in the brain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/8/34947?source=related_link\">",
"      Patient information: Medicines for Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=related_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28449?source=related_link\">",
"      Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/63/30708?source=related_link\">",
"      Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13955="Indium In-111 oxyquinoline: Drug information";
var content_f13_40_13955=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indium In-111 oxyquinoline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/6/37986?source=see_link\">",
"    see \"Indium In-111 oxyquinoline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15068244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15068275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15068303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acute inflammation/infection detection: Indium In-111 oxyquinoline labeled autologous leukocytes:",
"     </b>",
"     Adults: I.V. (based on 70 kg patient): 200-500 microCi (7.4-18.5 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15068304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; start at the lower end of the dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15157059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: Indium In-111  37 MBq (1 mCi) and oxyquinoline 50 mcg per 1 mL (1 mL) [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15068305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Not for direct I.V. injection; only indium In-111 oxyquinoline labeled autologous leukocytes may be administered I.V.",
"     </b>",
"     Waterproof gloves should be worn while handling and administering indium In-111 oxyquinolone. See manufacturer&rsquo;s prescribing information for complete administration procedure.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15068277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Radiolabeling autologous leukocytes as an adjunct to detect inflammatory processes (eg, abscess or other infection) when localization or diagnosis by other methods (eg, ultrasound or computed tomography) fails or is ambiguous",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15068220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15068289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15068285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15068286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Leukopenia: Autologous leukocyte labeling is not recommended in leukopenic patients due to the small number of available leukocytes in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Due to high radiation burden and potential for long-term adverse effects, children &lt;18 years should only be administered indium In-111 oxyquinoline labeled autologous leukocytes when the benefits outweigh the risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Accumulation: Cell clumping can cause accumulation of and prolonged radioactivity in the lungs, thereby leading to false positive results; accumulation can be detected by imaging the chest immediately after injection. Accumulation of labeled leukocytes may also occur in the colon, liver, and accessory spleens and thereby mask inflammatory lesions in these organs. Heart pool activity may occur when labeled leukocytes are contaminated with hemolyzed blood.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Blood-borne pathogens: Use standard precautions during labeling procedure and administration of labeled autologous leukocytes to prevent blood-borne pathogen transmission.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Deterioration of chemotaxis: Loss of granulocyte chemotaxis during storage may produce false negative results; injection of labeled autologous leukocytes should occur within 3 hours (preferably within 1 hour) following completion of the cell labeling procedure and &le;5 hours after the initial blood draw.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Impaired labeling efficiency: Plasma and red cell contamination impairs labeling efficiency of leukocytes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15163924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15163922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15068278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15068279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproductive studies have not been conducted. In a related compound, indium nitrate adverse events were observed in animal reproductive studies. Elective examinations in women of reproductive potential should be conducted within 10 days of the onset of menses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15068282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15068283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indium 111 is excreted in the breast milk. The manufacturer recommends that formula feedings be substituted until radioactivity has cleared.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Indium In 111 Oxyquinoline Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mci/mL (1 mL): $4291.50",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15068295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Creates radiolabeled autologous leukocytes to allow for detection of inflammatory processes such as abscesses or other infections.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15068297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 30% spleen; 30% liver; 4% to 7.5% pulmonary (radioactivity usually visible only up to ~4 hours after injection); remainder distributed throughout body and red marrow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Indium In-111: Physical half-life: 67.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine and feces (&lt;1%), mainly through decay to stable cadmium",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86618 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.44.181.18-7163832E31-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13955=[""].join("\n");
var outline_f13_40_13955=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068244\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068275\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068303\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068304\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157059\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068305\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068277\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068220\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068289\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068285\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068286\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163924\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163922\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068278\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068279\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068282\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068283\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570455\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068295\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068297\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86618|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/6/37986?source=related_link\">",
"      Indium In-111 oxyquinoline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13956="Patient information: Diastolic heart failure (The Basics)";
var content_f13_40_13956=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86003\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\">",
"         Heart failure action plan - page 1",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\">",
"          Heart failure action plan - page 2",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"           Heart attack symptoms",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"UTD.htm?1/41/1691\">",
"            What do labels about sodium mean?",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/41/36499\">",
"         Patient information: Medicines for heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/32/7684\">",
"         Patient information: Systolic heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/50/28450\">",
"         Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diastolic heart failure (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1817872083\">",
"      <span class=\"h1\">",
"       What is diastolic heart failure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diastolic heart failure is a type of heart failure. Heart failure is a condition in which the heart does not pump well. This causes the heart to lag behind in its job of moving blood throughout the body. This can lead to symptoms such as swelling, trouble breathing, and feeling tired.",
"     </p>",
"     <p>",
"      There are 2 main types of heart failure:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        In",
"        <strong>",
"         diastolic heart failure",
"        </strong>",
"        , the heart is too stiff. When the heart pumps, it doesn&rsquo;t relax and fill with blood normally.",
"       </li>",
"       <li>",
"        In",
"        <strong>",
"         systolic heart failure",
"        </strong>",
"        , the heart is too weak. When the heart pumps, it doesn&rsquo;t squeeze normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These differences affect how much the heart squeezes with each heartbeat. With each squeeze, the heart pumps blood forward out of the heart. The amount of the blood in the heart that is pumped out of the heart with each heartbeat is called the &ldquo;ejection fraction&rdquo; (also called the &ldquo;EF&rdquo;). People with systolic heart failure have an ejection fraction that is lower than normal. People with diastolic heart failure have a normal ejection fraction. Because of this, diastolic heart failure is sometimes called &ldquo;heart failure with normal ejection fraction&rdquo; or &ldquo;HFNEF.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1817872098\">",
"      <span class=\"h1\">",
"       What are the symptoms of diastolic heart failure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms of diastolic heart failure include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing &ndash; At first, people might have trouble breathing only with activity. Over time, they can also have trouble breathing at rest or when lying down.",
"       </li>",
"       <li>",
"        Swelling in the feet, ankles, legs, or belly",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1817872113\">",
"      <span class=\"h1\">",
"       Is there a test for diastolic heart failure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have this condition, he or she will order some of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Chest X-ray &ndash; This test can show if there is fluid in the lungs. It also shows the general shape of the heart and large blood vessels in the chest.",
"       </li>",
"       <li>",
"        Electrocardiogram (also called &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in the heart.",
"       </li>",
"       <li>",
"        Echocardiogram (also called an &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create a picture of the heart as it beats.",
"       </li>",
"       <li>",
"        Stress test &ndash; During this test, a doctor records your ECG while you exercise on a treadmill or bike, or get medicine to make your heart pump faster.",
"       </li>",
"       <li>",
"        Cardiac catheterization (also known as &ldquo;cardiac cath&rdquo;) &ndash; During this test, a doctor puts a thin tube into a blood vessel in your leg and threads it up to your heart. When the tube is in place, he or she can do tests or unblock a clogged artery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1817872128\">",
"      <span class=\"h1\">",
"       How is diastolic heart failure treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Taking medicines &ndash; Doctors can use different types of medicines to treat diastolic heart failure. The right medicines for you will depend on your symptoms and other medical conditions. Some medicines will reduce your symptoms, such as swelling or trouble breathing. This will help you feel better and be more able to do everyday tasks.",
"        <br/>",
"        <br/>",
"        If you have high blood pressure, your doctor might prescribe medicines to control it. If you have a heart rhythm problem called &ldquo;atrial fibrillation,&rdquo; your doctor might prescribe medicine to control your heart rate. If you have fluid in your lungs or swelling in your legs, your doctor might prescribe medicine called a &ldquo;diuretic&rdquo; (water pill) to help with these symptoms.",
"        <br/>",
"        <br/>",
"        It&rsquo;s important to take your medicines every day, even if you feel well. Tell your doctor or nurse if you can&rsquo;t afford your medicines or if they cause side effects. There are often ways to help with these issues.",
"       </li>",
"       <li>",
"        Eating a low-salt (low-sodium) diet &ndash; Cutting down on salt can help reduce your symptoms. Avoid adding salt to your food at the table or when you cook. Also, avoid foods that come in boxes and cans, unless their labels say they are low in sodium (",
"        <a class=\"graphic graphic_table graphicRef61514 \" href=\"UTD.htm?1/41/1691\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Treating your coronary heart disease (if you have it) &ndash; In coronary heart disease, the arteries that supply blood to the heart get clogged. Treatment can include medicines, a procedure to unblock a clogged artery, or surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1817872166\">",
"      <span class=\"h1\">",
"       What else can I do on my own to protect my heart?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help feel better and reduce the chances that you will need to go to the hospital, you can do the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Call your doctor or nurse if you are dizzy or weak, or if you lose or gain weight suddenly. Weigh yourself every morning after you urinate but before you eat breakfast. Wear roughly the same amount of clothing every time.",
"       </li>",
"       <li>",
"        Follow the action plan your doctor gives you. An action plan is a list of instructions that tells you what to do if your symptoms change. To use an action plan, watch your symptoms closely and weigh yourself every day. If you do not feel well or if you lose or gain weight suddenly, look at your action plan to see what to do (",
"        <a class=\"graphic graphic_figure graphicRef72459 \" href=\"UTD.htm?19/63/20474\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef75501 \" href=\"UTD.htm?31/48/32522\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Call 9-1-1 if you have chest pain or other signs of a heart attack (",
"        <a class=\"graphic graphic_figure graphicRef52579 \" href=\"UTD.htm?1/15/1268\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight.",
"       </li>",
"       <li>",
"        Stop smoking.",
"       </li>",
"       <li>",
"        Cut down on alcohol if you have more than 1 drink a day (for women) or 2 drinks a day (for men).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1817872249\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=see_link\">",
"       Patient information: Medicines for heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7684?source=see_link\">",
"       Patient information: Systolic heart failure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/40/13956?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86003 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13956=[""].join("\n");
var outline_f13_40_13956=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817872083\">",
"      What is diastolic heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817872098\">",
"      What are the symptoms of diastolic heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817872113\">",
"      Is there a test for diastolic heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817872128\">",
"      How is diastolic heart failure treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817872166\">",
"      What else can I do on my own to protect my heart?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1817872249\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\">",
"      Heart failure action plan - page 1",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\">",
"       Heart failure action plan - page 2",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"        Heart attack symptoms",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?1/41/1691\">",
"         What do labels about sodium mean?",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7684?source=related_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13957="Pantoprazole: Patient drug information";
var content_f13_40_13957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pantoprazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     see \"Pantoprazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22231?source=see_link\">",
"     see \"Pantoprazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Protonix&reg;;",
"     </li>",
"     <li>",
"      Protonix&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pantoprazole&reg;;",
"     </li>",
"     <li>",
"      Ava-Pantoprazole;",
"     </li>",
"     <li>",
"      CO Pantoprazole;",
"     </li>",
"     <li>",
"      Mylan-Pantoprazole;",
"     </li>",
"     <li>",
"      Pantoloc&reg;;",
"     </li>",
"     <li>",
"      Pantoprazole for Injection;",
"     </li>",
"     <li>",
"      Panto&trade; I.V.;",
"     </li>",
"     <li>",
"      PMS-Pantoprazole;",
"     </li>",
"     <li>",
"      Q-Pantoprazole;",
"     </li>",
"     <li>",
"      RAN&trade;-Pantoprazole;",
"     </li>",
"     <li>",
"      ratio-Pantoprazole;",
"     </li>",
"     <li>",
"      Riva-Pantoprazole;",
"     </li>",
"     <li>",
"      Sandoz-Pantoprazole;",
"     </li>",
"     <li>",
"      Tecta&reg;;",
"     </li>",
"     <li>",
"      Teva-Pantoprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat ulcers of the swallowing tube (esophagus).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat syndromes caused by lots of stomach acid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702676",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pantoprazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Granules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix granules with 1 teaspoon of applesauce or 1 teaspoon (5 mL) of apple juice and drink it right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10947 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13957=[""].join("\n");
var outline_f13_40_13957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022940\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022942\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022941\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022946\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022947\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022949\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022944\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022945\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022950\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022951\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=related_link\">",
"      Pantoprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22231?source=related_link\">",
"      Pantoprazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13958="Instant glucose and intravenous dextrose: Drug information";
var content_f13_40_13958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Instant glucose and intravenous dextrose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/45/16084?source=see_link\">",
"    see \"Instant glucose and intravenous dextrose: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/7/16502?source=see_link\">",
"    see \"Instant glucose and intravenous dextrose: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BD&trade; Glucose [OTC];",
"     </li>",
"     <li>",
"      Dex4&reg; [OTC];",
"     </li>",
"     <li>",
"      Enfamil&reg; Glucose [OTC];",
"     </li>",
"     <li>",
"      GlucoBurst&reg; [OTC];",
"     </li>",
"     <li>",
"      Glutol&trade; [OTC];",
"     </li>",
"     <li>",
"      Glutose 15&trade; [OTC];",
"     </li>",
"     <li>",
"      Glutose 45&trade; [OTC];",
"     </li>",
"     <li>",
"      Insta-Glucose&reg; [OTC];",
"     </li>",
"     <li>",
"      Similac&reg; Glucose [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote, Hypoglycemia;",
"     </li>",
"     <li>",
"      Intravenous Nutritional Therapy",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hypoglycemia:",
"     </b>",
"     Doses may be repeated in severe cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 10-20 g as single dose; repeat in 10 minutes if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 10-25 g (40-100 mL of 25% solution or 20-50 mL of 50% solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hyperkalemia:",
"     </b>",
"     I.V. (in combination with insulin): 25-50 g dextrose (250-500 mL D",
"     <sub>",
"      10",
"     </sub>",
"     W) combined with 10 units regular insulin administered over 30-60 minutes; repeat as needed or as an alternative 25 g dextrose (50 mL D",
"     <sub>",
"      50",
"     </sub>",
"     W) combined with 5-10 units regular insulin infused over 5 minutes; repeat as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     More rapid infusions (&lt;30 minutes) may be associated with hyperglycemia and hyperosmolality and will exacerbate hyperkalemia; avoid use in patients who are already hyperglycemic",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F158919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/7/16502?source=see_link\">",
"      see \"Instant glucose and intravenous dextrose: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hypoglycemia:",
"     </b>",
"     Doses may be repeated in severe cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Children &gt;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &le;6 months: 0.25-0.5 g/kg/dose (1-2 mL/kg/dose of 25% solution); maximum: 25 g/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &gt;6 months and Children: 0.5-1g/kg/dose (2-4 mL/kg/dose of 25% solution); maximum: 25 g/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hyperkalemia:",
"     </b>",
"     I.V. (in combination with insulin):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 0.5-1 g/kg (using 25% or 50% solution) combined with regular insulin 1 unit for every 4-5 g dextrose given; infuse over 2 hours (infusions as short as 30 minutes have been recommended); repeat as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 40% (38 g) [tropical fruit flavor; provides dextrose 15 g/tube]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GlucoBurst&reg;: 40% (37.5 g) [gluten free; contains potassium 10 mg/packet, sodium 30 mg/packet, sodium benzoate; arctic cherry flavor; provides dextrose 15 g/packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glutose 15&trade;: 40% (37.5 g) [dye free; grape flavor; provides dextrose 15 g/tube]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glutose 15&trade;: 40% (37.5 g) [dye free; lemon flavor; provides dextrose 15 g/tube]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glutose 45&trade;: 40% (112.5 g) [dye free; lemon flavor; provides dextrose 45 g/tube]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Insta-Glucose&reg;: 40% (31 g) [contains sodium benzoate; cherry flavor; provides dextrose 12 g/tube and additional carbohydrates 12 g/tube]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion: 5% (25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, 1000 mL); 10% (250 mL, 500 mL, 1000 mL); 20% (500 mL); 30% (500 mL); 40% (500 mL); 50% (500 mL, 1000 mL, 2000 mL [DSC]); 60% (500 mL [DSC], 1000 mL [DSC]); 70% (500 mL, 1000 mL, 2000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 25% (10 mL); 50% (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 15 g/60 mL (60 mL) [gluten free; berry burst flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 15 g/60 mL (60 mL) [gluten free; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enfamil&reg; Glucose: 5% (89 mL) [provides dextrose 4 g/bottle]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enfamil&reg; Glucose: 10% (89 mL) [provides dextrose 9 g/bottle]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glutol&trade;: 55% (180 mL) [lemon flavor; provides dextrose 100 g/180 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Similac&reg; Glucose: 5% (59 mL) [provides dextrose 3 g/bottle]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Similac&reg; Glucose: 10% (59 mL) [provides dextrose 6 g/bottle]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 4 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BD&trade; Glucose: 5 g [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 4 g [assorted fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 4 g [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 4 g [grape, raspberry, tropical blast, watermelon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 4 g [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 4 g [raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 4 g [sour apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex4&reg;: 4 g [watermelon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GlucoBurst&reg;: 5 g [gluten free; sour apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GlucoBurst&reg;: 5 g [gluten free; sour cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Infusion, injection, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Must be swallowed to be absorbed (see Warnings)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Not for SubQ or I.M. administration; concentrated dextrose solutions for peripheral venous administration must be diluted (maximum concentration: 12.5%); in emergency situations, 25% dextrose has been used peripherally; for direct I.V. infusion, infuse at a maximum rate of 200 mg/kg over 1 minute; continuous infusion rates vary with tolerance and range from 4.5-15 mg/kg/minute; hyperinsulinemic neonates may require up to 15-25 mg/kg/minute infusion rates",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Treatment of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% and 10% solutions: Peripheral infusion to provide calories and fluid replacement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     25% (hypertonic) solution: Treatment of acute symptomatic episodes of hypoglycemia in infants and children to restore depressed blood glucose levels; adjunctive treatment of hyperkalemia when combined with insulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     50% (hypertonic) solution: Treatment of insulin-induced hypoglycemia (hyperinsulinemia or insulin shock) and adjunctive treatment of hyperkalemia in adolescents and adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;10% solutions: Infusion after admixture with amino acids for nutritional support",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Glutose&trade; may be confused with Glutofac&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (hypertonic solutions &ge;20%) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Inappropriate use of low sodium or sodium-free intravenous fluids (eg D",
"       <sub>",
"        5",
"       </sub>",
"       W, hypotonic saline) in pediatric patients can lead to significant morbidity and mortality due to hyponatremia (ISMP, 2009).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Most adverse effects are associated with excessive dosage or rate of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Edema, dehydration, hyper-/hypovolemia, phlebitis, venous thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, hyperosmolar syndrome, mental confusion, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, hyperglycemia, hypokalemia, hypophosphatemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ketonuria, glycosuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (oral), nausea, polydipsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain, tissue necrosis, vein irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema, tachypnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to corn or corn products; diabetic coma with hyperglycemia; hypertonic solutions in patients with intracranial or intraspinal hemorrhage; patients with delirium tremens and dehydration; patients with anuria, hepatic coma, or glucose-galactose malabsorption syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: An unexpected rise in blood glucose level in an otherwise stable patient may be an early symptom of infection. Rapid administration of hypertonic solutions may produce significant hyperglycemia, glycosuria, and shifts in electrolytes; this may result in dehydration, hyperosmolar syndrome, coma, and death especially in patients with chronic uremia or carbohydrate intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Administration of potassium free I.V. dextrose solutions may result in significant hypokalemia, particularly if highly concentrated dextrose solutions are used; monitor closely and/or add potassium to dextrose solutions for patients with adequate renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyponatremia: Administration of low sodium or sodium-free I.V. dextrose solutions may result in significant hyponatremia or water intoxication in pediatric patients; monitor serum sodium concentration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; hyperglycemia and glycosuria may be functions of the rate of administration of dextrose; to minimize these effects, reduce the rate of infusion; addition of insulin may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Very low birth weight infants: Excessive or rapid dextrose administration in very low birth weight infants has been associated with increased serum osmolality and possible intracerebral hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral forms: Do not use oral forms in unconscious patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Rebound hypoglycemia may be associated with abrupt withdrawal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Hypertonic solutions (&gt;10%) may cause thrombosis if infused via peripheral veins; administer hypertonic solutions via a central venous catheter.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (injection, infusion) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients who require parenteral nutrition for treatment of hyperemesis gravidarum, dextrose is part of the parenteral nutrition regimen (ASPEN, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9835684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (BD Glucose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (6): $1.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dex4 Naturals Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-6 g-mg (10): $2.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dex4 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (60): $3.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-6 g-mg (50): $7.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dex4 Pouch Pack Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-6 g-mg (24): $4.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dex4 Quick Dissolve Glucose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (40): $5.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Smart Sense Glucose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-6 g-mg (50): $6.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Glutose 15 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (37.5 g): $3.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Glutose 45 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (112.5 g): $11.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Insta-Glucose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (31 g): $4.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Dex4 Glucose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 g/59 mL (59 mL): $2.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (1000 mL): $4.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (50 mL): $1.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (500 mL): $2.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (500 mL): $3.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30% (500 mL): $4.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (500 mL): $7.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (50 mL): $6.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70% (500 mL): $10.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dextrose Thermoject System Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (10 mL): $3.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Glucose Nursette Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (59 mL): $1.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood and urine sugar, serum electrolytes, I &amp; O, caloric intake",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F158896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal blood sugar:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 0-2 years: 60-105 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;2 years and Adults: 70-110 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F158903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dextrevit (MX);",
"     </li>",
"     <li>",
"      Glucose Braun (PL);",
"     </li>",
"     <li>",
"      Glucosum (PL);",
"     </li>",
"     <li>",
"      Glukoza (PL);",
"     </li>",
"     <li>",
"      Glukoza Braun (PL);",
"     </li>",
"     <li>",
"      Injectio Glucosi (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dextrose, a monosaccharide, is a source of calories and fluid for patients unable to obtain an adequate oral intake; may decrease body protein and nitrogen losses; promotes glycogen deposition in the liver. When used in the treatment of hyperkalemia (combined with insulin), dextrose stimulates the uptake of potassium by cells, especially in muscle tissue, lowering serum potassium.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Treatment of hypoglycemia: Oral: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: Treatment of hyperkalemia: I.V.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapidly from the small intestine by an active mechanism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized to carbon dioxide and water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 40 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/40/13958/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ASPEN Board of Directors and the Clinical Guidelines Task Force, \"Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2002, 26(1 Suppl):1-138.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/40/13958/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice, &ldquo;Plain D",
"      <sub>",
"       5",
"      </sub>",
"      W or Hypotonic Saline Solutions Post-Op Could Result in Acute Hyponatremia and Death in Healthy Chlidren,&rdquo;",
"      <i>",
"       ISMP Medication Safety Alert",
"      </i>",
"      , August 13, 2009. Available at file://www.ismp.org/Newsletters/acutecare/articles/20090813.asp",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8711 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13958=[""].join("\n");
var outline_f13_40_13958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158911\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158922\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158912\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158919\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158895\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158884\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158898\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158897\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158927\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158920\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158901\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158887\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299170\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158890\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158892\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207749\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9835684\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323104\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158893\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158896\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158903\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158886\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158900\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8711\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8711|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/45/16084?source=related_link\">",
"      Instant glucose and intravenous dextrose: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/7/16502?source=related_link\">",
"      Instant glucose and intravenous dextrose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13959="Ixodes nymph populations in US";
var content_f13_40_13959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Nymphal Ixodes scapularis populations in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 535px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIXAloDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBkrbULYJ2gnArzbwp8TodVvNRXVYI9Pt4VZ4cbnd1UnJOOOldR8Q9aPh/wAIajqCwyTFI9mI22ld3y7s+2c18jWF1JbRRiXUGja7jZTuYh+evPYfzrpo0HUi2eRmeOnhZQ5PO68j0/4veMNR1W5isWto7OxjdZYzndMeO5Bxg56Vo+C/inqFtq+n2Gqt9rs7q4MLTMP3iE4AwB2H8q86ikn1vTrOPTLSVpwjh4mHmmQhj8wHYbary2639zHNoYeG4iWNAm47/M6fJ+Pp0q6MEqajiLJq93tbWyb1dr203PDWOr/WPaxk7X2+5tbW0va/+Z9kKcjg5FOrl/h3rq674bilaOeC4tyYJYbgYlQr03D3GDnvmuorjPsk01dBRRRQMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2jNVudO8CrBb7BFeziGUn72B8wAHvjk18tp5czOqyPE8pRZF2Bt6qcjax+6R/8Aqr6j/aRnsIfh2/22BpbmSdI7Vl4Mbk5Jz6YByO9fM1i9s2my7kJuEIJbsQTwB7+texgVH2F2up89nF4zU99vz/zOphv7m4uhfzPK5CeUsyhUEp/u4HTHrTdNtbia+DRuod224HGHz057e9YGl6vb6fPGdUhnubSMlvKSTYTkY4Pbk59+ldxDqml3OiiK0mt/tBRnjdogS4fjH+yR2JrhxTng5KnSp3UtL20S6XS1067JX00TS8p4T2ydetNRWt7t3k9/NXe1+9tD0vwR4ngj+IdxCt0r22qwxgxhGG2dAFAGR3APPTpXslfJJSVdVtE0ud7owFWibyypMnXCjqOa+htI8e6XqH2ONRdmS4+UOLdgm8AbufQd64KNOFCjTpxeysr72W3RdF26HuZXmP1jnVWyd+m2vbV318+qOwooFFantBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWL4tnvrXQ5rjTbhIJomVyzx7wUB+YY7ZHftQhSfKrm1RXF/Djxo3i+C9aW0FrJbsowr7gwI9cDkYrtKbTi7MilVhWgqlN3TCiiikaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwHxw0Ftf+H97FDbpPdQFZoQz7SpB5I5AzjPXivjhjKPONuJyNoKbMcNn+P/OP0r62/aG1aPTvAMlvPbtJHeyCHzFYAxMDuBHucY46V8rBkkv90AYRFskFug9Cf617OXxk6TT2PFzOdp6K+nyJp4YIVeJZmkTckisoB3OP4cHtXSW+k3NjeKlxDMrynz/nVQfm5xheB+FUNGCrpesXT29u8luIxE80QkjVmcD94ey4J5PQ10Vvf295ayDbDHdW7/ZhFa/LEqqB8w9cg4I6g+tcuJxcoVuSCvbR+tovyS0ev3dk/CxEEsK3J+9v022f3u2i9dtnKbifUrTEgjd5VBcjAQDvVq/1WeyuJ5be7FxKt20gkjGFaQnllH9KwIb2B53tXmDy7iu3kHjqAe5Hf0rRubN7Zow8kMwKh8xsGByOBnsRXLPDU3UjGbXu7LRaLVu//DWfc8ynWqUYPTfrr8vn5nt2k/FjTBDo8F3HMhmQLc3EzALF23E98n8s16cjBgCpBBGQR3r5OuI9U121srHTbUXkViS62joXQls5Y4HUEkgnI9q+hvhZo95ofgnTLPUppZLpYwWV3LCMdkXPIUDoD2rGLk1eSt876f1/w7PtcrxssXFuWu3Syv1W+vf+rLraKKKZ6oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAeleb+PPi3pPgvX/AOytRsb6abylmDwhSpBz6n2r0g18nftM/wDJSl/68ov5tXVg6Ma1VQlsY4io6cHKJ6Sn7QvhxjgabqYPuqf41M/x50Uws0Gl37vjKhioBPoTnivlmtqzffEgOMhQK9SeXUY6q54eIzOvTV1b7j3m9+Ok72qSWGixxtv2v50pcYxx0x/kVRHx31Ey+X/Z+nmQDJUFsj8N1eVW2RYXa9RhD06HPX+Y/GslLN1uVbcnlrK0w+X59xGMFvT/APV0FYrC09rHG8zrtXc7adj3AfHTVBx/ZFk3v5jDP4c1lat8Ytb1SK9sxa2KWtxG0TRgEsoK4POevOeleWSblXduAHoOo96xXT7O6/PDxHtHlqfn5zls9/f+nFWsHTvpEmGPxVVNe0/BHvHwM1mS28UJYmXNpcwuxBwArgA5JPsvavoWORJBmN1Yf7JzXxLoWoJLZ+TczgOjfu88Y/Guvstau9LQJo+rTx+coeYQkoN3p15+tcmJw7dTz9H+ZWCzf6lT9jVi2o9b9PJO1/0Pq49KYkiuAUZWB6EHOa+eYfHXiC40+OxbVTHAyiN5goMoGeTn7xJ6UkUkema23k3V/b2ts4EcG9kl5x2znqTx6Gvn8VmFOhLl3er08v11/wA7H02CrTxyU6EHyt2u7JX+b1st7X6JJ9PoqivMvDvjm6g0W9n1aAPHAJGhd5gJJCGP7txj5Wx09cV0XhDxvpniOBNrra3buyLbSSAu2O49RXZSqwqrmg7/ANa/cOOJpTaSerV100+Z1dFV727gsrSa6upFigiUu7scBQPWuY0P4i+GNY0576DUo4bZZmg3XH7vcyqGOM9eDWqi2rpGzkk7N6nX0Vj6b4m0TU544NP1WyuZ5AWWKKZWcgdeOtWrbVrC61C5sLe8hlvLbHnQqwLJ9RRZhdF6iszVNXgsyIk/fXRIAiXJwffGcfTqal0g3b2Qk1Ajz3YttC7di54XGTzikMvUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJJFjGXZVBOBk9TTs15F8d9d0i+8EahZ2t+txfQTqjW9vKN6Mp+Ysuc8Y69iaunBzkokVJqnFyfQ5D46eLdF8TJb2EMkTQ2V40TXAYhlJiDbgPTPy8jkivHIUS2nEMSLdvMvyhc5YHoPb60XMcdzosF0spkkgkMMzFDlVPKknv3GataZay6ebWS702aCS4ja4trq4lMMUsajJVeOcj8B1r2ZShhKD1+Xd/h6u3Q8OtB42ppe3bZeWttL7etump21vpb6Ra3D20q3lvewqbqMKuwAMAB69cVmKkcD+VHGkSp0Crt21qWr29z4bhaJDHdQsJCx4Plvz83qQxH4VDbs1xdEvIGfO7c43bz/8AXr57C1mo1K1V3lrfpe22i8rfKyPAx0XWrQoR0vayurK+jV3bZq1m2r3d9dcyPShZXym888W0DtJHB8p8ssMkg9+pIHbJpsDXtzGJoZYYYXG6NJIt7EHoW5GPXA6V1+iwW/iyC+0ywt5bGC/la0t550DwyOI/mVTn5H4JDY+YAgdKxtR0vVtCuY7DXNOu4r0YjVooHkjuGxwY2UYbPp1HQ1hi8ViZU41IKze6S1X59fPofc8KZFltetUlmDU0l7t9E9Xd9LvZ69291p6l8BLfTp4767XzBrFtiC5jYfIob5lZD3DAd+RyO1exAYry34JeFb/SYdR1nVoGtrjUFjjht5MiSOFNxG8dmJYnHUDANepV005TnBSqb9TprYfD4apKlhP4abt6f116hRRRVmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyd+0x/wAlLX/rxi/m1fWJr5P/AGmP+Slj/rxi/m1d+W/x18zmxavTZ5PWjp8gAyxAAHJJwBWeaWOIynYCAQQwyMjIOeR3Fe/UV4ux8/iKaktTrdPl32tysbBkkizlTnOCDUW3hj7dKraAy20qtMdwaQvJsGBz1AH+c1oSR+TJKh5KEj61xbPU8isrJW6afr/mZ1znYfUisKX73J59637hw+75fwBrKEixzqzRq47huRiumm7G+Fm462HaMhlvEQDIJ5z0FdvY20rYCoBvOxR61k6SkUqOLZbfGScNFhsHn8cV3c37jS7dPs0TQiFHaSLDMuTgMxHQnGCDXhZrmU8PKKhC93a39fI0w2HoZjXlHE1PZxir3s35vp2vpp6lGDRtSKO8drIAhIZgQNuDz39akjvY4I3lLtPPNsd3c7nVlbnbn2A61Wv9IvdZjk+wwQXgCeUhkuTE1uxx++46qAMZ/h7dTVaV4v7Ps0JX7RGm2SRV2bue/qfevnYVJYtulVte6uktbbpPVu19tF80dWPoU8nmpYGq5WTtJ7X0T5baXSeur+9BrN5PcGdlllETyeZtLYz1OWHSsLStaJl80PPFPgSR7cxkjP3lI/Dj6GtJxJI2xk2gZweob61jXumJbK5soXBIwCHLeVzkgegr6qhRp0oKlFJL+up4Ea7rzlOtJ87d7/PU1Na8c61qUMFte3txJYxkL5fmHDKP73r685rmpYLjUJreG0SURMDKdmfL3dNwA4HQCotM068vZ1uVRkskmRZ7l0LJErHG4jv/AJPavp74L+EvsWkS31/5jGSVkgBhMKzRK3ySmM8jd1APbB708RiaeEfsqKvLr2Xr5+XX0PpcLgK9eSqyk7Weru/ku/36fceafDj4RajqDJf3z32muUDCVSYywPv949Bx3r6E8K+GtP8ADlikNjGWl2hXnkJaST6scnGe2a3KK82pVnVk5Tdz36NFUoKG9uvUz7HS4rS6kmV3YtkKGPCAnJ9ySe59AKvkhQSSABySaCcV4N8afifOLV9H8Lsvlzv9mmvw3CsSPlUj7vUcnOQTxxRSpSqyUYmkpKKuz29tSsUaBXvbZWuDiEGVQZD/ALPPP4Vbryf4T/Cm08PWkeo+IFj1HWWZZYzKoZLTA4CZ788ke1esClUjGMrRd0EW2rtWCiiioKCiisaTxPosepnTm1K2+3iVYfswbMm9uQNvXp36Cmk3sBs0UCikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFRXM8VtBJPcOscMalndjgKB1JoBu2rJaK81134taPZzPBpcE2pSIWDOh2xgjphu/4V5R4y+MOv39w1naRraRJtmP2dirgDnls56de1dFPDVKjskefUzPDwk4KV5Lov8APY+jdW13S9IVDqV/b2wdiq+Y2OR1rzrXPjHaW7TRaZZNM6ybY5pD+6kXPtyCe3BrxawvG1NWnl34uScO77mcHnJPrkdKiur46VZRFYI5HMoZHdtuxhkg7hyDxx70Omoxu1d7W/4Op5E85q1pqnD3Ltru7/l/l12Lvi34o+J9Ut32aw9nFI5L21qNjxc/cDYzjgdTnrXIeHi17fmDYxv5opI1ndmZ3YjhFzxubpzUF7M99Y3V0rIsP2oswV92+bGPlPcY5zXR6PGI9M/tGW4ktZJYDteR/LEjKCMhvU9u5PSvQnUjRw94pJv87ddNbB7WreKqpybe1/8ALS2und2W7KNnbWVppM8Ru7a+E5CTiNiFt33bVV++c4PHFbdnGH0uK31Vp53iIihM4HlwKp4eHvgjue1cRplv/auqpZwziMNGE8ww+WSqjPzLn2/D869Jt5GudPtxeO87pC0a3DS/60oMKQSPf7vXtXn5jU5ElJ3bd33S6W0t0tbrZXvqXVg6OGnU57NtWT1v8O63Xe9utkXdUY6NrLrafPN5ageaitjI9B8p49ayrZ5Ld5HjCqxBT5lzkHg4z0I9azdXga21qOwu7nyEMW8+VNjzG4wNw6YHbv8AhXR/DeFPFWpPoU9w7YeUpdEgSTxnaWIY8OVPB9vWvKw/s1BUfidlrb4u3fo9vuJlw/i8XQ/tNNRjKUrRu24u9tfmt732vudv8FvDMtp4jur65tfKNujYSVW+R5MEun8OWA+Y9cAdK9tAqGxt0tLOC2iz5cKLGufQDAqeu3Toe/haH1ekqSbdu4AYooooNwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAPSvk79pQ7/AIkOcY2W0cf143Z/8e/SvrE9K+TP2kP+SjT/APXOP/0AV35b/H+Rz4n+Gzys0+BtsgPtTaQ8c19E0eNWjeDNiykDAc9DW3dMGMTZHzQr2x2x/SuYs2xGD71uzyK1jbSBsny2Q57EHp+RFcdSNpI8WpT0kl/Wv/BKdx8it/E5ICqvViTgAU86PP8AbLaFo1iaXd+8L71AAyRjg5qk0iuWUkhsZBB75yCK3b9YWgtnu7id77BZC5CKinHI24+f3PB9K83HvGRnGOHdk738n39D2sqrZTh6UnmEJSndcqWia0uvuFsrBlvbiGW5lWSJVaJ4DsAU54K8gnjvmtqxlZ7aa1eV3vUkVCgOBLGRlHx25yPqOKwrW/FhDOJLO4lkVVkklVgxkyPl3ZPBPp054q7omotp+oyanfQSZjeNrqzcjCR/wsjc8jqexORivlp4jE0qsnVbbXTTf9PwWx93mORZZmmWx+oQjGT1Ukmvdu21fS7sra66PfU6EWV3bx4tzcpKqMZwp2gAHoOckYxmmWsduul3EzoslwrAbXOAqnoRjqc1u6sb7UY5NQBQIA7pIH+dlLZP+9t+7WfBHpGyIXTyrE8TPmMgvG/ICtx04Brnw+LlUpc0lZp6uN7q2rTt9y2PiMZklLBYiEMPJO9NySnKLV3pp9ltb7a208qcaWX2rcouJLby1ILLgGTAyCR0XOarXOmSz6tLaWLR3K7cjy24J7kHjNaOpaxNBp0s+nxxmCSOKy+y7+N7DG8DsflY55pvgvVNJfVjp3iyZLOaP/S4bm1fLzHjMRyM5wAR+NdVHGV+Z8r1tazd/O7VlqvLc5FkU6mF9pCCcOa7mnGy02TTfzve1lotb+h/DTwVH9qW5kB/s+HaWjcAFpxyQy47NyPY16611bRyrG88SyM20KXAJOOmPWvNdQ8eSvbPbeG9PlgjCHyp7hMeYTjAVe5PPXniuEvNbh0jxJaXmsxSz6jbFXNrbfM104JO4uxwAo25J+gpU8bSpzVKMuaT1k7/AHv+vQ+yoUpYiEYrZK0bK+ySSt0crq3fV7I+jK5zWvGeiaNqqafqF4YpiEMjeWxjh3khPMcDCbiCBmuG0r4zW08pg1jSH06RziKU3CyQE9g74BT6kY7Zrxbx74vg1zxDf3UaeYb8rbyRrJsjk28I3IJ7Y4xuGAa9KlL22lFc3p/nt8jkx3NgWo4hcrfR/n6eZ618Wvirp1pHJouniW5WaIie4iLJ5Z7bGGOeOf8A9deL+CtVGi69FqOpXCmwuibmdGiExk2ligYHplsZIOax9V1m81WwhNwrPbxEReYzeZ8yZGN3cVjNI7KqM7FF+6pPA+le/g8K3StLS+/X/hmfOwxNavU9peyT2/4b8df8j1nUvjx4ouby1mtYLO0jiOWhQErMe+7POPYEfWva/hV8SLPxzYbXEdrrEWTNaKScKMfMpPUcj8a+NJYi7E/LyAMtnK85yK0tK1S+0i8+1aZcy20+0oXjcqSp6gkdqurgITi4wVmtj0o4mSabdz72EiGRow6mRQCyg8gHpkV5T8V/i9beDbtdP06OO71JGDXCSAhI0x0yDkN0P0r5z/4TXxObiaf+3tQ8+ZVSSQS4ZgpyoJHpk/nWNqt7c6pdzXWo3Ek91OcvLI2WY/X1rClljjK9Rpo0li017p6FJ8cPGks8zW17bxRM7FYntlcxg87ckc4rl/B/iS50v4jaf4m1W6uLiWK4aW5n/wBZLIjKQUweOcgew6c1zXyxhmZiSeSSeTXpVr8GPGN3o8OoW9taOswV44fPAdlbBDcjA4PQnNdc6WHpxtNKNzJTqSd462O48Q/tAGS0vY9CsTHI8arbyTrgoxzvY8444K8fWvUfhP4yj8X+FbS4nki/tSOMLdRKeQwJG7HvjP41816F8LfEGp+IrnRbmMaddxwvLE9wjeXcFCAQjd/vDmvUfAvwi8VeFtesNUt9dsCIeHt2WQgqw+ZeCM/y4rgxNLCxhywlrudFKdVu8loe7rIjSNGHUuoBKg8gHpkfhTq4HQvBmr2PjNtfvdfedpfMSa3VCEeM4KDrxg545Azxiu+rzGktmdKCiiikMKKKKACiiigAooooAKKKKACiiigANeH/ABw8TTvrFvoen3EwWNN1wsZwGZug45PGeDxzXq/jC/TTfC+qXUsjxCO3fDo2GDEYGD65IxXzfFa30tw+oDzLpwFmmuYjuKsRn52/vcc0pYiGGi6kt1smeTmVSU3DCQdnNrXsur01MbV/s1hoMkqPcLdh042ALtyM49TXBtf3T6l9plZ3fnJYDbjsAPTHr+Ndx8RLoPZ6RG9zCwjjLeUqEt1/i55FcE7GSZ9oxuPCqOPoK9XJacqmGVWre8m3r933afiefWwNPB4iph42ko3jzWtf89fTsdboF3Nesmn2Ucc99M26DOQqADLbsdDjOAK1tYtJpRJFF+985fLkiAHzA8EjOOfSuY8MCa18RJA817Cse5pDYzeXIp2nBDdueP0rp3ujPoVvqerSMzzO8EgaJvmYNjGOSx7Vlil7Ku7NcrS+93fptHy/HTjxCjGMalL3pRs/l06W6vo+5l6heWepaRewGBlS3uAY5YIgARtA5/2v6VbSEP4YFqZwqKkYiknAwZDkFQOm3OAD171m2xGmWkdubizka5HmRMZQ8a4OCd3G302nnNdZc3dlc6XatcWLSKyiF1QDYzgfK49QO7d/auOvUVOMKdJXhd2ej6b692n5bnqzhGlUdat8OjsujUrOOl7aNO/TRWuc/pvgqexOnz6gsguZQ7TQtL8yqCQpyPXr15HWuq05IYpLjyfN/wBICIdqbwo5B2g8BscA9apaFbRIxsIJyxaMyRwj/WN83IPqO4P4Vradptxa3aWtrFeF5CXeMyrvDKfm+iqcduPWvEzDGzlUlGvPbpblVrt7Nvb57bux9FRwdPF4dSpx9yzblre7UUku61l101k+XRPlZYF/tnUYr2H5pSjRiYZ3IFxjnuDnP1rc8KWtxdeM/D1tpqEXcd7HOCiZEMaffcjsu0lfqwra0SxtfEutI+q2MNxBH+72CEkbzwNx6g46MK908M+FND8MpIuhadBaGQASOoLPJjpudiWPXuauhhZVJqrJ2t0+7Z9v+GO7LM+UcqWDUE9OVS7rva2+vfz8jbXpS0UV6p5gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAB6V8mftIf8AJRp/+uUf/oC19ZnpXyZ+0h/yUaf/AK5R/wDoC135b/H+Rz4n+GzywdahSUuwGF53cA8rj1qajv8AWvoGm2rM8zSzTHRyFSB2rZVw+lIQ2dkrKwx/eAwf0NYXetTSX8yRoDykqkY/2gCVP5/zNRVWl+x5s6evL3Iw2LuFMQgSPs3zEhF4zk4+lXobp76JLiTb8+SAvIUZxxnt3FUJArr83QjkdaguLyWCZSSdu9VWMITuUjrn1/lWE1Z8zZy+y9rZLf8Ar+vkdLb5y2xYpg8flPDI+BIv19ef/wBVXY9ObyVRoPs1pIwkkLTCSWQr0U9cDgd+lYGn3gZx94AHaQwwQfQ12M9/C1nFaQ24Rk+d5CQWZuhAPZeOBXiY7ARlWjUhG7er1006tXR3U+Isfg8FPARkuWzSdlzK71Sdtnd+nRl291B7hkVGKQqix7F4GMc4HueaddnT9PgW6DyyBiVhicgO8gG4HkY2DGST2BqtpiSXltdRRJHiFDM7H7wUY6e/PSneLoRcaDpkqSbhb+basEGCI2XO/b3IJ69xkV4WNpLD8tCDs7tWXVWvd2XfTWzO3h90sZiZV8wSlDlVnLaD5rJK72+TS0uYd/4g+22iR6gtulu0vnNJAHhYnOcqSNrYOcDA47Gtmy8LRuo1Cx1RNQmeXzXCIrh1QBgVYjAGeoPORjgEisLT55tWt7KQxRR28Um4ur5LMuRgDAx75+la9kpTVLeySaSGxuyzTwR/cLLjbIR0HJ259xnpXnyk4e5HR636/wBbbH6NicnjTwjqYZc0PdtFuST0sndttWun5208+h1G5uri5guWuYS0iI3l2xb5SFGDjHB+lYviGWU6zHqWoXEciXEAiEnA8plYna3Ybuv4V1U6xwXkVvd3Enm27bpXj/1kaAcAP/HxgDGKjWKG9ijmQOqptkugUzEBuxtVT14HX3rz1VjFJ8um17dHt062Xrp3JynlwlHmU5Tas+aV2tFaSWmi0do7320OJ1IG7hNhaKk99c4SGEMMlieG9gMZyeOKy9ZXynaK7sY2lcBXaHrIS2NvORkmu4n0jTkkCWccVlAbg+ZJwRtc5Xao57cjNU7qCxGmalbKzXDvsNrdLHgxOrZ3YP5V9DleOhhqUuTVu2nztvt523sfJcTY2vmOZxjXp8lOkve6u2jbs1d6uydrPdbnAalabH2XbXNqG+ZEKq6Yz0+UjkZHaqv9mllVoLm2kXIzl9h5Poa6rxdoF7bLaT3V3Dco0IYeVGVVN2M9zlsdfSsbRbSSaG4KMrMh5jkHysPrX1OXY2VXCRr1JL5bb2PEzirhcJiZwwifIrWvo9Un92t1psQv4bvg5YRq0YDMQjhiAPT+lZt3aTW0u14nQEbgGHOK9NsEnvl8qYQWsLIqrEpCxybQcB+2ME81zGtapa6pMjCzlt4WIg81SBFuBxkD0xjvWVDOVKr7Kpb5fh+vfYX1HGqkq8ItxtfZ6q+6OQzjr16Y9a7DRPhnr2s+KNN0i5tHtBeQCaVyA5t4M53sAfkJ4AB55BxxXsfwA8DaYdPvNX1OxiuroXBjgeYB1QKOSo7HJ6+1e0Wmm2lpd3VzbQrHNcsHmKjG9gMZ+vTJ9hW2KzDVwgjvwVL2lONVvfU5nQ/hr4U0W4Sax0eASKirmUeZkr0f5s/N15FdeVwm1AFwMDjgU+sTxjrq+HfDepar5IuTZQ+cYQ+0sPr2ryW5Teruz0dEj5a8S+OfEfh/xpdx6bqMsd7ak299O8nnrdTK5+cBh8i4wABjAG3nGa6zw/8AtAamupWya3pts1hsVJXhJ80EA5cdiScccYrzTx94t/4S/VmvhpNjp25i7GBP3kpIGTI38R4rlZW2hcEAEgFj0Fe9DBUvZL2kbM8+VefP7r0PqrwL8Z9K1ieVdYvdPtozAJ1aPevksWwYX3D5iBghxgHDZAxz6xZXdvfW0dxZzxXFvINySRMGVh7EV+f0Tb0DEDJJ5HQ+9fVn7ONzKvgiC1lurBogC8FtFxNGCx3Fxk5yec4H0rz8Vgo0aaqRd7nTSrucnFo9cooorzzoCiiigAooooAKKKKACiiigApG6UtB5oA8K+O+s6hdPDZR2dzDpdrL+8mdSFlk7Y7EDt65rzS08Rwx2xtbWeRJhIDJGvST6/Tpj3r3v45WFxe+DQ0E5jjt7mOSVM48xSdoH5kGvlrXNIubWQ3kauY5ZmClQc5B6gjr+Fd9Gjh8VTVKt309T5bMIShjG1Nxbjo+2u1+m3k/v1b4udJNcvGtvM+y+biIy/eYYHJHQdxxxWMhIYbTgg8e1a11f/bNOzcwzxtI2EndMxsw6qp7dPx5qmLMrJEHw26MzMqnHyDng+uK9fDOMKSp/wAunrZDjiJVOZ19JNtvz6v8TT03UZ7K0vEnjQu0obeV+cvjG3I7Y5xXWR2iSaKDi4XyZFnhnXkK7/eYg/3u4xg+1Z+naXbX3h1NQjSW3SBwWKTASSORwQMZ244NVxDqa39vPdSO/nqs+8S5iETLkRhM5BB4x1GM8g4r5/G1KdWb5fdaevqktvl59TnxEJUISrRkk2rNdLNaXuu6031XoyLVoNUjS0txDb3bo7mGUKDK5bLszDuSPXp2rpNPTz9G3iMRuGVppiT8oB/1e3oAAeoGayPGoe1s9Jmtg0Mkh3NP5wyzgYAwORxXR+FbhNQhjnlEI+zjZKARs3AckD+IfTrXLi60vqlOtCK5bvbve3drV/jq10PZweGhiZum3bmhzO+rejdlsrXs7b22fU0PBczW+n3jPeWttqm0IBLECi/PncH2k528Y6VTl8N3trfW0lxdB11HUEeR413XaeXwNj56MD144JGDnNSeIY7k6PdyyXcNgrFFeYqygIGDZDdzxjaMnFafhhtI1jVX+x6r5V4fnhhmQxyH027gM/UV8vip8jni72Um+ZWvayVldK6V22t7W13Pb+rVJRdKleEqVop62cW0tLe7dRS16ttrZFjwdJe2Pjm1urkiIozh4yoAKBTnOOA2P1r3+0ure7QvbTRyqMZKNnGRnn04IryG00i6FpcwXBiQvieM7clpAQvIr1XRbGKxswkcaJK/zz7f4pCPmJr08nxjxUZciXJGyTXXT7vl087nFhcNLDwcZNttt67/AD+6/wA/I0KKQsB1IGfU0teydIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAB6V8pftEyRR/EW4863E2Y48ZkK4+QelfVp6V8mftJgn4h3AU4YwxgH0/diu7Lv43yZhiPgPNzPa/8+A/7/vR9otf+fAf9/wB6oQoV3ZG1TjC7s89zmpK9+Mbq7v8AezznKzt+iJZ7+OM4FjYjClsuG5x2HNaOm3KgvO1nbRQohy2CCSQQFHPJOayfr65qzbvFJbm2uZPLCnfFIVJCE/eBx2PH5VEqe/YipK9gV+AKiuWjChZX2qTkc4wRzkH29aWWJ7adopMbl7g5GOoI/Ckki8zaVkaN9pUkAHINVLbQ8pRUZWloWbUrGdp+bJ3MWOSx9c1r2UzyTMQucdTnoKr6HpVveWE8rXMkXksUUKRhAAOWyOc/55qCxnkZYmJUsygE4/z9a8+li6WInOlDeGj/AOAdGaZNXwlCliatuWqrrXXpuvmb8Ey2bPdTStHCflJJPPtgdelXbS9gvkL2shcjAYEEFfqKyLyGS6t44oivmQybwX+63bkf5/Wr2k2VxFc3N1d+Wks+P3cR4X/6/wCfeuHFKbq2UdLb9TyJUMI8vlWnVarJq0OjXf8AF/1voR6dJN5kmnXKxXbvzC67klOPvYyMH6Hmug8N6NbrYyXt7dyXLTRlZDCil0IOdm08KOh65NcrDJcXM7PazLBDFIU3+WHZ2B5IzwB275qSK/Gno1tfszmXLRvEmBMQRtiK9jk53A9M8cV8rj4QqTcKcrSvrp96/rr+H3OCo59QyqnOpDnouNlFtP4muWVnfq7WeiXRbnW24S+tGVW+SFkSKaQBVVSCSZG6jGOO1V9H8R6JbW5juY9XltLlPLu2jgBiwCdu3ncR0OQMVyeoTan5UlsL2NH1I+TJCkI8sR5DMMn5uwGc81IbS5j/AHkF7O8w52y4KP7YA4/CvOqUITTi5aPa2n6d9fVH22V5bi50Iwx8EpwvZx5Xa99u1k1ovv791cu84NvYSw32ngAW8jxoDLkdAQOc/wBKx9R1CPTYR9qSGXZIQPJQnezDGwY64/pVnwLoT6l4Zjvng+z2kl1LIuD+9eM4BA+jBsexqn8SEtI7q1ttDQLdWoWeWN0IEQwfvf3mYdAB78VzUKtL231dO7V72WzXdrS7/Pz0JhQw3t41YK85Jra99dXve76dEtLLpX0O0fXm+y2gnSSJx5qXPypCHztbuCCQeR6Vdns9PVFNtHJDeBzHNCF/dBhxlSeTnrz61zXhnVUmvbuK/SEyXtsi2v2eUsFAJYh+PvH0/wBk471293M17HBEzB55W3HcNqL8oUFT9Fr0K2JxEJKEm1Hy+937rfs1bd3PFocHYFYhVYJSpptNSW6tp6O/4W0H6bYXFs0Zu0jt7FXDSyOisIx2J6/l0NcXqnhWztfEM9lFqM02mRyiWJCF+YnDHnp0Jxx/OvRotDv7PTLqBikNtd7WMyHecLngj0Oas+EfC2noLnVNQ8qWCzhd3WYnarjlHwPXn5TnpmscqrKviHJTTv22fW/XVarf5HLxJicXUxPsMK0oJK7TtprdWu/LZK1lfQ2vE9zqOhweHfDXhiWOSW5f/TTCB5yr8uWYDG0YbOevAx3r1eJSkaqWLFQAWPU+9fPvwW0+fVvGqajdraxHTbRkMlvGQ94XfdvlJz82eevXpgcV9Cdq+tc1JKx5mFqQqw56b917ei0MjxP4g07wzpEupaxP5FrHxnGdzdlHue1eKXPiez8S+C/iNqsEnlWkkirbJO/zvGAm4YJyNxBwOgzx3rW/ag1eW28NWGmRxxvFdyl5S+cqFwFI7Hlu/wBa+aEkdFdUdlWQYcA8MPevUwWDVSnzt63JrV+SXKR52oSc4AzTY5CzFSoB2huGyMGnNkggHBxwfSo4IzGSdoUbQMA5yR3r2JOXMrbHCrWZL716B8BtUfTPidpiLO0MN8TbzBVz5nBKqfbcBzXnLoxkyPUENn7oHUY75/8A1163+z34Yg1rxLJrE92YF0aRJtnQdCdzE/w8EY/HtWGKmvYz51/XQ0or95HlZ9Y0Vgw+LvD81gb2PWtP+yCTyjKZlC7uwyfUcj1HI4rdQhlBBBB5BHevmT1RaKKKACiiigAoooPSgAorA8V+LtG8LWb3GsXkcQUAmJSGkIJxkJ1Irx/VP2iLf7HMmnaLMLs5EckkgMYH94jqeO361tSw9SrrBXMp1oU/iZ7/AFn69qUekaLfalKkkkdpC87IgyzBQTgf49q+doP2gtYMNyJ9PtPOCKICinaW3DJfJ7jI4rj/ABD8WvFuuG6jkvxa2lxw1vbrhQvTbk84I6+tdMcurSeqsc08wpRWmrN74lfEzUtevX0txZwpauH/ANEnMsLBhkHfgZYZwe3cetclaXt/d3EVoL9kh2ORgA45GQmeh5zn6Vy6hIACkahG6gDHNEkjFQTyMBkZD90/X1rsrZfz0PZQaUujt17nlYadOWNjicRDngnrFvddv1OihW0sri8ScGaW3cuT1B3KMnaTgP6468Uw3emXF0rPK6mSLy12qAsYIxz71zXoB0HSnWs6LPl4FmQlolG7+PHBx1xWtLC+yglOV5Ws/N9zHG4SlWr1K1NOKd7JPZdFqdxp6RWRisobozPICYwxB2gD26CusXQ5rnUrCC1hidntkaWSFvMj37fmfr0zzjivMvDd4dI11We2W9UBlkt1OQ/ynHI9M5/CvRPBN3FpUTX2lXvzz7HlSKParFRjLZJ5bv6V81xDSrUoynTfRW00bd73ttZK+q16O97dGU5CsbWUJyvza3td+75W0TvbS9t3ZGbZ+Hb2CBk1ezSNYTs8u4n8wSXH8UuB0G3165HAxWlpMY0yAwpGInhZGt9qLtI7lh37etRa3rc+parfS6YscDNKyS3EmXO7jIVeBx0yfwqLR7gsHsrqFFu1QPA0LERugIDZU87uR3xzXixxdapQ9nV3drx7de/T8U36H6JhcihhJ0qlnyx+1p9zv0d5K/8Ahtbd0PGt9dXF3EJJWEKxebGqEkK24K7gf3gvT6mse6kggmSTTLl3aNTPuWUv5bjBjcE5wxbj3ya6+9s4rqLyrndwcqYzh0PqG7GsuS1ttLlhdlnvbp2JghlYKuR1YgADj+8cnmppxjBKO1un9fqe5KL5Zcqun1t/wVvotE7qyOhtfF9xceVBO1ywdmRZSp8syDlgj9cg5A7HBx0rufBOt3UcymCYSyjLOkjYM47gk/xe9eQ2bfZr77RqMUMcDOz+bHK5S2ZvvPsPHPQsPyHNd/4T0a41TxFFaWkiNFGRLI0gx+7zydo/Lr1IrneDkrPBPld7+V/NLy37nLiY0vZzhikoytfbp5aLqeuajc6BqWnxahqLwb41KpiQNJE/dVwfvA+lafhu4nm0/wAu8cSXMDeU8i8q/cHPTOCAffNef+DPAWnWWt3EmoXK3F1FMWhhXKhcHrn+I46gfQ131tq1qNYOkwRj93FlXjwUBBOU46EAZr6eLb3PhaMqko3qR5X2vc16KBRVGoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAHpXyb+0h/yUaf/AK5R/wDoC19ZV83/ALUlhaw32mXsUCrdzuUllGcuoTgH8hXdl0rV15mGIV6bPCaKKDX0Z5QUjDII9aWigTVy1qjH7RE5+9JBG7emSv8A9aqu/GSxwB3Jq1qX37fP/PtHyfpVBgsqfI6kZBz1GR61mnaKS3M61FOTZOojflgrg9+uR/WrkXD7kPXrWfEAituPJJbgcZ+lWoiVwc8e1Ll0vazZwVk9rm7Zuy4JcYHqeMV0dvIpRWDckbh/jXFyfvolUbSyMJNr/dbB6GrulzyxhYtyqA5bCfdQMc7Vz2rjqQcnY8jEYbnjzX1Nq3ZtOZoHime3Z2eKSKMuFBOdpA54JP1qaDT5ddmEoWS2itAZIZJYyMzfw5HZSMjP+1nHFSrdJ55SJyJEx8w7H61r6fqM32eSylgNzHI6uR90K2RyT78da+RzDL3RlKrBWv389/wPrsHxxjp4WGAqtLlStJJ3fLZxT102V2k9DD1C1vzc2qDS7+PUUffHC0Jw6ng/P93afXPvWmNJ1uS5e0XS5Le5UYZ7iRBEnGchgTvx6LXbS6mFCT2tlFLA0iR3EaowMrKMDa2cNg55A4qhrIgs5o9tvHcPcReY5uG81o2yR8rLgdAO1fLLEVnJQcEu3XX71ovn016H6phMynirSpzXvK+i7afJ6W87aLTTN8MTvor2KRSTSw2wwAGPzepx05JJ/GsvxVPDB4p1G4eb/R76RZ45XbgMUAaMntgjgehrK1OcSarcw3l/NbxQqrQqsvlggjJk9zn8q1NGke60e1e7QyvInzbh/rBk4JHuMHFdjw0VVdd7tWfz1OuCUasZw0aul6J2d1+X9IwJ7qI3lnFpaQyTfaPOd1HyLtGSWI69uO4rUjv72zlW5u5Irq2jO+WFItpVe+znt1wetXtc0xonsp7GHe0ETGSCNcHy2wflHqCM4rLjll1Bja6bFM9zJ+73NEyrET3ckcY6471XPGcU47db/wBaGqdOXPOrK0ultNLdFfXW/wDkexaVJ5jidJjLaTQgLCfukEZB/KoPGdjt0IrZCURysrSKp/dnryaxb/R7lfCa6VpcgRoo441y5QSKuMqWHK7gCMjkZq3pMi+GPC99Nr4W3s7h2+zWETmZoyQMRp6kkFto+VfpXylGUsPUVejO7vblW7X+fy6avY+TzbCvE0nC1m1a/wCn9anU/AqPy9G1QFQr/aueOcbRivTj0rxb4ZeOdAsrs6fcWd/ps99KFjuLtldGOBhSyn5CSTgEd+te0V+nYeV6a1+4+cpYSrg6UaNWLi0lurHy7+0zdXZ8SRWl1LOxBV7RFKiBIMDduH3vMLg5JyMbcYOa8cr3L9qbRIoNa0nWYXQTXMbQSoX+Y7eVYL6YJHHtXhi5J4ya+py9JUE0zzcXU/eOLFqKZnBUIWAweVXcSewxUpwVVkdGBAI2tnHsfQ0u0OjKG2llI3DqK65e9HQ5J1lAYisVUsAD354zX1h4e8F6D4T+GF+kt1EW1Oy/0i8DFRKSpK4wScfN0HUdR1r5VtrfYWJEahgBtjzjjv8AWuo1Hxjrd/4ch0S9uxPZQFTAXQb4QoIwrDnGDjmuLFUqldRinZdRYbF06MpOSu+hz2uanea3qc19q1x9quJAqF/KWMEKMD5V4HA7cDoMDivpL9m3xg2r6HL4fuQ5uNLiUxySSl2ljJPr0C8DFfMMnXjkdK7n4J60+h/ETTZAYlhuCYJmlbaFQjJIPTPHeqxeHjLDuMVtqjfC4qTqrm6n2dRSKQwBHQ80tfOHthRRRQAUjdDS0jdKAPjD4reGNU0DxFcSazfR3TyzMLcNKzyiLkqSDwq44AyTXECvef2n/FUMklp4dSytHdHEwvmfe0XUMqgfdbgA5PQ/SvBYmLxqzDBI7V9LgqrnTSlueViKajO6Fxz7USbo3VdhLvyoHp602VSyYHqCRnG4emaRIx5YVwDgk4yePbNdMnK9l/X9f0jnUUlckkKyWe0vtjkG7c38I6HNMhB/eYdQSwBVQV7cHB9u9SCJpI/LSN2Q8bUHT8qnt7KVtpWK5LE/O5jJwPUD2qGrSTZkpKC5Fv2HvATMrW4wPMC7TyFb29R70l4zR3EnmeX9p3bZHRAMbem0itu3soLS7ZZJIEleBiuZM7RjLHA4U7cgAnrSpZaRJC+J522RJJFI6cSFhkKyDkjtxWHt482qvby/r/P7jnXNFKU2rfjvs/69digbZ7RHa9uWtpY4x9m8lQTLlhnkYwMHqee1bnhKyu2vF1Q3Fu8DNIrpEcfMOASoAGD2rS0XwXcTXNsl9c20unylriWTacr8u0DGeuccfjVnR4IraN49N2R224pcIVyzuvQ57f1r5/Ms0pzpzo0pXl100Sd1bunpfrrvZPT67hrBqriIVm9Fqls29LtaK67+TWrKAK6U0kN1uSDezxTbSU2k5wzdiCcc9e1W9Pt5dQuE1CKJ/sFmSDKw27pGGAADyRjPPTpWjcajFYW8nnXAijlwhXqZCDkLgc9abDqFrqE8ptpMuvJjKFGQH1U8ivluV6ztr/V/6v8A5H6Iqr0ocy5Vt30tpv8ApsvUo6pNJJdpYwyPEpi82Z0OGxnCqD2zzz7VmSQRabeJdqGFrsZJSzlhGSc7+eme5+ldT/YE2qFLy3vNPtJoldUF3cCMXAxuZFX7xPGcgGuWs7WPULWK7vkE0kyhgpYlEB6BR/XrVSjKEVKWkX+P9dwo1KdacqdOzqRd79u2tn6NeuxftopNdn/srRVW91C6UxpEhyFyOWc9FUDkk19S+FvD1p4e0u3tbRd0iRJHJO3LylVAyT+GcdK8v+A2tzLqF/4dnCvEtuLu3lKfvMBtro7fxYJXBPPJGeK9qFetgqMIU+aDvc+Sz3GV6+I9nWSjyaWWu+t/mZ1ho9pZOHiRndSxVpXLlMkkhc9Opq3DbQwu7wwxxtIdzlVALH1PrU1Fdp4gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfPP7V/D+G8cbjMT7kBcfzNfQ1fPX7WP3/DP1n/AJLXXgf94j/XRmNf+Gz5+ooor6Y8kKKRiFUliAB3NCkMAVIIPcUr9At1LWpKJLez3Zy9uAT9GIH6AVURCCzMdzNjJAx0q5e/6iw/64f+ztVaojFbmk29hhFSRPs6HBptNbitNzjrUk1cupMAhAAyVI/+vUkN08UoIYDA9OtZ4kx3FMll2ozDBIFZuKs2ziVDndjobO+Mc5Z2GDzkDpmujS/Bfy7ebexGHCnAIrhbJ3mR/wCNV4V1U4atfTlvY33NaylOOsZ/OuStShUjdnFiME73S1R63p+tnUINOsodJPmRDakgmK5GPmwAMA+/WoJRaXNqv2eFYJRllcMTuHTY2eh78etYuh6veWY8omUwCN1jLSLtBbs3qD6cVsaXKHtoftbI0YnaUW6KT/Djdu9CRj8K/PMZl08JVfLG0b6Wk3u3ff8ALZdz7rhzOFCPsak5Ko/7sUtI6Xtvr7qWrd1ojm9Ulkurw2qeWgt9rPK0ayEMRwq54BA5J69KSDVJtHlhkvZJLu13CMNsHmox6cjhgTxzjHFafiPSJNPupNStLeQ212cy2okV5YmXjfgYypGPfjjNY8un3+pW5mggaBLZluFFxhWnwfuKucjjPJxziuWNSFSKv8L06b7P8f6sfpMKtGdFzv7/AM/lp1Vrf8BlyXV9XknefybNQ6GMwBm3bf8Af6Z/DHvXeeFEbVNPgvLcM8Tjcc9UAYg5HqCCCPavMl1O0c7UkLSk48kKfMz6bevXv0r2L4caJLpnh1Ir6Norm4ke4fDghGZvuKPYAZ7ZzXkZ1L2GGvazukvT/gaGGY16OGUY0p35vO/z8vyNaO2E0pCjaOpPt615P8V5NXTxdZNcpKthE5htVW3/AHIVlXLtL/ebBGDyCABnOa9nvVjtrC4dJCjBTh1YBgfQe9eV67q/9oaDeW15dRzyvcndA8ZyyAY3E9DXmcPwnOt7dK6Xu6rVX6r+vLqfI5lnsMBUhN621Wtr26evbf0OQ1KJp7SS1iiaae5HkwwoMtK7cKFHc5r630iK4g0qyhvpRLdxwIk0gGA7hQGP4nNcZ8LfCOg6ZomnanaaVbxao8I8y4YFpFJGCAWJKgjsMCu+r9KwmG+rxave5rmubf2nKE1HlSXq9Tx/9onwe2vaRY6rbrmbTi4lxyfKYZJ/AjNfMV3FG29kTy4iNoRWOcY6/wBa++LqCK5t5YLhBJDKpR1boykYIr4s8daAvh/xTqWl7mKQTERtkcoeVz74Ir6LLq106Uj43NaThJVk9NjkY4TvYkgsQB0xwOnFWIY8AZqURxq48wMcdAD0pwK5O0YB9a9W9lZHkTquQwMiMqF1DnkLnk/hQ/zAjNQy25eV23LtdlZhty2V6YPb+n40+TJGD344NTG7eoWWlmQl42BCFTg84OaY0Zwcg4xxSwWpUgsQSFCAKuOPevTPgn4d07xJ4vl0/WbeGe1+yO+x3KtkEYKY7/0pTreyg5yWx004KdRU6b3PpD4YahJqngDQry4uVuZ5LVRJKBjLDg59xjB9xXU1k+FtCtPDWh22k6d5v2S2BEfmtubBJPX6mtavmJNOTa2PqYppJMKD0oNNflSFbaxHBxnFSUeceLvixYaJqkunabp8+rXMDBZ3ilWOKNu6bz1YegHsSDWZ4k+M+gxeC7u8t5bu01VlaKO0dF86KTB2sRkqU6cjNeQG2n0+8vdOvj/p9rcSJcAkZZi5O/A/vZ3fjXK+K2s7u/jje4EbwxkO6qXzkghcjoRjNcmBxE6+M9hKOmv4dz6LMMpw+Gy1YuE/edu1nfovT9NTDur2bULma5upWluJGJkZ+ueveoieTzVlDZQ5KRTXLk8vO+0H8F/lmnf2jcqMQskA9IUCf/Xr7iLla1j4WSV9WNSwuWXe0YiT+/MQg/WnGOzgGbi63n0hXIH/AAJuPyqs/mSEyPvcjqzZOPxqN1y0bDHyk8HkGiSlbcnmguhow6iLVXWyt0j3Y+d2LtxyD2ANWU1ISh11p7icsN0TK5+QnrwCBUFlpTR6lFaXHmxIqlw0sRQuFGcYPTPT2rWv9B8yCa6htpLVI4RO++ZZQ7MNyIu3pkZ55x3rknXoxklLd9f61fbS/mYV4RcW3K3ppLp93z32INKtbZdVhKxwFchoQWJ3EHIcDoRxjBq3qLLc+KEvL94obeXcjmPC4K8H5Rjbntim+E/Dt1NLLcw3U6GCFJGzGAxcsAyKM/MMdxx096brll58k81patHIkjIgVCzuVPzFj0B/2etefHE0sRirQlrZpvqr+vyel9mZfU+SE6jqc21kndau13Zu1tntZ9U7J7l3eR6hcHTYbozWkaeZMVJXzOcKp9R1J79KguLaLT4pLywjSCeJd3yjCuo6qw75/Otm50LbYafdWwe1upYDOvnHzCASAVfGN2cA5GMcVUOl3lxHGdSNslm5P7uFizS7T3J+6M9uvvXxlaUXUvTfu7a+Wj20ezP2DKOVYGMKivNq91d76q0pXat569UNlmFxrM7tF5TRwQrEp6+WVzu9ixzn6Cs/xFff2XZpqEaLJcW8g8tGztfPBViP4ccn6V0j6UuqzLnzEeIFzNG+wovU5J4xx0PU1EvgzUb9xdaRa3WpPChM0ckqsXiZeQq8KDjHGMnGO9FOk5SVSO3bfb+vxN6uJp0aLwsmlfrdJK7bva97rVq19t1sYOnpFd/ahewQzXYYC4mOJBKxGc5x+nbit3wd4S1zXZtSg8PxWT2dk8ShZ5Wj2bwSQCFIIXGcdcMKzdF8O69dXn9keHbC5WQMIzHc2Lxi0z3kY4GB788Y5NfUHgbwtaeE9DjsbUCSdz5t1cEfNPKQAXPtxgDsABXVh8K6k3Kovd877nBmObRw1GFPDNe0XVcrSXbTR9OnnZMxvhh4E/4RKC6ur65S51i8CpM8QIiRFJ2ogPOOSSTySfpXd0UV6sYqCUY7I+Rq1Z1pupUd292FFFFUZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV89ftY/f8M/Wf+SV9C18//tUW81zJ4bEEZcr55IBAx9z1rqwLSrxb/rRmVdXpux889qKfdabchXlHlOqgAlJgxj564H+fXimE9+MV9JGfM2eXKHKkNdd4HOCCGB680xo2EJVDlidx/hzzyPapMj1H50uM/Q03BPUSk0XpGgh2JJbSSBVBiV5/uxnkA4Gc5J+nSo/tFr/0D0/7/vUmoyNJa2HmsXm8oksQM7c4UZ74A71QZgqlm6Dk1nTglHX82aTk+bQtm5gCt5dhCHwdpeRmAPuKr2lxJDu2xR8qozMgc5HXHbn/APVUavuJBVlYc4b0NOp8kZWZLm1oWv7RuVP7vyYz/ejhVT+eKjm1i+ibi5xhd3zAc89BxUFGORTlTTWiIjNp6lsajebsm5nHsHI/QcCn+bJuB3ux5J+Y81mxyEsvy4DAlTkc4/lVlHJB9fSklFq8Tz68JxdmzpNHeRQvkKJHOBtJwD9a6PT9ZktJpL27nntlgUs5jjV9gA4ULwDz/OuAlaSS3cI+CcE4YruAPTI5H4Vu6Lewjz1nQwwzEmOAvvRAeCucfie3OBXlY/CRrRkpRvddlf8AG55M4TpP20HqmttHp6P9Pmeh2t+l7bXMF7avp0kKRXFw4KzNLvGYuf4f4hgd/bmoYrmySFi93IGDHykWENk9PnyeB9M1ztiIDAsMe2CRic5YtvC8DJ5+6OAOw4FSyRvG2374HPHIr5CeV8kpKd9f8u7Tv+iskfSPjPHYaChhElHzV9dOl9NvS931R2M3iuws7qG6gWOO1htxHMskSqNwHJ3dSp/yK0pPHVpdBHggaYw58icMVwcYYFexHIwR6V59LA11p89pJDhZHR1lAw8ZU5G0nj65znFSRrMfNa4lje5lfzJZCyoWOAoGB0AAH/1682WR4dyTcHdab/ntfqn+vTnqcRY3EUnKpL3nbTl00+Xzve9zo/EfiV7u2S3ti8Ub4ZkBzlvr61yup6jaw21uXRbchdrtuLGZ8k5x9Ow9M1PMDLIrSXEbbQBxngflWZPYBr2GSG8mgkjDFXEYcYPBXBNe5l2VUo0tNLf1r3+Z4GIr1cVVcq0la3dfhvbXse4fAbXWvLK+015HmWMLcRSFtw2NxgH8Aa9arwn4BRQWmq3EFq7ACLaQ5BZxyc/n/OvdhXXTVo2PtMqk5YSDbvvr6NpfgZniLXLHw7pU2o6rMIbaIderOx6Ko7segAr5e+KeuReLNbh1K20abTrVYyssjFGkfnO50Xp6dSa9g/aBsbufw9pl7CryWVhd+bdRqudqlGUSnvhCf/HvavFZrmCC3M8kiCEDduzwR7etctfH1cJVj7Nf8HyPrstyHCZrhajxE2umjSt1vqv+AcNK6IPOIQxIwLHPBHcZoiYTiZ4wVVDyrDBXPIH5VFbRiaMxum1CCNufujOQPqOOfap1jZQxeR5GIxuc84HQV9onJ20sfllSMYNxTvZ7kZoBHP8AOmuTkCpEU5+bFaE9B0S7c9yetfUH7PujWEHg6HVobZUvrrMcshOS21iPwz7egr5r06za+vYIFLIssioZAuQgJALfhnNfZHgax0/SPD9vpmnSWzfZ1HmrA+4K7ckkZJGTk15eY1PdUD1snpN1HUa20OhopMiszXte0zQLJ7rVruO3jQA4JyxyccL1PJ7V5KTbsj6Bu2rL13PFa20txcOEhiUyO56KoGSa+WvEnxl1szIdE1O8S6eSY3UclvH9nhAYiJYjjLfLySTySDxjFavx2+KUGswDQPDcyT6ZKge5ulLDe2chF6cDv+VeHHsO1etgsBzJVKv3HBXxdvdgaGrzzX7W2oXk0s13MrLLNI5LuVbGS3fgj8qzXIijG1RjIAHQZJq8v7zSXA6wzBz9GGP5gfnVTAIwwyPQ16sYpJ8uj/qxzyne19RsbbgcgAqSpweMirWn2j3t7FbRkKz5JYjO1RyTVfG0AAYA6AVZ0y7NhqEVyFLhMqyA43Keo/r+FZYv2yw8vY/HbT1NsF7B4mn9Y0p3V/Q6VfD62sYe3mkmZfmeGXGyYd14Hy5HHesiBI7kzXNrpqeQZfOaPzT/AKPF/cY+h9evFat14ntfs7fZUmecqcK6bQh9WJ/pmsPRkuZLhCm+VFUIxU84Ht3PtXg5RHGzjOWKuu3NdevVf15XPc4nnluFlTngFF783LZr+7q01ff9dTRvrpbKCScTT3dxccQXE5J2x9yoJO4dua6DSow+iw3DSRbyFHlg4ZsgkkDpjiuYsLSVZ7ERW7zTG5Du4b5hH3i9F452kZzzntXViwt0uZHkXZD5u/G0kxf8BHJI9uD6VpiKqpw5Ve6e9r3s7WS6fk3fqz8+zGMKzjaScpP59Ul6L1LieUxaDTZCt1AjJcs/7r7Mx4DAjqoJGa6Dwx4Xu7SWD+0b2G+3xh2miJ2QM4+SQ9NxPUEj61Xv1hjkGotd20tyRutXWPLXBIwJGwcDB/hIHSiHxDfaVZJdywm51C6mAUqQkbyIMsWU9vUjgcDvXxuNxNetSf1d25t77362bSsld7W/ladnf7jK6WEw+IWDjFOpstmkrXvLlunK9rJ3lez6JK/rFtDpubFLr7RcRSEOTxs+Xp9O9ZLR7FUkrlsggdRj1qTT9RXWL28lkt3tpo3H7guHChhncG7rkEc0MrZVZF+XGQcYwPb1Fc+HcrKnUd5aX21uvL+vzPv8PH2ELpaa373u29/Nu66dL9a9nr76TqbLaWcF7OqBnS5YiFM/d3AfePfb+or0X4Z/EUSalb6HrOnWFi102y2nsFKxSS4J2shyVJA4OSOO3FeQXhFhf3M8/FrclWWXBIVwMFW9BwCO3Wuj+H2i3PinxPpv9no7afZXUd1dXYyqKEO4Kj9GYsAMDPGc4r08NWqqcacV7v8AV9TlzLBYOeHqV6rtU6a9tErea/zPp7HuaWiivaPiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKQkKCSQAOSTWF4F8U2HjTwtZa/pCTpY3m/wAtZ1CuNjshyASOqnvQBvUUUUAFfPP7WQBfwzkA8z/ySvoavnr9rH7/AIZ+s/8AJK68D/vEf66Mxr/w2eAwyPDIskTFHXoynBpYLiaKUSqsSz/PuuAPnkDdQwPH4/lUdFfRypxm02eXGcoqyLg1O9GNs5XHQKigD9KZcXFtMiedALeRpf3lxEflCnqdnr75qtiik6ae2g1N9dS7qKXDR291OpxMpCnZtXCnA2j+7jBGeeaz2dQSCrEdGOMgZ9auxTRDTbyOeUqAUkiXOdz5xjH0JqjsjlG/7wPoSM49fpUR5lHkT1Rb5W+Z7MWMRruEZB5wcHNPqOKMoclgcKFGFxx71JWsL21VjOe+jEYhVy2foOSaEbdnggg4IPahlDKVYZU9c1HEw6BXXdlwW53e9JtqS7BZcoMVjY7I8sRuYrgcVIrkcg8GmuiSY3qGx60v480Ri032Oau4teZcjOCGHTrirMTyBiwG5O4IrPXcrA84qRrpI8H5gw+Y7VJCj1NROy1Z50qblolc6bTS1zGShU4QjIOMZ9a3bOa4G+CZsJjMTKxG0+h/z3riIL6WOdZDhWByzA/eq9b6nOzBRP8AJyOTXFXwrq6StY8+VKrTk5Q2OqdZBJh/TOSc5rNiFxfKJoJlt7Y8x/u9zuPU54APp1qeKYC2t7eUgvtIkXuFPTn8/wA6r297Hp9tHb3rMoiARJghKOOgwR0OO1fPZnSrUqUXRV9dbL7tD6ngzAZXXx1SGZtOyXKpOyb666Xa7evYntHkM729yF8+NQ+5BhXUnAI7jkYIq0c5II6dMVRs5Bd3z3QVkRYvLjV1IbBOWYjtnAwOvFaAIyB39K7MHTnGgnUVpPc+Z4jo4OhmVanl7vST06rZXs+qTuk+xa0TUrvRdUhv7Jws8RyDgcjuv419R6Le/wBo6TZ3hTy2niWQp/dJGSPwr451uyuZZZZ4IxMREPKPmFGhZTkkD+LP/wBbpXbeA/iVrWk2D2UMlneWwAmDmJh5bN1j5P4+o74qJULP3TuyTHRwtOXtZe5v6P8A4N/LbRPc9u+KfieTwn4XN/DBFLLLMlspnBMUZfPzOByRxjHckcgc18cRWE9/cTXExtYneZ2C7gqfeOSijhRnsMV6D4i1fU/EF08+qTvKSpQK2NpU5/hHpmudu7GOOJfLXCoQp4r0cLS9jq9zXE57Gu+SCdvUpQ2MdsMXFzEPaMF//rVXvzAIysEd0xDDdh1VivcDggH3q3KmF5GfSqjqN3HKiu23NuzihW15rIWyEA04yzWbFhOVUPKchCMqGPrwf60s93IkT/Zre2WTadv7vOT25OaW2O6C7RumwOB7gj/E1VY04w6M3lVk2pIIb27uN4mnuJIsLgyjYd38QwOMf/q561p6Bqsmj6hFcxh5I0zug81kWQEYw20g4rK3HHPWk3Gn7NcvKxe0lz86ep3kPxV8R2CtFpl01tZCTzEgY+cU9t75Yj2NcFrOtXmq3bzajNPcbXKhnfIjLHOFB6DJ7VFK+ARmqkgjWZHYp5rfdJPJ7D/CnChGnrBJHVGrUq6VG2h4f5XUn5T69qhSXcApUqGG5c45H9KlIO4DPXpStbeTGsioAkhIDDjOOox9a3d7qxdOUIr3t2WtM+eWS3/57xsgz/eA3D9RVMHgGtTQo4xqUbSybJEI8uNcHzm/uZ6DI9fpWW8uZ5IwsWMlgUOdozjB9P8A62O1R7RKfL3OlSc43jsv6/qxHNKUPBQYUt85POOwqTPQ4Iz2NBHANPUooYOpY44wcYPrWiTTbuS5aLlIRExuFZSi/MpDt/Bj+n+Tmux0XVdMtg0upSyedE4eEWkYP7xej9uD+npXGzRPIw2gMSCoBYrtPrWpBAoktEOWWVwrRZGSRwTnsD6VyYihCspQndLyFXlGMoTe66af1/wUdbqA1Fr101C5WGGKUBLIqI53yARkqPmYfeOT079qeS91cSRxTTRRW7BWkjbDyPjJG7qAM/XNVNOvLghIoWZrLloIZCHDuOhz1Gfu8mo7Ce/Et7cyWocyTEy20XBiIGDt7MOOnWvnMbhavseWlbmXay02enfvv6t7dfDtbAPMFVzBL2drLmV0pXvG++yVr+Su7XNG3mfRZlaJmlhnPkhpjuMJbIBBI5B6c5PIINaH+jX0FvBeXE1vNBNuhuI1DeWpGHBU8EHjj2rMs2ur66hnFtJawWsoc+bjdux8rMvYZ7euKs6ncvq96Y3nlP2dFEsqHaXJHCDA4AGDnqc14c6E6cOautervqu11/XmtWevjofWs7hRyCSjZXttC+vNLTW9rK6T8noegeDdGttJjmnNwmo3F3IEnkddsZjVCQEABIXPOTzmuS1nWopLyRNJtJbmzRseb5iqpA7R5+9j8BVG1v73R7WeCzvZ0tbqE2bJI5cQ7+A6E5IIJ6d81Ba7YIBbyILea2URywMQDCVGCp+mOvSvKp4b2cpYm/M5afd5K1uy8l8j7nLcJiYV5UMZP3kua6+1dvXXt6djUsbtLuLfDuU52PG4wyt/dI/yDXvfwq0+ew8JRLct/rJXdIh0iGcbR+IJ/Gvn/wAHWLax4hlS3k2Q3JjhSQDId1zll9cA4/CvqnTrYWdjBbCRpBEgTe+MtjucV7uAp6uf9d2ebxBiNI0E+rf3XSfz1/4Ys0UUV6Z8wFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGF481AaV4I8Q6gTj7Lp9xMD7rGxH8q4f8AZc/5IT4Z/wC3r/0qlqX9pfVP7L+CviN1bElwkdqgzjO+RVYf987qi/Zc/wCSE+Gf+3r/ANKpaAPVaKKKACvnr9rH7/hn6z/ySvoWvAP2r7WRrXw5djb5KSyxHnncwBHH4GuvA/7xH+uhjX/hs+dWkAY/KSqkBm9Caf3ppRC4YqNw6GnV9JG93c8uTXQKa7bFzgnJwAO5p1IyhlIYAg9QabvbQS31FgmkjlSaFjFPC+5W4O1h+hHPTuDU97CkNwfKzskAlGeo3c4quqhV2qMD0rQmK3WnCby9s1tsidl6OpyF47EY6981ny2ak99jS904oz2YLjdnJOAAMkmhWDKGU5B6Gkdd2OSCpyCOopVUIoVc4Hqcmr97m8iHa3mLTFREOVXGRj8PSn0U2k9Sbu2g0+1ABPQUuOKSmc1RND1JzznilaNZT87MMja2DtyPQ0zICnC5bBwPU0y3Zm3ZZmAA5KbcHuP89KzlZtRa3MFF2clpYuJFJK3lxRlpDwFFO+yJAd19JtP/ADyiIMn49lFJDdJbCWRwzfunX5evIxn8P8aqyo0NxNA7Rs0TAFom3KcjPBqeb3uS5rQilFyaua0epCS7eYrs3YwgJwOMf0q8brzl+R8GNQ54JABOOQOWJOABWDZQm4lEajk+pAA+ua0rFmjlYKHO4rhkQvtdCSDgdRgkED1zXFmPPToSdD4l+X/DFZdh8HWx8FjH7ut7uyvZ2u9LJvfVeq3Ni2vJLJilz5hiADsJIQjqCQNwwcFQSMjqM1rCeNZ2jLDeDgj/AD2rmdS1RbtWHnQyOYzGBCjbUDfeJJ6nAwAPX8aVLoFvNVyrema83K1iK1Jyr38v67GvGGWZfRxUfqFldapbX6dXZvW69Hpc1dTv54brZCyrhFaKMxF/tDE8rkfdwP8AHpVy41OKJZozDcOsDEyyImVjOOQfU9M4rIivGLBvN5HoafHNcLHdx20sAhkDy7mUloyeuPX29K2xcK8IJ0Fd369jy8kweX1q7p5jJwhyvWK1b0t0fm/XqloXtQmZrKYWxYyGM7CPcdvfHSsyc2HmWo05HVlJ87CsMLtPD5/izjGefwpYbkJHGi/LGqhVH0qS4YhN7uD6KTWlXB+0qwqOTXL06MWXZnLL8LXwipxkqul2tV6f1uQSKXyMHb2rPncRx7mIAGTzUWqvJcSrtVXRYyiguV2Hswx1/n6d6qzyNsAZt/GMkfnXoU4tuzMaVHRNssaXdrLfxxsrqJgUwwwSGGMj8xUQk6g4yPSqlttt5ElQHchB684BzgVNq6mDULhUO1fNOSq52g89PxxWiTj8R608KnBcg9pDnFAfPSqSXBVP3isSBlmAxgdiR+uKkDFe9XG0tjmlQcVqSy8qaiZSTNllCyKocbRzg8YPamSLIz5Xf1G1g3yqO4I7/wBfbFWLd1Vs7irD7p9DS+JNNFWcI6a/0ixPbRlsxMSCBjPG4n0qRLS5eAKsTSxM2EI/vdwKdueRZFtlcxHJby1+XjkdelVo7o7FyBIEOQrZ2jPX8aV5NHKnNr0H6UB/alsMlQJVydoODn/GpdUhkuro3iQ/69DNJsGACDhvy4/Ol0CNP7SgmmUsitlUOQJGHIXd0HPrQ7wS2kSXkk0E8Tv8ojJLIxyMDgY+tTJ/vLr+tz0YN2cY/j8jOG3Ckkls4I7Y+tR+cjSgJnY2dpYjdx1yO1XzJZJjZavLjjdK+AfwX/GpobthY3UkCQQSoyNuhiCttOQcnr6VUnLRo6qUI6tsNN06WaUi4jaKAoxZ3+TGBnjNacWl2WmX1pLqd6sMTRxSp3LBhuDem3H5d8VWsJYtNkjuri5k/tJomZARu8sMCBknvjt/tVWW5k1GQB/KgMELNviQAhVXAGD3Bxj/ACK5q3tpN8j0t/VjKdOMpuLvqvl+H9Jfh1KrZ3N5PPY+S1pBKHK+aS8a4+9tAHHtk9qimuZDbSzrL5cbXB27RsDIOhwO5HU81h6HcWsOoQXEc7W7J95JvmQjGD8w9vUVqW95bXenNb+RMrkbVgt0OdhyOp4A9MkVzVYxw/vz2SS1/wA2edVwtaq1Tw8W2+kVe9tdEi1oOsJbRRFC++4Uxs0kZKSk5GNx6npjPtiunsfCuqanp97rVhHEBDCN8Ug8tJo0ByyuAQHHTB+97YrkbOO6vrOOyMcSR27IJSSVk2ryMIRx06g49Ca9K+Gn9qyalfQadKUElrKmW5j3YGM9umcV83UbxEnKuvi8910PbiqGS5tSjgKs5O2t1blk9000tLW06d2cdbWU15qAttVilsEhdX2KyySNIDkBsHCqOvBOfavSvDX/AAi2q6tBZeJNLsbi9VygneEH5x91t/UjHHPHSuG8URRWWtyxWfmiEEbWkByw/vVJK8Ev2jzTJPM20QNF3BHp161wum8PNTj06etv6/4Y58ZxBi8Ri51cS05Rduy5dXZdn523ep7tD4Ps4PFVlf2tjaW1naRYiWAbPn9SoGOOxrrxXlfwX8RTXsl9p19LJJLgTRu56/wsAPbAr1WvVptNc0ep7NDFLFUo1U9LaX6eX3hRRRWhqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHzf+21rIt/CGgaMrYe8vWuWA/uxJjn2zKPyru/2XP+SE+Gf+3r/wBKpa8M/al0jxj4r+Jzpp3hfXLrTNNt47e3mtrKWWOUsPMZwyqR1faef4PWvc/2XP8AkhPhn/t6/wDSqWgD1WiiigArw79qz/kWdE/6/T/6Aa9xrw79qz/kWdD/AOv1v/QDXTg/48fUyrfw2fNXqT0HXNBpkqlthAU7Tna3Q0sSbIlQnJA7dK+mu+a1jyrK1x1NeREI3sAT0zTqjkj3EkMVyNrY7iiV7e6KNr6iysY42bAyPXoPrVzSpDKl5AdrB42Ax0Zl+YH2xzVYcDjirOnypDcqZOEZTGWHGwMMbvwz0qZxb1Lg0tCsOahhkZ2w2DxkgKRtOela15pRs7hoJr2yDqAcByeCMjoPSovs9sOJL+Pd/sRs4/OlzKVmn+YcjV00VKjil3kAgDcu4YbPGcc1f8mzXlr12HokJB/U4pAmnx5INy+7rtVU/wAc03Jtq35Ao2WpVpCPSrm6wHIhu2P91pFAP1IGaPtFsPuWCH18yVm/LGKrmfYlwT3ZSdtq5PQAmkt5DIT8qnaoclX3AA9M1e+3On/HvBbwehWPccfVs0sGp3MDkqYijZ3xmJdrg9QwA5/ziofPe62MKlKmosTQraaa8WSZZBbRZad3YbPUYP0/w61WnfzZ3fYq7mJAUADk+laWpyQfY7MQK6bt0oU8hFPG0HvyCapIQ6MwClgOc9fwqaSt7xy1XysZuKqduD+FWLa5SDJ8wNLGMogbgEjByPpUQ3QxmXzU8pSCX9D6c1SRc7SHVkBYqQOeeuT3/wA5qnq7IiNJVE09v60LJkx97LHGBzTBdYbGw7QwUsD0J9qbzTSi+YH2jeO/eqlFvY1VJJe8rl6NyjfWr+n3KG62u6gbWTHYsVOAT0yax43IPrWxbatGmi/2c9sWLZQvkbSCclj3zz09a4MwqVqUY+xp87bs/JdzqyvA4XE1JfWqvs0ldabvsSu6W0MRnRsvlgnQ47VQuLsy8gYHWq2vSmHUJoFm2pHk75PmZucBfr79CeOOtV9xZVJG1iASPQ100uWTsjy6eEaSlLdltHyxzUExyfxpEbaPpxxTWOWJrdLU0jC0gPTFW9WO67EoOfNjSTPqSBnH4g1RlZkiZ1XO3GcjgfWrUjmawtJGw2wvCHHG8KQR+W7FS5JTS/r+tD0k+anIrGJJMMy8gY+vf+dL1oJwD6DJP0pqPuOCrKcBsN3H+e1Von6nNBSkvJDoZlY7VJOcnp1x6VKiBkLvLHEOg3tjcfQVBHGqMp+bAGFBPAB64qe5tE+yiSOaJ/NXY425ZOc4Gen8v0qG5peZE1GMrLr1LyRTWjI0E3zgCQRtkbwe+O44702OX7VcxQRw5aUlSI8ZYk549PrVZpyI440Zii/NgnJDfX04qyjNBpJnRVLXLtEXI/hAGQv17nr+dJq2vUyo0HN3mSPMNNtzE8+2+l+VYQc+UnIyfRm/PFZ7zPJne2Sccnk4HAGahaPexbcQrEMyjncR39aSOXeRldu4bl+YHI9/SiHuv3t2d8aEbJpDZvMLfLv6DbtIAznnP+f1q7aXS2zyK0H2gTIVCZwNw5BJ9Ae3fpVYMpcqGBYdRnkUrIJBtZd3fFNwunZm0XytaCtc+c5nn8yV5Tk8/MzGrloY4rCScviebMUar96MA4csO2RwPXOaZp0UckxaQYihjaXI4AIHy9OnOKrZJA4HT/JpWk3y9AdknJbssWyRyZTKoQd4Zj1GOmK6zwmyHT5QGDTLK3mEHr6Y9sY/WuNV9oIAX5uNx6j6Vp6WITDO7SOk6Rs6PExViR6Edue9ednGAljaHJF2adzoyXN45JjHiakHKLXLpur2d1/kdxYIW8TaUyW8lx5bM0yJ18o8c/ViuAeprutD1g6Lrl5KYSNPglk+0wOihthGHzzjiuM0+502wsblrSwkEjMjxtK/mSluMiQ55HXjtntWzr2oaTrGg2gMFzDfLIk09u+3yJTGMCPIOVAzwSDg8kNXx8cuqRlCd9U7fr3a8tvmjfH8R0cfjZ4mDjFWtZ9dHHfTW7T3aVk1c6j4nQ6zqD2xs7FDoYjU2zRqCFUDABOAVPT5fbivOdVa50HzVuImSa2wcBfnBOMAZ6cmva/gvE+maD/Zl1qtnfwlt9r5co+QHLNEIz8w2n1z61R+MHhS3lS6114rc2qwbblN215nPygnPBAGOOpr1fZqbszx8dl/tU8VCT5tOuyW6VvvKvwaHmX/AJxgmtZgNs1vMwkILJuV1cfwEduDnqOmfZBXA/Cfw2ui6LazCCG2Z4SDHGSSSWyWYk8nhRXfVNOHs4qPY9zDq1KKtbT+tOnoFFFFWbBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V+y5/yQnwz/wBvX/pVLXqteVfsuf8AJCfDP/b1/wClUtAHqtFFFABXh37Vn/Is6J/1+t/6Aa9xrxL9qZo18N6IZojKv2xuA5X+A966cH/Hj6mVb4GfM1FW/Os/+fFv/Ag/4UnnWf8Az4t/4EN/hX03M+35f5nl8q7lWmCQbgNrYztDY4J9KvfabZfuWCe/mSs35dKYJbYSeZ/Z8G7r998Z9cbutTKUtLL8hqMerK9A61b+1w9rG2B7csf60n25v+fay/78Cqu+wuVdyD5rhU2ibzYUIkLOCjRjoVHXj07DrTKvRapdQMzWphtyylWMUSjcD1BznipII7O9iuysQtpYYvMZhL+7BHAUKecsffjtWUb0t9i5WqbbmbRTXYIhYjPTjOKFYncCMMp2kA5rXmV7GVna46mSoWQqMdRweh9jSyBjGwTO72OP17UkYIByCBn5QTkgUpO75WhrRcwRKUUg4GSSFHQe1OpaazEFVUBmbOATinpBC1ky5cfPYWcq8CMGAj3B3Z+mD+lUEl/fBSR94rtX73TqfarNncAIQyl4JQN6Z546EH1HY0+4tvLj86J/NtydokAwQfRh1B/yKjtZkTpp3VtSG7KylRGvl7cEd+R3pka7FxnJJJJxjk05hz1zxmgCrUVe5FHSCiFKkbyyLHEjySN0RBkmkq5pN+2m3v2hYhKChRlzg4znIPrxWOKnVhRlKjHmktkd2Dp0aleMMRLlg932KLAq7KysjKcFWGCPqKXJB4IHuan1G6e+vprqRFjMmPkBzgAYHPc1SmjMmOI24K4kGRz3p0p1JUoyqRtK2qOPFUaUa8oUpXim7O266GprJUajLkZbIbkdCVBP8zVInpVvVo3i1CSF92YlRAW6kBRg57/XvVSrp/AiVTtN+onT6UsibCOQfpUcsZfaQEbGRtccc05F2oq5zgYz61Sb5rW0KnT0TTJLe+NjJ5itGrEfxruGPXH9a0ltpLnSm8tDJLFNuYcKEDDoPXJHSsoQtMWEPm+ZtIxGu7K9/wD9dacUcaaXdLdYiJ2yWqq/O8cZx6Y7+3FZTbv9xlCMXK/lqUbvT7mKGF5oWETk5y20MMdCex9jiqttCIYggHzAYPJP0GT1xWha3Ij3JNvkikBWRS2R7MB/eB5pfLsn+SKaVJO0swAQ/UDJH15ppWlzS3NI3+BFVEd22oGY4yMc8Dk0ytEJp4JQ3NyoXgsqBhJ/u8gj8aq3F9ES1v5McdujqykAeYQTg/7xx69xxim6qjq0OlSk9GSaaiPep5ih1UM5T+9gE4A7/SnXOoS3VnHFIkQO4yPIB80rdAT9BwMVINulSGaRkkk8vzLcBdxwTxIV7DGevOexqhnJz1zzmhcs5X7GsouEUtgHbFIqqhJVQpPXAp3XtSVpYlMjWLDA7jtUllXHQn3rS0hjFPNMGC+VC53dSpIwCPfJqjVh5vJ0oxiMGSeXzNxYD5EHP6ms5pRjbuawblK/Yc947wupiiWSQAPIowXHXBHTk96q0isGUMOhGRSmtIpJaGcm3uHQj2phQi480bclg+4EhgB/Dj0pxz1py7ScvnHfHWplFS3OapdO6Ol0e4hjinDNI25ghKtk4I6+3pmrlveWmn6kizI17aMhWSIS7HGe+7nke4rjra5+z3avG0iEHbuUd/TNbNre3dxJJ5SG4ZhjySOZOOB9a5J0ldyvp1PJnhJ0qvOtb9/8me3/AA2it4PFFldaddQTWk4UmOUAToh6Z7AhuoB5Haun+N2qOy6b4d2qkOoSI0k2NzKA4GAv1I5rxP4c3Ng2twDVpRHZAq1w7q8e5+uxAOQVOPqODg8V77rthY3o8LeIYtZWOe2mjjjnuJFiE0bN8ygN/GRxj6968epaFTmep9Fg6P8AszoxVr7q/fffZWO30OCS10iygmx5kUKo2OmQKvUCiuQ9gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryr9lz/khPhn/t6/9Kpa9Vryr9lz/khPhn/t6/8ASqWgD1WiiigArw79qz/kWNE/6/W/9ANe414d+1Z/yLOh/wDX63/oBrpwf8ePqZV/4bPmqiiivqDyAooooAYJFL7QeeRnHBI6jNPpgjAYEFuMkLngE+1PqY832inboFS2UHnD7PuRXUu8ZC/M7Efdc/TpjqTzUDPhgqYZycY3Yxx3qO0UqEkG1cDAK9Sc5yTWU7Skki4e6m2Ply0TBRkngjv7jnvSQLsQqFKruO0HqB7/AOc1pXcrXGnxTTbWm85kLhQCRtBwcdeSao1aV3zMUnZcoUtMEiF9ob5uR09OvNOq009iGmtwpGVXGHUMPQ02XdtG3d1GdvXHfFLFu2fPnOTjd1x2zSbTfK0O1lzXHdsY49PSpILh7d98bY4wwxkMvcEd6joqmk9Cb9SW8j26jNDbRSNEJNqFfm6jIGOvfFRdCR0I4IPapHmdtjHarxjAkQbWIAwMkdcDge1WdTdmNqJDukEClifvEnJ5PfjH4VlDnWkjRqLV4lKkYhVLMQFHU02UEhcBmUH5lU4JH+e1IEYxKrsQ453ZyQe3PeqcndpIlRVrscCGXKnI9aZI2wgKFJwW+ZtowKei7c5O4k5JPepYbeS6mjghiM0rsAiBckmh35ezEox5u5ZuGafSrCaQEFd0KlhyyjBH4DJFU6tai6mWOKL7lugi3f3iCdx/MmqZdUYB3Ck9MmlDSN2E/ishwpVweGJA9R1p9vBJc3EcMIzI52jJwM+57D3qe2tSNT+yXKkOjMrR55JAPy/jjGapySJ5XJWJbWeey02V45XgeZ18tozhnAyGz32/1qlK7Ss8krlpGIyT3p9zP9oZSsYjjRdiRgk7R1xk9evWoKUY9Xuwkk/hF4xQaKO9WFkFGASCQMjoaijl3lflwHBKnOeB6jt/nvUtSpKSuimnHct3UMd5aRSw7s20IScFsEjd97jqvIHqKoGQBiNh2hghYHgH6VZtbiW2mWWFgHGRgjIIPGCO4q7BpcOqXSnTTCkzn/UzNtKccYP8Q6jPaspfu9dl3Nf4iM0EgEfnR+QFKQVLK3BBII96Q2c9zcJFDDvmZSBGyk9e9aylZXRnGN3YDwDngd/aruuR/wCmiKQI6RRokY64XHGffnkU51s7FwgH22RRsfzBhAR1wQcn61TmlkmkaSViznqf5VK99p20LfuK19RlAoorQyIULqS0m8AKd5Y5B9NtPRyxwylDgMASDkH6U/k01I1jHyKFB5471nGDjZJ6FykpboaY1DbueucZ4z649atWV5cWc8ctrNJDLGwdHQ4KsOhB9RUGMsFAJY9AOSasxafcsA7xeVH/AH5mEY/Wm1FLU5qsJT1XQ6/wdqpup5tK1MW89pdgu8l0+14yoLfJIeVJP51e8S+NblZLCLRIbD7HBZtbCG8t/tCgSACUHd1YkcsMZHy1wk/lW7Rqk0c8jZbbG2BtHJ+Yjr/+vpWpbX0U11BLY6dCxYqypKC27vgjOK4alCnKd7fojKNetSSinbz3fp+Z9keArmK68I6UYPPAit0iZbjPmKyqAQ2e9dBXjnwm1e4tcy6lH9jW8CSPbiMrHGrcK6kk5O4YIOCNwr2MV4M1yyaPpYS5ophRRRUlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXhv7Rlx4nPijwHp3g3Vbywv7pr6RY4Z2RLh4o45ER1BAYEgrhuPmPvXuVZGqeHNK1XWtI1e/tfN1DSWkayl8x18oyKFfgEBsgD7wOO1AHk/wB8b3fjjxx47vpZ7xbMRaaYrGeRilpIYXEyIpOF/eK2cAZxk1tfsuf8AJCfDP/b1/wClUtdvoHhHQ/D+saxqmj2C2t9q8iy3siyORMwLEHaSVXl2PygZzzXJ/s4abfaR8GPD1jqtnc2N7F9o8y3uYmikTNzKRlWAIyCD9DQB6VRRRQAV4d+1Z/yLOh/9frf+gGvca8O/as/5FnQ/+v0/+gGunB/x4+plX/hs+aqY77W2qu44LcnHAp9Iyq4G5QwHqM19NJNrQ8mNk9QUhlDDoRmloo7VSELSDrQKWgCBIACBIEZVBAwvJyc8/wCfepeAMDAA7CloqYwUdipScty2fm0gY/5Z3B3f8CXj+RqpT4oma1uGC/MkqOZN38BBXbj6/wCNMqacr306jmrWGCMBs7m2g5C9gT1/z2p9FFWoqOxLbe4UVE5fzDjd1G0BflI75NSmlGXNdA42CmGRQ+OeoBOOAfTNPppjUtuOc5zjPGfXFEub7I426kkYVpEV/ulgD9M81Y1Td/aNwrgqVcqFIxhRwv4YxVX61aiutypFeKZoFGAf44x/sn+hod07oaaasyrRVyWzVommsna4hQhXym11OOpXnjg81TpqSexLi0FaWh5W4uJQTtjt3ZgFJLdAAMdDkjms2tDSZzapdT7FkVUCmJs/Nk8E47AjP5VFXWLSKp/ERJp120bO8flqOCZjsyfqaY+lTsXaVvJt9nzzBfMUrnjaR1JzjFNmuZpldZJXKO5kKE8bvXFRB2CsoZgrdVB4P4UnCUlZj5oxeiNOM29rbzXNpdkNJGYUh/5axk9cnpjGeR1ziqq6hdCIxiXjbtDFRuUex69OPpVWiqVNddROb6aB2ooFQwyGQgfKcru+X+Hnoabkk0n1JUbq6JqKKbI2wLjA3MFyegpt2V2CV3YQhI9zhOScfKOSfSlVt24EFSpwQe1IhEsOWUENkEdjz29qGBSF/KHPUdyT3Puai/2lsVbo9yaGJ5pBHEpZz0Aqedlhg+zRMGJw0zqcgkdFB9B69zTVE9nayxTxMj3GMGThxGD0I9CfXniq9EXz69Bv3NOpea+gkQvd2kcky8+aG2hj0y47+vuage/uJ42DXDOjE7uevt9PaoDC80T+XHK4X5iY0LYI5p1na3M24iIEsolL7gFw3TJ7dPxqG4wmk/6/yLXNKNxv0oq39kSP/j5uoYz/AHU/eN+nH60xZNODbR9qnbnB4jU4646nitHUiZ+zZX7VJDDJOcQRvIf9hSan+2Kn/Hva28fuy+Yf/HqZNeXMy7ZZ5Cv90HA/IU7yfQLRW7CbTpRERcPDbg8gSvy3tgZPtSWRtIEYzwPM7NkRh9iIPqOSfpxUGOp9etFT7O7u3/X5/iPnsrJFs6hOFKwFLdPSFQv69f1qpKzSNukZnb1Y5NFI3fr+FWopbIyqNyWrNXw9d2i3kUGqIJ9NJKyRnGFYjhjwehwSO44ruPCXg+G21C7l8T3Vtb2tkNzQHDfbIyhY+QdwJbGCCPWvL7aPYeSpwoQBVxke9bkEGo6xI7qlxdvFH8zsS21FHTJ9AOB+VcdWnKV3flvuc/tIxajbmtse3+Jviz4Ui0sR6dpsmpW0KxrNLPMbebk4G04LMVAySeOAMk8V694V1JJ9Ps4zJK0M8Ils5Jz+8miwPvf7Y7+2D618m+DdNg8TXVr4clt0Qz3Pnm+WPfIgCECMegJ9+tfUtr4fh8O+ENOsY55Zhpbxukx+VsBueB6qTkd8142KoxovlW/6Hs4SvKvHne36nXUUCiuQ7AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArw79qz/kWdD/6/T/6Aa9xrw79qz/kWdD/6/T/6Aa6cH/Hj6mVf+Gz5qooor6g8gDRRRQACiiigAFLSUUAW7b/kH3//AGy/9CqqKs2fNpfoenlB/wAVYY/nVUVMd3/XRFS2QxZFY4G7nkEjAI9qfTURVORn0GT0+lOojzW94UrX0CiiiqEMaRVbBzxgE44GemTTn3BW2jLAHA96QxqWyc54OM8EjpkU6oXNrcp20sRxMx3ZJZeMMV289xUlHWiqirKwm7u5NaTyW86yQjMmCoGeuQR/WoXt5LS5lgkDr5ZCEM4Y7h15H+TR+lbli9leTefLK8WqFTtyhaNpAOGPp6k9jWVT3ZKZrD3lymMF2yosoaMEjO4Y4zz1q7dT/ZJ5obSBYV5TefndlP8AtHsR6VAl/c7cPJ5ynqsw3j9en4VHcztcS72VFIUKEQbVAA4A9Kqzb94V0lpuRUVFBI0h5+bK5OEIwe496tx2tzKFMVvKwboQhwfx6U1NNXJcGnYhNFW/7PuQMzIkA9ZXC8evrik+ywjg39vnvhHP645p88Q5GVaM1b2WK8NPcSH/AKZxhQPzPNHnWafcs2f182Y/0xRzdkHL5lSlUFzhAWPoBnirX2xRytnZg9j5Z4/WkbULsjAndF7LHhAPyovLsFo9xU068dgPs0i57uNo/M8VajhsrMq32y3muVIIO1mjRh7D7348cVjSSncVbLKGUEM3JJ9B3qSo+PS5V1DWxcb7FvZ3lupmJJbCKu4+ucnH5U37TAn+psoQfWVjJ/Piqvp69Kvf2e0KmW8wIVByEYEls42Z7H19KbSW7BOUtkTafczzXkUs0/k20DKzkfKiDPTA6k1luF3vsA2lic4xnmrNxcI8CxQwiFN29gGLbj0HX0H86rURjZ3tYUpaWuA46cUxY1UgjdxnaCeFz1xSs+0gBWZjzhRk4pVIZQw5BGRVe63bsTqkLRSNnaduN2OM9M0yEOM7g4XA++cnd3/Chys0rAldXEdZDLkA9RtO7gDvkf5zUtNl3FRtyeRkKcHHfFEW4J8+c5OM8nHbNTHSTRT1imOpD0oOcHbgHHGelMhDjO4OBgffIJz3/CqcrNKxHLdNmjod1YWmopJq1g1/ZdJIUmMTfUMOlepfD7xP4ctLqfRNK0bVZ4dZkSGSK6ulJAJwNu1fQ856jvXj8LwLdRi63mPPzLGQGI9ieAa6nwlruj+G/EFnrQSW8mtZlEenyKVOShzL5g4IVsYGORknHAPHjIwlF7t+Xcmhzwknol5rWx9Z+HvA2g+HLt7zTbNIZCmG2jGQDkZA64NXUtzr4iubxZ4bFTmK2J2+bg8O46444X865D4NeIPEOv6bFPrcT+UYt0crf8tVLHEmcdScjHGAue9em18/UUlJqTu0e1TcXFOKsgoooqCwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArw/9qpWbw1ogVWY/bG4UE/wGvcK8R/anlki8N6I0Ujo32xhlWIP3DXTg/wCPH1M63wM+a/Kl/wCeMv8A3waBDMePJl5/2DT/ALbdf8/M/wD38NH2y6IIN1P/AN/D/jX03vHle6O+wXn/AD6T/wDfBo/s+8/59J/++DVfc395v++jRub+8/8A30aPeD3Syun3hOPs0q+7DaPzNO/sy8/54/8AkRf8apsS3DEke5zUBRvN+6cbhg8bdvcEetTJyj/w3/BGlFmkbCYcNJbIw6q06gj60fYwo/e3dohPT95uz+QNVMD0oqrS7ivHsaVrbosN6qXdvI7QNhU3ZOCCeo9Aazat6UC106KCXkhkRQOpYrwKamn3jrlbWbHuuP51Kai3dja5krIrUU6OC4e58khA+5lZGYDZjvnP/wCvt0NWfsRXiS6tEbuplyR+QojVjLYHTkioKKtfZrf/AJ/4f+/b/wCFL5Fov373d6eXCT+ecVXOv6TFyMqUtWsWC8F7uT3VFUfkTSedaLylm7H0kmJH6AUc3ZBy23ZVoyB14q19sQcJZWgX/aUsfzJqSG9m81Ftre3DEjCJCDuP45NK77AoruUfrW9p+lXljJDdzx+XuRjGpTdvBUj6Drjmsy7SA6m0cZWKAuASCWWP+9g9wDmp9fKrfCCJnMUESxKCfx9eQc//AFhUTbnaK6lwSjeT6EA0+ZABK8EWByHmXIHrgUn2a3H37+PPby42f/CqoAHQYorSz7kc0exo3upzPcMbWaaOIgYXAXacc4A6CqclxNKT5s0r7uu5yc1FS0RhGOyE5ye7Exz0FBoozVEhRRmigAoFAooAMDIOASOhx0o6VNawNcTrGpVc5JZjwoHUmpfOt4f+PeIyuORNMeh9Qo4/PNS3Z2RaV1dsltMWDrczOBNsLRw7MscjgnPC+vrVBnZyS7FiSWJPcnqfrQ7tI5d2Z3Y5LMckmm7vn2Krs+N2EUtgepx2paR96QXcvdiLRV6XTzbkC7ubeJsBiiv5jrnsQO/41GUsVUnz7l8jjbEFwfXk0c6e2ocj6lN0DY3A8dDnFOAAAAGABgD0qWzeCGVGa0LrtAkEkpcM2eWA47dj/SrTWkd2kkmmxzEIwUxN8xwc4bP4cipjP7TVinB7J3KFFW/7PnX/AF5hgH/TWQA/lyaYPsCPse5mlbOMwxYXP1br9Kp1IrqSqcivRVia1ZIzNEyzW46yL/D/ALw6g1VlTzI2QnGR6Z//AF0+a6uhctnqOBBGQcj1FBpqLtLE4yxyQowBU1rbz3l1Da2kZluJnEcca9WY9AKE9LsUrXsi54b8Pah4l1uHTdHge4uJCHeMEBQq9SSeg4/GvrXQfhN4V0yeK5fTIZ7mOTzUZxwjHsPVQegNWvhb4IsPB+iRCG3UahPGpuJmXDuffk4PqBxxWx478U2Xgrwpf+INViuZbKzCGRLZVaQ7nVBgMQOrDuOK+dxWLdWXuaL8z06NBQXvas1LKyjtJZ3jwPMK4AAARVAAUY7D+tW64TR/ihol5q02m6rDd6Bdx2K6kBqphjR7ZjjzBIkjpjJ5BIPXjg10C+LfDb2M98viDSDZW5UTXAvY/LjLDK7m3YGRyM9RXEdBt0VkP4m0FNGXWH1vTF0ljgXpu4xAT0/1mdv6151pPxifV2um07RrGS3g8Rf2H50mswwrInOJ0LqA5IGRGuSexNAHrlFYcvi/w1FqcunS+IdHTUIiRJatexCVCBk5Tdkce1Y3gf4m+GPGOkXmoadqEVvHZu4nju5okeNVOPMYBzhD2YnmgDtaKybTxNoN7pU+p2et6ZcabBnzbuK7jeGPHXc4OB+JrmfBnxHs/FnjrxJoGmRW81npMcEkeo292Jo7oSIG4AGBg5H3j07UAd5RXCar8SbWz8X6n4btNB13VNQ062S7uDZJAVWNgCCA8qsx5HCgn0Bqrrfxc0HTfCGk+J7a01LVNG1GQQJNZLFmKUnAR1kkQg5DDgEDackcZAPRaK8/v/irommeO9H8JavaajYatqcMcsZmWIxRM+4LG7LIfnJUr8uRkjmt7wV4usPF9jqF1psVzFHY30thKLhVUmSPG4jDH5eeCcH2oA6KiuG8OfEO21XwZf8Aii4068h0qK6nitjbRyXUlzDGxUS7ETKhiG45AAyWx0bB8UfDz/DKLx1P9sttHl3BI5Yx57MJDGFCqxBJZTjnpycc4AO7orgYviroEdp4hk1iK/0a40FI5b60vo081VkAMZXy2dW3bgODwSAcUml/FXQbn+1F1ODUNFn06wXVJoNQjQO1swBEi+W7g9QNud2SBjNAHf0VxHhH4k6V4k1mDSlstS029urFdStI7+NF+1WzHAkQo7f98thsc4rodX8SaHo06waxrOm2EzRmYR3V0kTFB1bDEce/SgDWorJsvEuhX17DZ2WtaZc3k0XnxQQ3UbySR4zvVQclcdxxXL+HvHt7efEB/CWsaNb2d+LD+0M2l/8Aa/JXcF2TDy18t+QeCwORz0oA76iiigAooooAKKKKACiiigArw79qz/kWNE/6/T/6Aa9xrw79qz/kWdD/AOv0/wDoBrpwf8ePqZV/4bPmr60UUV9QeQFA60UUARRM5fDZPB3ArgKc8YPf/J9qlooqYx5VZsqTvsFFFFUSWNPl8m+t5OeJB064Jwf50y6V0uJY5HLlGKZJJ6H3qEkjkHBHINXNVx9vldRhZMSL9CAaj7Rd/dKnXr0o6cdKKKsgKWkooAKKKKACren3Mdq0zOkjM8ZjVo3Clc9eo7jj8aqUdqTipKzHGVndGrpZgmvYFWwhWBXBd3dj5Y9S2eB+H51Rvnikvrl4N3kvIzJuOSQT3rS2f2ZoZcsGn1AFAuQyrGOpx/ez37VjVlTV5OS22NajslFhRRQa2MQpaSkyAeooAWinJHJI4VI3Zj2CkmrA067I3GBkU/xSEIP1pOSW7KUW9kVaKt/YXX/WzWsXpumBz+Wakgs7aR2X7YZGClwsUR+bAyRk4wcfyqXUiNU5FCjIHU4q35tkn+rtpZT6yy4H5L/jUUmptEzCC1tI1XGfkDMc9PvZz/WlKpyq7Q1C/UtRL9nt4zDC809xEfnGTsBJXAA78daiGnXQGZI1hHrK4T+fNJLf3kg2yXUxAGAA2Bj04qqRk5PJ9TzQoyG5RZpWunQyiZpbxPLhXfKYlLBR0ALdMk8DrVKaVSGW1WS3R12SbZDukGc4Y/4Yp/2iJdMeFzIj+aHBH3G4AAb0A5Oe1MNvKEmc+W6RPsZ4nDKc9CO+P5Go91y5ZsrVK8CIYHAAx6DioY42VwTjvls8tnpx/n2qajFauKk030MlJoKXJAIBIB4IB6/WmkhQSTgDkmkR9xwVZTjOGGCRTuk7Cs9xeAc4pvlqGB5wDnbngH1xT6BQ0nuCbQ+GWSGUSRNtcd8fofWrGy3uf9Wy20x/5Zt/q2Psf4foePeqlDEAZP8AKk49RqXQdcRvbPsuFMTejcf/AK66f4f+HL3VvFFhHJpGq3VngzstqfJZscoyyNgAbsdx69sV718G/hfb6ZocV/4hjN1cXsKt9iuVV44AecY5B7H2r1+CGOCJYoESONRhVRQAB7AV4+JzFSTpxXzO2lhbNSbMzwnb6ja+HNOg1ubztRSECZ92459C38RAwC2BkjOBnFcz8d/D+p+KfhTrujaFbfatSuRCIofMVN22aNj8zEAcKTye1d7RXkHaeL+JPhRLJ4F1y5he/wBZ8YXuippsRvJYV8lBtPlR7FRFGR1OSfXk5y9d+FmpweE/h3L4c0yCy1LRmt7jVbWxFtFNPMIkVpAzgxPKpDYL5B3HmvfKKAPnNvhlrVjLompaTo2sXFtZeI21a60zUb2zM8+5UzKgiKwpgqcJu/LoKUfw28YziaaTQ2hebx7HrvltdQEpafOS5IcjI3AbRz6CvpmigDx34beHde8L674qs9U8MtqUGqa8dRh1Zri32GIspDOpcyBkwWUBTyeq9a49vhr4wn+FGp+EhpzW97b62dShmNzCYL+LfkIPmJVv4sSIF+UfQfSVFAHzd4n+F2vaxpHiK607Tdc/tG/urK7urfWL2xUX5hLbkVbYCNMAg7mIz6Dqe6+HGga7B8W/G/iTVdFm0vTtWhtFtVmnhd8xxhWBEbtjGPp9a9XooA8fm0rxNofxr8S+JrHwzdarYX2mw2ts0F1bRgyqFzv8yRWVeDyFJ9Aa5HXPhj4m074N6L4Y0/TH1XV31UareNbTwxwwHcSUBkdSeCAMAjKtnHGfo6igDxDxf8N7/wAdfETVL/UtNmsNLvfDKWsFxLLEZbW9WcSIMI7HK45K5UjIB5rA0Oy8U+BPghq+ka1b+R4s8R6y9nZgSpJvkuQimTKEgYAkb2xyBX0dRQByl3pB8PfDkaJoWnXF/wDZ7EWUMFuYkdvk27iZHVevJ5z16mvIrP4d+KL/APZ2sPCM+lPYa/pFyLqJLmeForoieSTarRu2PlfHzAc+3NfRFFAHz14s+GPiXx3N8QNVurJdFuNWtLS20+zuZ43djCyOxkaNmUAlMDk9cnGOX6t8N/E3jjVPEOp6pp40J5vDcejWsE88cjSTBlkLExMwEe5SvXOCDjtX0FRQB4x4H8JeJbnx/wCGdb17Sv7IttA0BdM2vcRStcz4KsyCNmxHjkbsH29NHxt4R1jVPjJo2uWtiJtKt9FurSWYyINsrrIFXaTuOdw5AxzXq1FAHzd4J+GXirTYvhGt5pRt30SXUjqbpcwloBM5MZyGO7I/u5x3xXqXw9+GFh4Ev7q50vWtZujduZLpb37PI1wxzy8ghEhwSSBvxknjmu/ooAKKKKACiiigAooooAKKKKACvDf2qjnw7oqDqLl5PwCgf+zV7lXhv7VH/ID0b/rpL/7JXTg/48fUzrfAz5rooor6g8cBRRmigAooooAKKKjEuZAMDBYr15yB6elS5KO5Si5ElWrr57Gyk7qGhP8AwE5H6NVWrUv/ACC7X/rtJ/JaJbr+ugR2ZVprPggBWdsE4HpTqa6K4G9QcUSTt7oo2vqKCGUFehGRS0UVQgoopaAEpVUsyqoyxOAPU0mK0NI+yC11C4u4TKYlCW+8ZiaTPKtg56Zx78VFSooK7LhBydizfWFyLW1gdQZoQQzF1VUU/wAPXscknHeqJstvMl1Zovr5u7+QNQXczXVzJPMFMjnJwMAegH0HFV5SwI2lwuDygyc9h9Ki0oR1LbjOWiL/AJFoPvXxOOoWBv0NG6xTolzMevzsEH0OMmqYztXdgNjnHrS1fLfdkc1uhpI9s1nLJHYRBoSpbzHZ9wY4HcYwahGo3C/6sxRD0jiUD69KrQwE293JiPCvG2853jnG0dsf09+aZUQV78y6+pcpNJWZYe9u3Uq91OynqC5quxLElyWJ6luSaWitUktjJtvcQDHTipbSY29zFMADsYEg9x3qLFFDV9GCdncmvIRbXUsKklVb5T6r1B/LFQEAkEgEjocdKuXH72wtpf4kJgb8OV/Q4/CqIkBYDDYJ2hscE+lSpK3vFSjroPoooxVkBUtnN9mc7VBiZdkkY4Dqeo/r9arrIrnCk5IyOMAj2p9TpJFaxZPc25hVJEJe3cZSTH6H0IqCpre4lt2JhfaD1U8q31B4NWXghvpN9myRTyHJtmG0bvRD0Oew60uZx+IfKpfCUD+lNRFjzsGM4HXPToKcRgkEYI4I9KDVWTdybvYKKKKYgrtfhD4ck8Q+NtP5KW1pPHNIxBwxDA7AQMAkc89ga462glurmK3t0LzSuI40HG5icAfnX0b+z14I1bRLq81LVo5rOR/3fleYSrr7gfKeeQwz6cVx42sqVJ66s6MPDmmn0PdABgYpaBRXzR6gUUUUAFFFFABRRQelABRXFn4k+HwzAtd5BIP+jt2OKP8AhZXh/wDv3n/gO1YfWqP8y+87f7Oxf/Pt/cdpRXF/8LK8P/3rz/wHakPxL8PAcvdgf9e7UfWqP8y+8P7Oxf8Az7f3Ha15f4l+JkuiH4gQPaTyXOhpusGi0y6nhY/Y0mHnyRqUUb3IOWTC4Jx1rv8AQtUOrWZuDY3tj85UR3kYRyB/EACeD2rMvfB+n3dr4sgkmugniVCl4VZcxg262/7v5ePkQHnPOe3FbnEYyeOrW11C8t2TVtR1J7m3todPhjhwZXtRMRCSV+UIGZjK3BBwcYFZdz8RLu61/wAONpOk6vLb3DanbXWmLHb+eZrZ405YybAFO/kSAHPc4FaHiTwCSZdQ8OyzrrZvIbuKaS8W38ho7f7PlW8iUEGPIKsjA7j04qXwH4CbRLbSLrV72W51mzkvpndJA0btdyiR9xKgsRhRnC55OOcAA2tC8WWuuDRpNOstRe01Sza9jujBiKIDb+7kbPyud3A5ztbniqvxE1TWtG0r7fo0tnFBAkjzmXTri/kYgDYqRwspAPzbnJwuBx1IseHvCNtoEejxWOo6obbTLR7SO3eceVKGKnfIoUBnG3APGAT61Y8RaBNq80Mtvr2saSyI0bCwkjCyK2M7lkRxkY4YAMOcGgDhdX8d65bLo91NNp+k6Vc6RBfXF+2kXOp2yTufmTzoZFREAwdzHGDnOK9B17W7fQ9GN9dlpydscUUC5e5lbhI41zyWJ4GfcnAJrn774eWNxpcOk2+razZaGtkmnyabbzJ5M0K5G1tyM6lgSGZGUsOprVufCWlX099/a8P9q2V0YWWw1BVntrcxqVBijYYUkEk+poA5nRPE3inV/Bt3fvFpen6nZ6ncWt0q2k96scUTspCRRsHlfIUcFQeTjoK6L4da5d+I/B9hqmorbrdTGRXFuCq/LIyg7SSUJCglCSVJKnkGs3Tfhxpei2U1v4avL3QWlvZL1pdOWCMkvu/dlTGUaNQ2FVlO0AYPFdF4a0O18PaSlhZvNKvmSTSTTtukmlkcu7ucDLMzEnAA54AFAGpRRRQAUUUUAFFFFABRRRQAUUUUAFeG/tUf8gLRv+ukv/sle5V4r+1HZyS+EtOvFK+VBcGNl53EvjGP++TmunBu1ePqZ1vgZ8x0UZFFfUHjhijFLUUyMxGBuGCNu7bz2NTJtK6HFJuxJRSDIUAnJxyfWlNUhMKTA3ZwM4xnHNLRQAVbf5tKhI/gncN+IBH8qqGrY/5BB/6+f/ZKmXQuPUqUUUVRAUUYooAKKKKAFVS7BVUsx4AAyT+FWbq0htIQH2veSYdgD/qeuR6bj39MVJo6oLszvcm3+zL5wYIWJwegx0JzjPaq97Obq8muGBBkYthjkj0ye5rN+9K3RfmaL3Y36shooorQzA0UUUAWrb/kHX//AGy/9CNVqs2PMF+D08jOPcMMGqtTHd/10Rb2QUUUjMFAznk4AAySapu2rJtcXtRSKwdQynIpaE76g1Yt2X72G6tzzuTzEH+2vP8ALdVIIm/eBz1/HHX61PaSi3uoZiMiNwx+maW9iMF3NETnaxwfUdQfyqLLm1Ku+W5DRRRmrIGJGqEEZ4GACchR7U+iikklsNtvcBSqSrKykhlIII7Ed6SimJGlO9tqLiV5I7S7c4cFMRPx9/I+6Sc5qhNE8MrxSLtdDhh70w1Zu5mu4Y5EjQy2yBJ23gPICcKQvViBxnv+FZNqla+xql7T1K1FXdN02XUI7027x+ZawmcxE/NKoPOwdyByfauz8AeHdG1+wMd0Z3hXULWG6vI8KYjJkCNEPzMrZALDkHBAIyRNbEQoq8gp0ZT2L3wZ8Fab45MiSlo3sZle6cFj5kZ5VVI4U5HPqBX1jZ20NpbR29tEsUEShURRgKB2qtpGkWWkweVYwJFnbvYKAz4GAWIHPFaFfOYiu68+boenSp+zjYKKKKwNAooooAKKKKACg0UHpQB4TJo582Tj+Nv5mm/2MfStx/FunCR/9F6MR+tN/wCEt07/AJ9f1r8qbzG/8N/ej6H/AFnw386MX+xj6Uj6MShGK2/+Et07/n1/Wg+LdOxxa/rU3zH/AJ9v70P/AFnw386PWrcYgjHoo/lUlYvhTxJpnijSzfaLM81skhhZnheIh1xkYcA9+vStqv1aOx883fUKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvJ/2l5Hh+HCvE7RuL6EBlOD/ABV6xXkv7Tv/ACTVf+v6H/2at8N/Gh6oir8DPl77fK3+tSCXPDF4xucehYc1JDfQo4U2kQgClAdoMgyCCdx6nnvVCivp/ZxPJ9pIvvYRxSss10iRniFuu/PQnHRfU0p0e8EbvtTYoyrbx+86fdHU9RWfUttPJbTLLC211GAcZ49MGk1O2jHzRe6L7aO4ZEFxbrIDsnWRwvkP1IPqAOpHfiqslhdpcJCYJC8hxHgZD84yp6Ee9VW+ZizcknJJ9amiu7iKB4Y5pFicAMoPYdh6D6UWmutwvB9CwbBI3Zbi+tIyoJcKxcqR244J/GlWPThIJGuZjDk/uTHiQ4HQkcc+tUAKKfK3uxcy6I0lsIr0KdJkaSY4BtZcCXPcqejL+RqDBGlOpBDLcAsCMEAoQP1qp3HqOc+laa65eNC0N2UvYWx8twNxGDkfN16+9S1NbalKUXvoZlFX7qUXenrMYbeKSObYxhj2bgVyOPqDVAVcXdakSjZhRRRVEhRRSEgd6AN3R5JbbRNRuLe2aSTcEMyn/VrtOcjHTB/zisMcACtPRrlktdTi8wfZ2tmZ4/N2FmA4x689R3HFZELFg2TuAxhtu3PHPFYQdqkovr/l/X9M2krwTJOtFFBrcxCohIxmC8Y3FduOQP72f8/nUtGTUyTdrMqLS3Ldj/qb/wD69z/6EtVKt2P+pvv+vc/+hLVShbsJbIKRlDY6gg5BHUGlNFNq+4r22ERQqgL09zS9aKKaVtBXuFW7n9/a29wOWUeTJjsR90n6j+VVKtafIBKYHTfFclY3A6jkYK+4NTLv2Li+ncq0VLdwNbXU1vJ9+J2Q/UHFRVSd1dENW0YUUUUAFFH4UUAFCnbIkicSodyN3U+oopH3bGCEB8HBPrSew1udf4U0a/1TxPZSaKxjNwGAlTHDlDvjxnILfMPoc19ReDPh5oWg2um3B0mx/teCMF7lI8HzCOWAOeeoB6gZxjJryf8AZt8LeZrt34iFq0NhHCsMHmzrM/m/xsCBwp9OvTtX0dXzmMrupLlWyPVow5VcBRRRXEbBRRRQAUUUUAFFFFABQaKRvumgD5HuJZRczAZx5jfzNR+dL71i3Goav9pmxpt/jzG/5dZPU+1Rf2hrH/QNv/8AwFk/wrqWSR7n5zLL8Xd+6/xN/wA6X3pHmlKkc1hf2hrH/QMv/wDwFk/wpr6jrARj/Zl/0/59ZP8ACj+xI9xf2djP5X+J9r2ZzaQn/pmv8qydG19dQ1nxHYPAIF0a4jgMpkyJA9vHNuxgbceZjqeme+K1NPJNhbFupiXOfoK5CXwlrCa/4hurHWdOTTdcljkubWfTXklULBHCypKs6gZWPIJQ4J74rl2P0ZbFm1+I3ha6t5p4tRkEMUSz75LOeMSRM4QSx7kHmR7mUb0yoyCTjmr1v4y0C51BrGDUUku11BtLMSxuSLlYzIU6dkUnd93jGc8Vy9v8NJp7H7H4g1qPUbe30ebRbIR2XkmKKQIGeQ723yYjj5GwfKSACak8K/DG30LxLpmtNqUt3c2ti8M4aLaLm6d2Zro8nax8yUY54frxyDO10LWLHXtNTUNKn8+0d5I1k2MuWjdo3GGAPDKw/DjiuU0Px3calqumLNpCW+j6tcXFrp94LvfJI8Ic5ki2AIGWKQqQ7HgZAzXV6Fa31npqQarqP9pXYeRmufIWHcrOxRdq8DapVc99uTya5TQ/AlxpuraY82rpcaPpNxc3Wn2YtdkkbzBxiSTeQ4VZZAuEU4IyTigDuqKKKACiiigAooooAKKKKACiiigAooooAKKKKACvJf2nf+SaL/1/Q/8As1etV5L+07/yTRf+v6H/ANmrfC/xoeqM6vwM+U6KKOK+qPHAUGiigANFFFABRRTHcqQqruOC3UDgUm0ldjSvsPopAcgEdCMil7dx9KdxWL9msLaZcid3VVmRiEXJ6EfQc+tR7bD/AJ63f/ftP8ahsIillf8A3AQkY2p/EA/LH8/1qKsYXldvT/hjWbUbJFrfY/8APG7/AO/q/wCFHn2g4FiSPVp2BP1wMVVorTkX9MjnZb+1Q9BYW2PfcT+eaBqEyn90lvEezJCoI/GqlFHJEOeRuaJqVxJdPBMYpVmjZMSKqjp0zjjPqenWsRlKsVPUcU+3lME8coGdjBsZxnB6VqeJI1e6S9V9v2xRKIGGHj47jsM9Pb2rNJQqWS3/AELbc4XfQx6KKK2MhRSUZooAtWP+qv8A/r3P/oS1Vq1Ycx3qjlmt2wPXBBP6A1VqVuypbIKKKKokKKKKAEJCgseABk0+zxPdQxOrrvZcjuVJxkU2pdNaOzvYJtnyK4LAddv/ANYdKifN0Lhy9R+oTGa7kJ6IfLUZzhV4Az3471XqW7g+zztGG3IOUYdGU8g/lUVVG1lYmd7u4UUUUxEM0Zc5AVhtIwxI2n14qbtycn19aKKlRSbfcpybSQUCjrUlusb3ESTuyQs4V3VdxUE8kDvVN2ElqfWH7O9jqFr8PoZNTCL5shMC4AdYhwA364HpXqVc58P7Gx0/wvZ2+mXDXNsq4EjnLHjoT3x0z7V0dfI1J883Lue1FcqSCiiioGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXkv7Tv8AyTVf+v6H/wBmr1qvJf2nf+Sar/1/Q/8As1b4X+ND1RnV+B+h8p0UUV9UeOM8wbsbW27tm7tn0p9N2Jv37Rv9adUxv1KlboFFFFUSFNdFfh1DAdM06ihpPRgnbYKKKKALVl/qL/8A69//AGZaq1Nazm3dztDo6FJEP8Sntnsfen31uIJEMZ3QyoJYmPXaex9wQRULSVn1LavG/YrUUUVZAUUUUAWdNWQ30LRKCUO5ieiqOpJ7cd6frl+t9qUtzFEVSRtsaZycDpknv6mrEchstFfypUL342OuDkICcj6E4NZTKHGGGRnP4+tY25pOS9DVvlSi/URG3rkAjnGD1Bp1IqhVCqAAOgFLWqvbUze+gUUUUxFvS+ZpgOpgkAHqdtVKsaa4j1C2YnC+YAx9jwf0NQyoY5XQjBVipHpg1K+Jlv4UNopsoYxsE+97HB/A+tJCGIYAMRn5QeWA96ObW1hculx9FWY9PvHzi1l4/vLt/nTjp8q/62S3hHffKOD6EDJo549w5JdipRVvyLRf9Ze7j6RQk8/U44ozYJ/DdTEepEan+ZFHP2QcndhqPW1PY20eD9BzVStKGSO9tZrSO1SN1HnQBCSxYfeXJPORzj1FQLp12VDNCY1PeRggH59KmMklZ6FSi27oqUVbNiy8S3FpGewaUHP5Zo8m0T/WXjMfSKE/zOKrnXQnkfUqUVbzp/XZen2JSjz7UfcsVI/6aSsT+mKOZ9g5V3KqDc6rkAsQOfc1oXUenwXEscTXoaGQhXIQ7sd8cY5+tNjvI5Y5be4it4YpVxvji5Rh0Pr7H2qHUpUnvppYmLIxyDjGeBUaylZ6F6RV1qfaXwuure+8DaXeWbyvDcR+Z+9HzKSeQfXBzzXV14F+zN4ptjZyeHbm9ne/YvPFFICUWNdoCo30ydvbFe+18zXpOlUcD1KcueKYUUUViWFFFFABRRXnfx+8S6n4T+Fuq6nobGO+BjhWcAHyA7hS/PoDge5FAHolFeM6vJe+BviP8PrLSda1XUbTXfOtb6G/vZLpZdiKwnTex2HLZOzC4HSvPPgn4y1bwf4D8GJFFY3Wkazr8umyQ+W4uUZ34kVt+CB3XZ2688AH1TRXh3hv4xahJrV/b+Lo4dCurZbmaPRJtLnFxPHFGzgJdGQRlsAH/V4IIx1yIfCnxb8V6v8A2XevoIn0nUbS5neW30u7RNPdFYxh53/dzK20AlNuDn2yAe70V8/af8UPiJL8KE8fT6d4YfSwUd4LdLgzmMTtHK20thcAAjluhJ9BPrHxt1KHT9f1XTLKwudIXWodD0ecRSv5kpQtJLJtOXQY+VUAJyBQB71RXhOo/F3xTpWi6iL7QAL86tbaZpd9c6dc2NtdCYORIYpTvG3yzkbv4l5Hex8FEuk+MfxYXUJoJ7sS2HmSQRGJGPlycqhZio9ix+tAHt1FeFJDd+I/jl8Q9JvPEGuWVlY2NrLaC11OeCO1doUJcIrBDzkkMCDzXG3virX/ABD8MvhhrN9qWrWmoX+ux6XdTWd9NbLdweY6klY2UZO0DdjOQcEdKAPqeivm34g+IPE/hv40Xl7ot/qVzonh/TbW6vNKa5kdJbYnZI21icuAQ245PGSa3vhv4+msPgX4g8Vajf3OoPBeXZtXuZGkZyXxDGNxzgsygDtmgD3SivJv+Eav/CP7P15bW2q31hrFpptxqNzdW2wSSXBjeRwzMrYG44yuG+UYIrkdc8V67afs5+Cbq31W8TUNWubWzudQMpadUcuWbeTkN8oGevNAH0PRXy1488a+IvBcvxP0LRdWvpbSwawNnc3U7XE1n54XzAJHJY9SBknHbBq5408Va94D1j4gaRoer6jd2lroVte20l5cvdSW8zyxRMyvIWbkSM+M4BHAAoA+maK8O8CalqWj/F/SPD6avqOpaZqfhiLUp0vrp7kpcbiDIrOxKhsfdGF+bp0rT8d/ELxFpPxC1bw/o0ekrb2XhyXWhJdwSSMzoW+Q7ZFG0gY9RnPPSgD16ivEvCnxX1rVde8J2upafZPYeIdHmvxFZpIJ4ZIgxKglyHDbDgYUjcBk4yafwQtpJfiDqesHw1feEbN7IWFrpB0u4iWVVcN9onlMYjMp6D5ixyQScZIB7zRRRQAUUUUAFFFFABRRRQAV5L+07/yTVf8Ar+h/9mr1qvJf2nf+Sar/ANf0P/s1b4X+ND1RnV+B+h8p0UUV9UeOFICCTgg464PSnVFHFsIJKkKu0YXHGe9S27qyKSVnckoooqiQooxRQAUUUYoAQkKpY9BzWjEyXujzfuWW6sipL9zEeMEegPO73wazmAYENyCMEVf8Oho9bshAzB3lVCT8xIPBB9RjjFY1ebddDWm1s+pR70VJcBVuJhGCEEjBQewyajrZamT0CkPSlo7UAaeuyJus7dI9i28AQOVCmTPzbj781l5HrV7+0ZtkarHbrsUICIhnA7c5pP7SvB924ZB/dQAAfgBWcFKKtY1k4yd7lOO2u5Zh5UFw4ZsghfkK4/n/AJ6VbGnXIGZUWFe5lcLj655qKW5uJc+ZcSuG6gucfl0qBhnJ6tjrRGMl1FKUX0J7q3e2dFkKHeodSjbgQe9Q1e1kH7YhGDCYY/KI6bQo6fjmqNVB3imyZqzaQoYoyuOqkEfhVrVEA1GfZkq7b19w3P8AWqrKygb0dQwyCVIyPWuhttF1e9n0m+s7C6aGTyCLnyyIwwcKCW6AcCpnJRabZcYtq1jEt9kF4hu43KRv+8j2/Nx2IP8AKrV5c30DDFwBC2TG9vhUI9sc8ehr0v8AaI8JXGleJ/7YtbRF0u5iXe8KgBJedxbuS3XNU/Cnwr1/VtN06e706eKzeT7VlWUF4scAqe5IAHsSfSub6zTcI1ZdTX2Uk3BHmLl5ApkLsD0LEn64zSIjMf3cbNzj5VJ59OK+lbr4Mt4ivbO61cWulJEpWW3sTkNzkbeBgc4PfjNdnpnww0XTNHXTrN5oowVZpUCrKzDOCXA3dyOuccZrB5pTUVZalrCNvV6HxsffII6gjGKK+n/G3wTt9YuV1C0vXN4ilpUfP+lHqFLE/L6ZHPPtXmXj/wCGt5oulQXFrposgfMnnjkuPOEYUhdqy4Axg7vmwcVrSzClOy2bM54WSu0eW0N8zFmJZj1JOTTpEaORkcYZTg96ksrS5vrqK1sbeW5uZTtjiiUszH0AFd11uc9nsQ8ewor6r+G3wu0e28Mx2/iXw9E+oqQ0r3BEm8kDO0g8DPb2qTxZ8EvDWrLLNpsLaZdGMIvkH92mD94J03dRzxXnf2pS5rNO3c6/qkrXufKFFa+veHNY0KRhq2m3dpH5nlo8ybQx6jB7kjmsivRjJSV07nJKLi7MKKbI20oABlzgFjgCiJ/MjVwMZHrmlzK/KHK7XNXwxqk2i+ItN1O2m8iS2uFfzMZAXOGyO4xnivuHw9rNn4g0e11TTXZ7S5TfGWXace47Gvguvc/2bvHDWd8/hbUZYxaTky2bscMJSeY/fPUfQ152ZYfnj7SO6/I68LUs+R9T6TopF6UteCegFFFFABVXVNPtNV064sNStorqzuEMcsMq7ldT2Iq1RQBzGgeBPDug6lFf6fYyG8hh+zQzXN1NctBF/cj8128tfZcCs/QvhX4O0K6sZ9N0mRWsHeW1SW9uJo4Hb7zpG7sqsePmAzwOeK7eigDl7LwF4etNXg1Q213eX8CPHDNqGoXF6YlcYYJ50jBcjg4xmq+n/Dfwtp7ILOwuIoIzIY7UX1x9niLqVYpCX8tSQzchR1NdhRQBgaZ4P0LTPB58LWVgqaCYZIDatI7gpIWLjcxLclm78Z4qnb/Dzwpb+Dx4Wi0aD+wlcyC2Z3Yhy27cHJ37s/xZyOg4rq6KAOQuPhx4XutMvbC+sbi9gvGjeZry/uLiUmPOwrI8hdduTjaR1PqaveGPBmh+GL/Ur7RrWaO81LyzdzzXU1w8xQEKWMjscjceepzzmuhozQBx2sfDXwtq+tajq19Y3JvtRRI7x4tQuYVuERQqq6JIFYAKOCMVJr3w78Ma7b6Xb3+nyi20sqbKC1vJ7aO3ZfusqROoDDs2Mj1rraKAMK38JaJBrVzqy2ZfULqzWwnmmmklMsC9FYMxB9zjJ7k1zVz8K9Gj03QdI0XGnaBp2pjVJrAB5hdOuSqlnclV3YYjkHAGBXoVFAGX4k0Kx8R6VLpurLcvZS5EkcF1Lb+YpBBVjGykqQSCpOD3FZFv8PfDMHhSTw1/Z8k2huQfstzdzThMYxsLuWTGMgKRg8966uigDl7PwB4YtdJ1XTV0pJrXVW3X32qWS4kuSOheSRmc47c8dRik0r4f+GNLtdSt7fSxKmpRrDdtdzSXLzRqu1UZ5WZtoHAGcDtXU0UAc34X8D+HvC93LdaLYNFdSQpbmaa4luHWJfuxq0jMVQcfKMDgccCnal4L0DUtcutYvbDzdSurBtLmm86Rd1s2dybQ2BnJ5Az710VFAHLaX4A8M6VfaJeWGm+VcaLbva2D+fK3kxvncuCxDZ3HlsmupoooAKKKKACiiigAooooAKKKKACvJf2nf+Sar/1/Q/8As1etV5V+0rbSz/DGZ4gu2C6hlkycYXJHHryRW+G/jQ9V+ZFX4GfJ1FFHavqjxgoopaAEoooxQAU1pFVtpODx26Z6Zp1MeMMxOWAONwB4bHTNTLmt7pUbfaH0UHmiqJCr+kARvc3e3e1rF5iJt3AsTtBb0AznPriqFXtOHmwX0GQoMJmDbtvKc4z3Bz0+lRU+Eun8RR57kk9ye9FFFWQFFFFAC0lFHegYoVmIVVZmPAVRkk+wr2/R/gHc3/hOC+utRex1iWHzPssiho0JPG5hyOOo7HvXidtPNa3EdxbSvDPGdySI2GU+oNdnefFXxneWclpc6yXt5F2OnkoNy+mQM/rzXLiY15WVF27m1F01fnLkvw58Q27SaKYLe+mnV7ixa2uFcb0bD554yOMeo9q9m8F/BjRrKw0qbxDbQ3Wow2+2eNV/dtIW3BiepZemR1rw7wH45vPDen6nZadZK95fRMkNxGAJo3bPKn8eB619RfDOPWYPC1tD4kRxqSgNI+4FX3DOV9PcHoc9q8zGTr09JO2vTr/X5nZRVOWqRuHRtNKIhsLbamdo8scZ5NWLaztrWMx20EcSE7iqrgZ+lWKK8s6TJk8O6VLqcmoT2UU16+AZZRuIA6KM9B7VqgYpaKACiiigAqOaGOaNo5UWRGGCrDIP1FSUUAfPmqfA3Udd8VXF9fX8FnaT/NN5OWcyYxlARgJ0688HpXr/AIT8GaJ4XQ/2TZRRSsqq8iqAXKjG4+555966Sitp16lSKjJ6IiMIxd0gxQaKKxLOL+JngOz8dadbwXc8kElsXkiZDjLFSBu68Zwa+VvGPgfWPC2sQ6dcwvdSzozxGCMkuF4bCjJwPXvX27TGRS4cqpdRgNjkfjXXhsZOhotV2MalGNTfc/Pxh1V19iCKK9X+P/hHTfDuvG90xbyI30vmPE0OIAW3Fij9zkD5e2a8oxX0NGqq0FNdTzakHTlysKVWKsrIzKwOQynBB+tJRWpmtD6r+CfxJl8Vo2m6lFHDdwJ8jKcBwMcDPJOOfw5r1uvin4Z6jFBrQ0+9uprazuCJVkjl8vyp4wSjn1HUbc88CvrnwZealfaIk2rxBJyxCPwDLH/DIVHCk+lfNY2gqNRpbHrUJ88Ls3aKKK4zYKKKKACiiigAooooAKKKKACuE+Iqa21zafYBrDaf5MgA0dkWYXXHlmTf/wAs+v8As5+/la7uigCno320aTZjVTGdQ8lPtBi+75mBux7ZzXiviT7B/wAJdrf2ryf+E6/4SHT/AOyM/wDHx9j/ANHz5Xfydv2jzMfLnfu7V7tRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5x+0J/wAko1j6xf8Aoxa9Hrzj9oT/AJJRrH1i/wDRi1rQ/ix9V+ZM/hZ8gUUUdq+sPFCmyoXj2jHUHB4B9qdRSaurDTs7jIlKKQcDJJAHIUelPGc0UUJJKyBu7uMEgZgNpwSQrdiRT6aEQOXCjce9OpR5l8Q5WexasLG4v2nW1QO0ELTuCwB2LjOPU89ByasXuh6hZ6Lp+r3EAGn3+4QSqwOSCcggfdPB4NHhvUk0fX7DUZoWnjtZRI0akAsMEYBP1r6PvND0fx9omgWdnYmKyMbXf2WB/s6W5Ykeawxlg3IwOma5MTinh5RuvdZvSoqpF9z5eAJYAAknoAMk16To3hrUfEHw90+x8NafdXU8t21xeyOwVIs4UBVOCRgA5BPcV7/4M+FfhnwxMLqCyW4vshhLOS/lnBHyA529a7yNFRQqAKo6ADAFcGIzLnt7Nba6/wBfqdFLDct+Z7ny9/wz94jYkR6lp/1kR1H6Zrn9c+DvjDSriULYx3drGhkNzFIAuAOcgnI6V9h0EVjHMq6erT+RbwtN9D4DuNPvraHzrixu4YjgCSSFgpz05xivTPDvhrwxpvgmTWvEkOoreXiBbWKSHzBFgjMmAMd+j9R9Qa+rZIkkTbIisvowyKHiV0KMqlCMFSODVVcxlUSVrejFDDRg7nyx4u+FG+LTbrwJJ/aOnXSblkncq7t1PUABccgYz19K8pvrWewunt72GSCdCQUkUqeuMjPUcda+/UjWNVVAFUcAAYAryvxH8PtX1HV9Sv3l0y/FxIdiXUAZ1iwAEVmB24OenHPrV4fMpQ0qar8RVMNGWsdD5QJA68VpeH7XTr68+z6nfvYrIQkU4j8xFYnGXA5x9Oea948N/B+a18cG4m0u0h0AW5heKaUTuzHrIoOQpJHHoDXReN/hJY6jqei3fhm3tdLmhuVN1Mqbv3QBIwh+VjnAPsa6p5lTfuq+q37GMcK1qzyG88Ma38LdUsLu6sNP1z7cjoIFV24XBIBHPocjt1r2fw18XfBz2UFqLr7NNFGgeJImKKxA3BT3AJxXpS20flIjojBF2DKjpjB+leR+N/hNY6t4vsLiwitrO1mDCVYImVo2GWMoIOM7to7GvNdaFd3rb91/kdag6ekNj2CN1cZRgw9QafWH4N0IeHdChsTcPczAl5ZXJO9z1IyTgVuVxmoUUUUAFFFFABRRRQAUUUUAFFFFABQaKD0oA8O/arghbwzos7S7Z47wqkeR8wZfmPrxgfnXzVXu/wC0OdS1zxlZaDbvG8cMQmt4ioBLsCCN3vwOeK8T1DTL7ThEb+1ktxLv2bx97YxVh+DAg19Dl7UaSi3qebik3O6WhUooor0DlJLeZ7e4iniIEsTh0JAIDA5HB619a/AbxivifwmLa6kT+1LBikygbcqSSrAemPyr5GrZ8I+ILrwz4gtNTtHkURyL5yIxXzY9wLIceuK48ZhlXhputjehV9nLXY+7aKpaRqdrq+nW99p8yTW06B0dTng1dr5o9UKKKKACiiigAooooAKKKKACuX8U+OvD/he7htNYv/LupVEghjjaR1TON5Cg4Uc8+1dRXjvxO+H+u6t4tfWNCFrcx3MMUMsU8xjaJlJG4HBGzByQOc5IBzWdWU4xbgrs6cJTo1KqjXlyx6u1z1bSdRtNW063v9NuI7mzuEDxSxnKup7isq88ZaFZ6+ujXF6635ljhIFvK0SSSDMcbyhfLR2GMKzAnIwORUXw48PTeF/B2n6VdzJPcwhmlaMnZvZixCA9FGcAcfSuQ1jw7rz3+uaPb6W81hq+u2mqjVPPiCQRRm3MishYSbwbchdqkfMuSMGrW2pzySTaWx6XqV/aaXYzXupXUFpZwrulmncIiD1LHgUzRNUs9b0m01PS5vPsbuNZoZdpXehGQcEAj8RVGO1v9ITULw32r66X+aKxZbRCnP3YyFi9f43PA6565Pwhs9R0v4d6JpetaZcadfafbx2skc0kT7yqjLqY3YbScgZweDwOMsR2GDnrxS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnH7Qn/JKNY+sX/oxa9Hrzj9oT/klGsfWL/0Yta0P4sfVfmTP4WfIFFFGK+sPFCilNJigAoorc07w3eX2lQ6hGMWsszw+aPmWMqufn/uknAGetROpGmrydiowc3ZGHRXS3XgjXrW4s7e4snjmudmNwISPeMort2Yj+HGRXrHgv4DSfaobrxHdq8KjJt0Qrlu3Oc8H14PpWFTG0aau5GscPOTtY5P4IeAbfxhNqN3fiOW2tQI1icMB5jch89CAAeK+pdJ0q302M+UoaZx+8lIwX/wHtS6NpNjotitnpdrFa2ysW8uNdo3E5Jx7mr9eBicQ683J7dD0aVNU42QUUUVzmgUUUUAFFFeeeM/Fuu2Oo+IV0GPTTbeHdMj1K8S7jdnui3mt5UbK6iPCQn5iG5YDHBNAHodGKjtZkubaKePPlyoHXPXBGRUlABijFFFABRiuO1y/wDFdj4isxaHRrjTbm9ihWzEMn2kwEDzZjLvCrsyTt2EEADdlgKxbHxpqkfiy8s9eu7XTbWO7uY7a0m0O6R7uGIFg0d00giZio3YCngHjuAD0uivPfBfizXb/UfD669HpotfEOmSalaJaRur2u3ym8qRmdhJlJh8wC8qRjkGvQqACiuP+Iuuazoq6P8A2LF+5ublo7u5/sq41H7NGInYN5UDKxy6quc4G6sCXxlrl/HDF4a1DQrx4dHbV5rySymWK4BdljjSPzd0X+rcMWZyCPu9qAPT6K8pvPiJq9xaajrWkxadHo2lW9lcXVvcRyPPOJ40lcJIGVU2xyLjKPk56V0vxJ8Rt4ZTw7dNex2VjNqqQ3ssgXb5HkzOwJI45RTkc8e9AHY0Vwl/8SILT7Mo8OeIZpp7KXURCkMKulvGwBdg8q7cgghT83OCA3FaPhTxraeI7/7JFp2pWMj2iX9ubxEUXFu7FRIm12I5HRtrcjjmgDqqKKKACiiigAoPSiigDz74ifDzTfEt3bapJILS9t5I2kuS5AESHJ74/Ptmvnr4y65c614hTbafYdIhLC1t/lxuJ/eP8vGWIBr7DljSaNo5VV42BVlYZDA9QRXzH+0J4BXQ7qHXdJjhh0mXbA1tGCPKk5O4D0PfHevQy+ovapTfoc+Ii3B2PGKKkS3mkjmkSJykKhpGx9wE4BP48VGa+hueY00FFFGKBHt37OfjK10u/Tw9OjGXUJSVkIwFKr8oznGMA9s5PWvpgV+fkM0ltPFcQECaFxIhP95TkfqK+5/A+pnWfCOkai8/2iS5tkkeULt3Nj5uO3Oa8HMqHJNVF1PSwtTmjyvoblFFFeYdQUUUUAFFFFABRRRQAUnFMuJo7aCSaZgkUal3Y9gBkmvmDXvGGseK7s38moXlnZOwe1s7ScxpGgJ2MSuCzEcknjnGOKwr4iFCPNM78vy6tj5uFK2m7ex9RAjtS15P8F/GGoandXeg6zcNeT28Iube6kP7ySPdtZXwMEqSvPcN7ZrtLnxLLB48sPDj6VOsV3aT3Ud+0qbGMRjBVUBLf8tRksF9t3ONKdSNSKnHZnPicPPDVZUam6OkoqtqVxNaWM09tZz30yLlbeBkV5D6AuyqPxIrh5/iKV8CeGfEMenQRtrhiVVu73ybe1Lozgyz7DtHy7QdvLMoxzVmB6DRWB4O8Q/8JB4Zi1a5tRY5aVXXzRJH+7dlLpJgb4zt3K2BlSDiue8IfET/AIS23v7nQ7fSbtI7cz2tpFq6Ney/3BLDtxCG9S5IyMgHOAD0Ciua8K69qmp6lqun61o8Wn3NgISXtrs3MMnmKTtDmNCHXA3Lt4DKckGuloAKKKKACiiigAooooAKKKKACiiigAooooAK84/aE/5JRrH1i/8ARi16PXnH7Qn/ACSjWPrF/wCjFrWh/Fj6r8yZ/Cz5Aooor6w8UBSMyjG5gCeBk4zS1YtNHvtTbNjaT3KnEbiKPe3rhff/APX2qKkuSNy4R5nYSxge4uUWOCWdVIaRIlJbbnnp7V7X4a8CX2i+N0t9E1JbmJsziCKMS/ZAcFTJuOz5hleRu44xU3wy8O3eowW9jcaP/ZpM3nxNtyyQAFXMkgwwkzjZ9fTNe96BoenaDZm20q1jt42YySbFAMjkcsx7k4rxcZjXJuC/zO+jQUVcsLY2/wBr+1tChuSAN55I47f41booryzqCiiigAooooAKKKKACuS8U+BbHxFfXNxNf6lZre2q2V/DaSIqXsCsxCSbkYj77jKFWw5Ga62sXX9Vn07VvDVrAkTR6lqD2kxcElUFrcTZXB4O6FRzngn2IANlVCqFUAKBgAcACloooAKKKKAOUfwfKPE93rdt4l1u3lujGHgVbWSMInSNTJCzqhOSQGHLE9TSx+C4W1q3v9Q1fV9SitbiW6tbK7kjaGCSQMpK4QO2Fd1UOzBQeO1dVWLaarPN401XSGSIW1pp9ndowB3l5ZLlWBOcYAgTHHc9eMAGZ4W8C2Ph2+trmG/1K8FnatY2EN3IjJZQFlJjj2opI+RBlyzYQDNdbRRQBj+IdFm1b7M1trWq6TLAW+ewaP5wwwQyyI6n2OMjsa5+6+G2mtY2trYalq2miKyfT5ZLWWMvcwu25hIXRuSxZty7WBZsEZruKKAOM1H4d6XeXLGO81GzsJUt47rT7eRPIuVgI8sPuQuOAFOxlyAAc1r+LPC+meKrext9ZiM9taXQuhCQpSVgjptcMDlcOeOOQOa3KxfBGqz694L0DV7xIkudQ0+3u5ViBCB5I1YhQSTjJOMk0AZen+A7GzdGOoapcmPT5tLj+0Sq5S3kdW27tuSV2gKWJOOu481f0fwtZaTf2N3by3LSWemppUYkZSDEhBDHAHzcdentW/RQAUUUUAFFFFABRRRQAVR1rTLTWdKutP1CIS2tzGYpFPoR296vUUAfOXxb8IS6F4GtdEsZbjU5YLtZoXaLbIkDfJsd+jfMVA788+teIala/YbyS1Z980J2y4GAr91HrjpmvuzVtIsdWWFdQgWZYX3ordM4xz6j/wCtXy3+0J4Xt/Dniy0nsI/Ls76DcECgKrrw3I6k5ya9fLsTeXspdbs48TS05keXUlFFe0eeHUYr7F+At2938K9EMiKvlK8K7e4VyAfrXx1X1d+zOJx8NQZxIEN5MYt/TZx932zn9a8zNV+6T8/8zrwb95nrFFFFeCeiFFFFABRRRQAUUUUANdVdSrqGUjBBGQRXz54h+Fuv6RfvF4ftF1TS2fMBM6xywgknY4bAIX+8D0xxX0LRWVajCtHlmjrweOrYKftKLs2edfCjwNc+GVutS1h4jq14ixGKFt0cEakkKGwCSSck8dAMcVs6v4c1e98daRr1vq1hDa6fFLALSTT3kd0lMRl/eCYAN+6G07MDJyGrrKKuEFCKjHZGNatOvUdWo7ye5iR+HbLTF1CfwxYaRpWqXnzSXS2CkSNnOZAhRn6n+IcnNclpvw81Sx8LeG9MGv2Ul54fk/0OZtMYwyR+UY9s0JmJZsMx3K64yOOufSKKoyON8N+DbvRdOsbBdZV7ASXct/bJZqkdyZyWCxjJMKIzEhQTkcE96ytL+Huq6eliIvEkAk0jTpdO0iVNMAeBXCgPNmQiYqEXAAQE5JBPT0eigDnPBuj6xotp9l1XU9Pv4VUbGt7GSCVnzlnkd55N5PU9Oa6OiigAooooAKKKKACiiigAooooAKKKKACiiigArzj9oT/klGsfWL/0Ytej15x+0J/ySjWPrF/6MWtaH8WPqvzJn8LPkCiijpX1h4ooBJ4BJ9BXS/Du61Kx8UWV3pSzloy7FoscKF+Zvm+UkA/rXOwSGGeOVRlkYMBkjke45r234V31h4gv2a30WPT4bWeOS5ZH3ieeZlQKq/wJgMTjr0NcmMqOFN+7dWOjDxUpLXU918G2dxHpq32pqP7TvFEkx2gFRjheOPc47k10FIBjpS18yeoFFFFABRRRQAUUUUAFFFFABWV4h0Cw8QQ2sepLc/6LN9ogktruW2kjk2MmQ8TK33XcYzghjWrRQByv/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP11VFAHK/8IHpH/P54k/8ACj1H/wCP0f8ACB6R/wA/niT/AMKPUf8A4/XVUUAcr/wgekf8/niT/wAKPUf/AI/UK/DrQVu5LpZfEAuZEWN5R4h1AOyKWKqT5+SAXcgdtx9TXYUUAcr/AMIHpH/P54k/8KPUf/j9H/CB6R/z+eJP/Cj1H/4/XVUUAcr/AMIHpH/P54k/8KPUf/j9H/CB6R/z+eJP/Cj1H/4/XVUUAcr/AMIHpH/P54k/8KPUf/j9b+k6fa6RpVlpunxeTZWcKW8Ee4tsjRQqjJJJwAOSSat0UAFFFFABRRRQAUUUUAFFFFABRRRQAVyHxI8DWXjrSIrK9ma2eGTzIp40VnU4wRz2P9BXX0VUZOD5o7iaTVmeBeKfgDpVtpNzd6Tq97DJbwNIUnVZVcqMnpgjgdBXzuyspKupVhwQeMV+gp6V8tfFnwTpTeMtY/sXU47bVCVuG0y6Gzzt653QMSd5LcbexNergca7uNV3OTEUE1eCPHXJCMR1AzX238KtMttI+Huh21kS0bWyzFic5ZxuY/mTXy/4W+GfiPVWkurrSprexsz5lzFchopZEA3FUGMkkZAI719S/DnSF0Xwvb28STwwuTLFBMxLQRtyqH0IHXHfNGZ1oTUYxd7Bhaco3ckdPRRRXkHYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwPxzsLzUvhnqtrp1rcXdy5j2wwRmR2w4Jwo5Nd9RVQlySUuwpK6sfDX/AAhHiv8A6FnXP/ACX/4mj/hCfFf/AELGuf8AgBL/APE19y0V6f8Aas/5Ucn1OPc+Gv8AhCPFf/Qsa5/4AS//ABNep/BjS/E2l2Gr2kmhX1iySw3/AJ1zZuhuERhvgUkZJIAIA719JUVlXzCVaDg4l08MqcuZMbG25FbBG4ZwwwR9adRRXnnSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVRm0nT5r9b2axtZLxRtE7QqXA9N2M9hV6igCC7tku7cwzZMbEbgDjIBzj6VOKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Predicted and observed density of infected host-seeking",
"    <em>",
"     Ixodes scapularis",
"    </em>",
"    nymphs (DIN)/1000 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Diuk-Wasser MA, Gatewood Hoen A, Cislo P, et al. Human Risk of Infection with Borrelia burgdorferi, the Lyme Disease Agent, in Eastern United States. Am J Trop Med Hyg 2012; 86:320. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13959=[""].join("\n");
var outline_f13_40_13959=null;
var title_f13_40_13960="Sickle cell trait";
var content_f13_40_13960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sickle cell trait",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13960/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13960/contributors\">",
"     Elliott P Vichinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13960/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13960/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/40/13960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H662841\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell trait (Hb AS) is a benign carrier condition, usually with none of the symptoms of sickle cell anemia. It is generally only a laboratory diagnosis in which one sickle cell beta-globin gene has been inherited along with a normal beta-globin gene (ie,",
"    <span class=\"nowrap\">",
"     alpha2/betaS1beta1).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    diagnosis, differential diagnosis, and complications of sickle cell trait will be discussed here. Homozygous sickle cell disease and the variant sickle cell syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for sickle cell anemia is widespread throughout the world, being present in Africa, Mediterranean countries (especially Greece), the Middle East, and parts of India.",
"   </p>",
"   <p>",
"    The prevalence of sickle cell trait is approximately 8 to 10 percent in African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and as high as 25 to 30 percent in certain areas of western Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/3\">",
"     3",
"    </a>",
"    ]. The Hispanic population is also at risk for sickle cell disease. At least 1 in 180 Hispanic births have sickle cell trait.",
"   </p>",
"   <p>",
"    There are approximately 2.5 million people in the United States and 300 million in the world who are heterozygous for the sickle cell gene. The presence of sickle cell trait appears to be protective against severe falciparum malaria, explaining the persistence of this gene in the world population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link&amp;anchor=H4#H4\">",
"     \"Protection against malaria in the hemoglobinopathies\", section on 'Falciparum malaria and hemoglobin S'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link&amp;anchor=H5#H5\">",
"     \"Protection against malaria in the hemoglobinopathies\", section on 'Sickle cell trait'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618142\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell trait is not a disease, and it does not alter the life expectancy of the 300 million people worldwide who are heterozygous for the sickle gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, these individuals are at risk for certain complications under specific circumstances. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin levels, red cell morphology, red cell indices, and the reticulocyte count are entirely normal in those with sickle cell trait, and irreversibly sickled cells (ISCs) are not found on the peripheral blood smear [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/7\">",
"     7",
"    </a>",
"    ]. The diagnosis of sickle cell trait, as distinguished from sickle cell disease, is made exclusively via hemoglobin electrophoresis or high pressure liquid chromatography techniques (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"UTD.htm?8/51/9023\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"UTD.htm?17/56/18316\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Sickle cell screening tests cannot differentiate carrier states from diseases. The sickle cell prep test is not recommended. In this test, the presence of Hb S is detected by adding sodium metabisulphite to a drop of blood and looking for sickle forms in a microscope. This screening test has been replaced by the sickle solubility test, which is sensitive in detecting Hb S levels as low as 8 to 20 percent. It is not utilized below six months of age because of the low Hb S levels. The sickle solubility test requires confirmation by electrophoresis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is reasonable to screen adults for the presence of sickle cell",
"    <strong>",
"     trait",
"    </strong>",
"    under the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For antenatal counseling of couples at risk for having a child with sickle cell disease.",
"     </li>",
"     <li>",
"      For screening of competitive athletes prior to the beginning of conditioning training in order to review and reinforce hydration, heat, and conditioning recommendations needed to prevent rhabdomyolysis and metabolic complications.",
"     </li>",
"     <li>",
"      For evaluation of adolescents and adults with otherwise unexplained episodes of hematuria, priapism, enuresis, thrombotic events, or unexplained hyphemas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Newborn testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn screening programs for hemoglobinopathies utilize techniques that detect sickle cell trait. However, the reporting of the results to families and providers is highly variable. Presently, many carriers are unaware of their newborn screening results. &nbsp;",
"   </p>",
"   <p>",
"    The newborn with sickle cell trait will have Hb F, Hb A, and Hb S, the FAS pattern on hemoglobin electrophoresis. The quantity of Hb A is greater than that of Hb S. If the quantity of Hb S exceeds that of Hb A, the FSA pattern, the presumptive diagnosis is sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia (",
"    <a class=\"graphic graphic_table graphicRef51810 \" href=\"UTD.htm?10/51/11069\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It may not be possible to distinguish FAS and FSA patterns in newborns; thus, DNA-based testing or repeat hemoglobin testing at age three to six months is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of sickle cell syndromes\", section on 'FAS and FSA patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Older children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;On hemoglobin electrophoresis, the usual partition of Hb A and Hb S in sickle cell trait is 60:40 because of a greater post-translational affinity of alpha-globin chains for beta A- than for beta S-globin chains (",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"UTD.htm?17/56/18316\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"UTD.htm?8/51/9023\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link&amp;anchor=H4#H4\">",
"     \"Introduction to hemoglobin mutations\", section on 'Assembly of the mutant hemoglobin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=see_link&amp;anchor=H2640293#H2640293\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\", section on 'Surface charge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Coinheritance of alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When alpha thalassemia is co-inherited with sickle cell trait, the above-noted preferential affinity of alpha-globin chains for beta A-globin chains results in a decreased percentage of hemoglobin S relative to how many of the four alpha globin genes have been deleted (",
"    <a class=\"graphic graphic_table graphicRef70184 \" href=\"UTD.htm?16/17/16667\">",
"     table 3",
"    </a>",
"    ), (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=see_link&amp;anchor=H2640329#H2640329\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\", section on 'Concomitant alpha thalassemia'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Four alpha genes present",
"      <span class=\"nowrap\">",
"       (aa/aa)",
"      </span>",
"      &mdash; 40 percent Hb S",
"     </li>",
"     <li>",
"      Three alpha genes present",
"      <span class=\"nowrap\">",
"       (-a/aa)",
"      </span>",
"      &mdash; 35 percent Hb S",
"     </li>",
"     <li>",
"      Two alpha genes present",
"      <span class=\"nowrap\">",
"       (-a/-a",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       aa/--)",
"      </span>",
"      &mdash; 29 percent Hb S",
"     </li>",
"     <li>",
"      One alpha gene present",
"      <span class=\"nowrap\">",
"       (--/-a)",
"      </span>",
"      &mdash; 21 percent Hb S",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the number of inherited alpha genes decreases in subjects with sickle cell trait, there is also a progressive fall in hemoglobin concentration and mean corpuscular volume (",
"    <a class=\"graphic graphic_table graphicRef70184 \" href=\"UTD.htm?16/17/16667\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In symptomatic individuals who &ldquo;appear&rdquo; to have sickle cell trait, the laboratory diagnosis must be verified. Hemoglobins other than S that polymerize may account for reports of sickle cell trait associated with clinical problems. Examples include patients with heterozygous Hb S-Antilles (which has a lower solubility than Hb S) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/11\">",
"     11",
"    </a>",
"    ] or those with compound heterozygosity for Hb S and Hb Quebec-Chori [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/12\">",
"     12",
"    </a>",
"    ]. In the latter disorder, the hemoglobin variant can be distinguished from Hb A using high pressure liquid chromatography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=see_link&amp;anchor=H11822099#H11822099\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\", section on 'High performance liquid chromatography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare cause of symptomatic sickle cell trait occurs when sickle cell trait coexists with pyruvate kinase deficiency. Pyruvate kinase deficiency lowers the hemoglobin oxygen affinity, resulting in hemoglobin S polymerization and sickling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEWBORN SCREENING AND COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn screening programs detect a large number of infants with sickle cell trait and genetic counseling is essential for the parents. The parents should understand the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Their child has a benign hereditary condition and not a disease.",
"     </li>",
"     <li>",
"      There is a rare risk for sudden death in athletes with sickle cell trait following",
"      <strong>",
"       prolonged",
"      </strong>",
"      physical conditioning and exercise (eg, military boot camp, training for athletic competition). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Risk for sudden death and athletic participation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There is a 25 percent risk for a subsequent child to be born with sickle cell",
"      <strong>",
"       disease",
"      </strong>",
"      if both parents are carriers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic screening is not benign and carries psychological, insurance, employment, and discrimination risks. In addition, there is a high prevalence of misleading information communicated during genetic counseling sessions for sickle cell trait and other carrier conditions by clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In order to avoid this, clinicians need to be aware of the inherent difficulties in communicating and comprehending genetic information. The reproductive implications of sickle cell trait, as well as the risk of other family members having this condition are important issues for discussion.",
"   </p>",
"   <p>",
"    Counseling considering athletic issues is discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prevention of adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While sickle cell trait is not a disease, individuals are at risk for certain complications under specific circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/7,17-19\">",
"     7,17-19",
"    </a>",
"    ]. None of these alter the life expectancy of individuals with sickle cell trait.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes of hematuria are common, as is impaired urinary concentrating ability, which tends to be less severe and occur later than in SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. These complications are directly related to the intraerythrocytic concentration of Hb S, which is in part determined by the percentage of Hb S [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Thus, for patients with concurrent alpha thalassemia, the concentrating defect is related to the number of alpha globin genes inherited [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H6#H6\">",
"       \"Renal manifestations of sickle cell disease\", section on 'Renal manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal medullary carcinoma is a rare and aggressive tumor that is seen almost exclusively in young patients with sickle cell trait. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H14#H14\">",
"       \"Renal manifestations of sickle cell disease\", section on 'Renal medullary carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is some evidence that black patients with sickle cell trait and autosomal dominant polycystic kidney disease develop end-stage renal disease earlier than those without sickle hemoglobin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The frequency of urinary tract infection may be increased [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous studies have suggested that pregnancy complications (ie, preeclampsia) may be more common in sickle cell trait. However, the data remain conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/27\">",
"     27",
"    </a>",
"    ]. Pregnancy in a woman with sickle cell trait does not appear to be a risk factor for either small or large for gestational age infants [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20458?source=see_link\">",
"     \"Pregnancy in women with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic infarction can develop at high altitude, including mountain climbing and flying in unpressurized airplanes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. This complication occurs more commonly in Caucasians than in those of African ancestry [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic infarction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of venous thromboembolism among African-Americans with sickle cell trait appears to be two to four times that of African-Americans without this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Splenic sequestration crisis, pain crisis, and sudden death have been described in subjects with sickle cell trait, but are very rare and most often due to other concomitant medical problems. These complications can happen under extreme conditions, such as high altitude, increased pressure (ie, SCUBA diving), low oxygen, severe prolonged exercise, or dehydration.",
"     </li>",
"     <li>",
"      Priapism has been described in patients with sickle cell trait. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=see_link&amp;anchor=H10#H10\">",
"       \"Diagnosis and management of priapism in sickle cell disease\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risk for sudden death and athletic participation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine fitness training does not increase the risk of mortality for individuals with sickle cell disease, and overall it appears that sickle cell trait has limited if any effect on the physiologic response to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/17,26,33-39\">",
"     17,26,33-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is concern about an increased risk for sudden death during prolonged physical conditioning and extreme exercise in subjects with sickle cell trait, presumably in association with intense physical activity, heat exposure, dehydration, rhabdomyolysis, myocardial ischemia, and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=see_link&amp;anchor=H31734801#H31734801\">",
"     \"Causes of rhabdomyolysis\", section on 'Nontraumatic exertional rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This relationship was illustrated in a study of enlisted recruits undergoing basic training; the unexplained death rates (per 100,000) were 32.2 among black recruits with hemoglobin S as compared with 1.2 among black recruits without hemoglobin S and 0.7 in nonblack recruits without hemoglobin S [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/40\">",
"     40",
"    </a>",
"    ]. After the United States Armed Services implemented screening for sickle cell trait in 1982, the incidence of exercise-related deaths decreased dramatically and none occurred in the Services during the following 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/43,45\">",
"     43,45",
"    </a>",
"    ]. A general reduction in training intensity and earlier recognition of heat-related injuries may have contributed to this decline in deaths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H27#H27\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Sickle cell trait'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of sudden nontraumatic death among young athletes with sickle cell trait is intensely debated. Many of the deaths in young athletes with sickle cell trait are reported in the form of case reports with an assumed causal relationship; careful epidemiologic studies are limited. Despite these limitations, there are growing concerns about the association of sickle cell trait with exertional heat illness and rhabdomyolysis. As an example, in a report of 160 nontraumatic deaths in high school and college athletic activities between 1983 and 1993, cardiovascular conditions accounted for a majority of the deaths. Seven deaths were attributed to rhabdomyolysis and sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, of 10 Division I football players with sickle cell trait who died during the early 2000s, half had been performing serial sprints or drills without interval rest periods at the time of sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prevention of adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above observations indicate the need for raising awareness of the potential relationship between sudden death and sickle cell trait, to increase the number of scientific studies evaluating this association, and to provide measures to reduce this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/43,48\">",
"     43,48",
"    </a>",
"    ]. Anticipatory interventions to prevent dehydration and hyperthermia need to be enforced and expanded for all athletes, not only those with sickle cell trait, particularly at the onset of conditioning training. Dietary stimulants, use of which may not be disclosed, can exacerbate hyperthermia and dehydration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=see_link&amp;anchor=H16909000#H16909000\">",
"     \"Non-hormonal performance enhancement\", section on 'Stimulants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As compared with individuals without sickle cell trait, those with sickle cell trait may be slower to acclimate to high altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H4#H4\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'Acclimatization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are ongoing discussions by different professional groups whether all athletes should be screened for sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/44,49\">",
"     44,49",
"    </a>",
"    ]. However, in the United States, the National Collegiate Athletic Association (NCAA) has approved",
"    <strong>",
"     mandatory",
"    </strong>",
"    testing or confirmation from newborn screening for sickle cell trait, with a written opt-out provision, for all student athletes participating in Division I and II sports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/50\">",
"     50",
"    </a>",
"    ]. If screening has been done, the sports counseling component by the clinician and trainer should be detailed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/44,49\">",
"     44,49",
"    </a>",
"    ]. Each branch of the US military has its own policies on screening and activity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations and protocols by the National Athletic Trainers' Association (NATA), the American College of Sports Medicine, and NCAA are detailed and useful guidelines for counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Newborn screening and counseling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some sports and medical experts recommend a modified exercise program be instituted for all individuals with sickle cell trait.",
"     </li>",
"     <li>",
"      The athlete with sickle cell trait should build up slowly in training, tempo of drills should be slowed, and longer periods of rest given. The athlete should run no timed serial sprints or miles and should avoid lengthy, sustained sprints or any all-out exertion beyond 2 to 3 minutes without a rest.",
"      <span class=\"nowrap\">",
"       Work/rest",
"      </span>",
"      cycles should be adjusted for heat and altitude. The athlete should stay vigorously hydrated, and any asthma must be controlled.",
"     </li>",
"     <li>",
"      If any athlete with sickle cell trait begins to struggle in any drill, the drill should be stopped and medical attention should be prompt. The athlete should lie down, vital signs should be checked, supplemental oxygen given by face mask, and the athlete cooled if necessary.",
"     </li>",
"     <li>",
"      Failing immediate improvement, 911 should be called, an automated external defibrillator placed, and an intravenous line with normal saline solution started. The athlete should be moved to a hospital urgently, and the emergency department told to expect fulminant rhabdomyolysis and its grave metabolic complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11594?source=see_link\">",
"       \"Exertional heat illness in adolescents and adults: Management and prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link&amp;anchor=H25619306#H25619306\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Society of Hematology (ASH) opposes mandatory screening of athletes as a prerequisite to athletic participation. Instead, it has urged athletics programs to adopt universal interventions to reduce exertion-related injuries and deaths, since this approach can be effective for all athletes irrespective of their sickle cell status [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/53\">",
"     53",
"    </a>",
"    ]. Similar policies have been developed by other professional organizations, including the American Society of Pediatric",
"    <span class=\"nowrap\">",
"     Hematology/Oncology",
"    </span>",
"    (",
"    <a class=\"external\" href=\"file://www.aspho.org/\">",
"     www.aspho.org",
"    </a>",
"    ), which opposes mandatory sickle cell trait screening for sports. The Sickle Cell Disease Association of America (",
"    <a class=\"external\" href=\"file://www.sicklecelldisease.org/\">",
"     www.sicklecelldisease.org",
"    </a>",
"    ), the major advocacy organization for sickle cell disease, also supports a voluntary policy.",
"   </p>",
"   <p>",
"    <br/>",
"    The legal ramifications of this controversy are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7649235\">",
"    <span class=\"h2\">",
"     Symptoms of sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very rarely, individuals with sickle cell trait show symptoms of sickle cell disease. A number of circumstances may explain this situation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Such cases are most commonly seen in variants in which the B6Glu Val substitution is one of two substitutions that are capable of producing sickle cell disease in heterozygotes. These heterozygote variants include Hb S-Antilles, Hb S-Oman, and Hb Jamaica Plain [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare cases of sickle cell disease in patients who are reported to have sickle cell trait may be, in reality, compound heterozygotes for hemoglobin S and an electrophoretically silent hemoglobin A variant, ie, hemoglobin S-Quebec Chori.",
"     </li>",
"     <li>",
"      In a unique case, a 14-year-old boy was found to have symptomatic disease secondary to conversion of inherited sickle cell trait to sickle cell disease by virtue of postzygotic uniparental disomy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/55\">",
"       55",
"      </a>",
"      ]. This resulted in mosaicism for SS (92 percent) and AS (8 percent) in his erythroid (BFUE) colonies as well as in his circulating red cells (31 and 69 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In anemic, symptomatic trait individuals, extensive evaluation for such rare events is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BLOOD DONATION ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While those with sickle cell trait are fully suitable as blood donors, there are two issues that need to be taken into consideration:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Donating blood for exchange transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with sickle cell trait who have 40 percent hemoglobin S cannot serve as blood donors for subjects with sickle cell anemia who are undergoing exchange transfusion to reduce their percent of hemoglobin S to less than 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the management of sickle cell disease\", section on 'Prophylactic preoperative transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bone marrow donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Those with sickle cell trait, if otherwise eligible, can serve as donors for a matched, related allogeneic hematopoietic cell transplantation for a sibling with homozygous sickle cell disease. If fully successful, this would transform the sibling from symptomatic sickle cell disease to an asymptomatic carrier state (ie, sickle cell trait). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link&amp;anchor=H3#H3\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\", section on 'Siblings as donors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Leukoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult to leukoreduce blood from donors with sickle cell trait, due to blockage of the filters used in this process. Blood centers that are 100 percent leukoreduced will generally contact and defer African-American donors whose blood is difficult to filter after the second failed attempt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H18#H18\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Donors with sickle cell trait'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention has a website which provides additional information concerning sickle cell trait and sickle cell disease. It is available at:",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncbddd/sicklecell/index.html\">",
"     www.cdc.gov/ncbddd/sicklecell/index.html",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13960/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sickle cell trait (Hb AS) is a benign carrier condition (ie, it is a laboratory diagnosis rather than a clinical diagnosis) in which one sickle cell beta-globin gene has been inherited along with a normal beta-globin gene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link&amp;anchor=H9#H9\">",
"       \"Introduction to hemoglobin mutations\", section on 'Hemoglobin S'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence and significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complete blood count is entirely normal in a subject with sickle cell trait. The diagnosis is made on hemoglobin electrophoresis or high pressure liquid chromatography, which shows approximately 60 percent hemoglobin A and 40 percent hemoglobin S (",
"      <a class=\"graphic graphic_table graphicRef64715 \" href=\"UTD.htm?17/56/18316\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"UTD.htm?8/51/9023\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with sickle cell trait do not have an increased mortality rate compared with the general population. However, there are a number of complications associated with the presence of sickle cell trait. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Episodes of hematuria are common, as is impaired urinary concentrating ability. The frequency of urinary tract infection may be increased.",
"     </li>",
"     <li>",
"      Renal medullary carcinoma is a rare and aggressive tumor that is seen almost exclusively in young patients with sickle cell trait. The presence of gross hematuria should prompt evaluation for this malignancy, especially when accompanied by flank pain, abdominal mass,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H14#H14\">",
"       \"Renal manifestations of sickle cell disease\", section on 'Renal medullary carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals with sickle cell trait may be at greater risk of thrombotic events, especially under extreme conditions (eg, high altitude, scuba diving). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is concern about an increased risk for sudden death during prolonged physical conditioning and extreme exercise in subjects with sickle cell trait, presumably in association with intense physical activity, heat exposure, dehydration, rhabdomyolysis, myocardial ischemia, and arrhythmias. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Risk for sudden death and athletic participation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/1\">",
"      Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med 1973; 288:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/2\">",
"      Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/3\">",
"      Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Rev 1989; 3:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/4\">",
"      Bunn HF. The triumph of good over evil: protection by the sickle gene against malaria. Blood 2013; 121:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/5\">",
"      Ashcroft MT, Desai P. Mortality and morbidity in Jamaican adults with sickle-cell trait and with normal haemoglobin followed up for twelve years. Lancet 1976; 2:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/6\">",
"      Castro O, Rana SR, Bang KM, Scott RB. Age and prevalence of sickle-cell trait in a large ambulatory population. Genet Epidemiol 1987; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/7\">",
"      Sears DA. The morbidity of sickle cell trait: a review of the literature. Am J Med 1978; 64:1021.",
"     </a>",
"    </li>",
"    <li>",
"     Bain BJ. Laboratory techniques for the identification of abnormalities of globin chain synthesis. In: Haemoglobinopathy Diagnosis, 2nd ed, Blackwell, Malden 2006. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/9\">",
"      Bunn HF. Subunit assembly of hemoglobin: an important determinant of hematologic phenotype. Blood 1987; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/10\">",
"      Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood 1986; 68:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/11\">",
"      Monplaisir N, Merault G, Poyart C, et al. Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes. Proc Natl Acad Sci U S A 1986; 83:9363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/12\">",
"      Witkowska HE, Lubin BH, Beuzard Y, et al. Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. N Engl J Med 1991; 325:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/13\">",
"      Cohen-Solal M, Pr&eacute;hu C, Wajcman H, et al. A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry). Br J Haematol 1998; 103:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/14\">",
"      La Pean A, Farrell MH. Initially misleading communication of carrier results after newborn genetic screening. Pediatrics 2005; 116:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/15\">",
"      Farrell MH, Kuruvilla P. Assessment of parental understanding by pediatric residents during counseling after newborn genetic screening. Arch Pediatr Adolesc Med 2008; 162:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/16\">",
"      Rosas-Blum E, Shirsat P, Leiner M. Communicating genetic information: a difficult challenge for future pediatricians. BMC Med Educ 2007; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/17\">",
"      Heller P. Risk in sickle-cell trait. Ann Intern Med 1973; 78:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/18\">",
"      Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am J Med 2009; 122:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/19\">",
"      Goldsmith JC, Bonham VL, Joiner CH, et al. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol 2012; 87:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/20\">",
"      Atkinson DW. Sickling and hematuria. Blood 1969; 34:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/21\">",
"      Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int 2000; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/22\">",
"      Reeves JD, Lubin BH, Embury SH. Renal complications of sickle cell trait are related to the percent of Hb S. Blood 1984; 64(Suppl 1):52A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/23\">",
"      Ahmed SG, Ibrahim UA. Haemoglobin-S in sickle cell trait with papillary necrosis. Br J Haematol 2006; 135:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/24\">",
"      Gupta AK, Kirchner KA, Nicholson R, et al. Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest 1991; 88:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/25\">",
"      Ashcroft MT, Miall WE, Milner PF. A comparison between the characteristics of Jamaican adults with normal hemoglobin and those with sickle cell trait. Am J Epidemiol 1969; 90:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/26\">",
"      Tuck SM, Studd JW, White JM. Pregnancy in sickle cell disease in the UK. Br J Obstet Gynaecol 1983; 90:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/27\">",
"      Tita AT, Biggio JR, Chapman V, et al. Perinatal and maternal outcomes in women with sickle or hemoglobin C trait. Obstet Gynecol 2007; 110:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/28\">",
"      Tan TL, Seed P, Oteng-Ntim E. Birthweights in sickle cell trait pregnancies. BJOG 2008; 115:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/29\">",
"      Lane PA, Githens JH. Splenic syndrome at mountain altitudes in sickle cell trait. Its occurrence in nonblack persons. JAMA 1985; 253:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/30\">",
"      Franklin QJ, Compeggie M. Splenic syndrome in sickle cell trait: four case presentations and a review of the literature. Mil Med 1999; 164:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/31\">",
"      Castro O, Finch SC. Letter: Splenic infarction in sickle-cell trait: are whites more susceptible? N Engl J Med 1974; 291:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/32\">",
"      Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007; 110:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/33\">",
"      Bile A, Le Gallais D, Mercier B, et al. Blood lactate concentrations during incremental exercise in subjects with sickle cell trait. Med Sci Sports Exerc 1998; 30:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/34\">",
"      Pearl W, Zeballos RJ, Gregory G, Weisman IM. ECG in sickle cell trait at rest and during exercise and hypoxia. J Electrocardiol 1994; 27:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/35\">",
"      Sara F, Hardy-Dessources MD, Voltaire B, et al. Lactic response in sickle cell trait carriers in comparison with subjects with normal hemoglobin. Clin J Sport Med 2003; 13:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/36\">",
"      Weisman IM, Zeballos RJ, Johnson BD. Cardiopulmonary and gas exchange responses to acute strenuous exercise at 1,270 meters in sickle cell trait. Am J Med 1988; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/37\">",
"      Weisman IM, Zeballos RJ, Johnson BD. Effect of moderate inspiratory hypoxia on exercise performance in sickle cell trait. Am J Med 1988; 84:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/38\">",
"      Weisman IM, Zeballos RJ, Martin TW, Johnson BD. Effect of Army basic training in sickle-cell trait. Arch Intern Med 1988; 148:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/39\">",
"      Stark AD, Janerich DT, Jereb SK. The incidence and causes of death in a follow-up study of individuals with haemoglobin AS and AA. Int J Epidemiol 1980; 9:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/40\">",
"      Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987; 317:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/41\">",
"      Sherry P. Sickle cell trait and rhabdomyolysis: case report and review of the literature. Mil Med 1990; 155:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/42\">",
"      Rosenthal MA, Parker DJ. Collapse of a young athlete. Ann Emerg Med 1992; 21:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/43\">",
"      Sanchez CE, Jordan KM. Exertional sickness. Am J Med 2010; 123:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/44\">",
"      Anzalone ML, Green VS, Buja M, et al. Sickle cell trait and fatal rhabdomyolysis in football training: a case study. Med Sci Sports Exerc 2010; 42:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/45\">",
"      Mitchell BL. Sickle cell trait and sudden death--bringing it home. J Natl Med Assoc 2007; 99:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/46\">",
"      Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc 1995; 27:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/47\">",
"      O'Connor FG, Bergeron MF, Cantrell J, et al. ACSM and CHAMP summit on sickle cell trait: mitigating risks for warfighters and athletes. Med Sci Sports Exerc 2012; 44:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/48\">",
"      Scheinin L, Wetli CV. Sudden death and sickle cell trait: medicolegal considerations and implications. Am J Forensic Med Pathol 2009; 30:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/49\">",
"      Eichner ER. Sickle cell trait. J Sport Rehabil 2007; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ncaa.org/wps/wcm/connect/public/NCAA/Health+and+Safety/Sickle+Cell/Sickle+Cell+Landing+Page (Accessed on November 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/51\">",
"      Casa DJ, Armstrong LE, Hillman SK, et al. National athletic trainers' association position statement: fluid replacement for athletes. J Athl Train 2000; 35:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/52\">",
"      American College of Sports Medicine, Sawka MN, Burke LM, et al. American College of Sports Medicine position stand. Exercise and fluid replacement. Med Sci Sports Exerc 2007; 39:377.",
"     </a>",
"    </li>",
"    <li>",
"     ASH Statement on Screening for Sickle Cell Trait and Athletic Participation: file://www.hematology.org/Advocacy/Policy-Statements/7704.aspx (Accessed on January 26, 2012).",
"    </li>",
"    <li>",
"     Bain BJ. Sickle cell haemoglobin and its interactions with other variant haemoglobins and with the thalassaemias. In: Haemoglobinopathy Diagnosis, 2nd ed, Blackwell, Malden, MA 2006. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13960/abstract/55\">",
"      Swensen JJ, Agarwal AM, Esquilin JM, et al. Sickle cell disease resulting from uniparental disomy in a child who inherited sickle cell trait. Blood 2010; 116:2822.",
"     </a>",
"    </li>",
"    <li>",
"     www.aamds.org/aplastic (Accessed on July 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7145 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13960=[""].join("\n");
var outline_f13_40_13960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662841\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H618142\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Newborn testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Older children and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Coinheritance of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEWBORN SCREENING AND COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risk for sudden death and athletic participation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prevention of adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7649235\">",
"      Symptoms of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BLOOD DONATION ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Donating blood for exchange transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bone marrow donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Leukoreduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7145\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7145|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/51/9023\" title=\"diagnostic image 1\">",
"      Hemoglobin electrophoresis at alkaline pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7145|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/56/18316\" title=\"table 1\">",
"      Hgb electrophoresis patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/51/11069\" title=\"table 2\">",
"      Sickle cell diagnostic test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/17/16667\" title=\"table 3\">",
"      Sickle trait alpha thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=related_link\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=related_link\">",
"      Diagnosis and management of priapism in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11594?source=related_link\">",
"      Exertional heat illness in adolescents and adults: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=related_link\">",
"      Laboratory diagnosis of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=related_link\">",
"      Non-hormonal performance enhancement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20458?source=related_link\">",
"      Pregnancy in women with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13961="Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis";
var content_f13_40_13961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13961/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13961/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13961/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13961/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/40/13961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium is an intracellular protozoan parasite that is associated with gastrointestinal diseases in all classes of vertebrates including mammals, reptiles, birds, and fish. Along with Giardia, it is among the most common parasitic enteric pathogens in humans. The organisms infect and reproduce in the epithelial cells of the digestive or respiratory tracts. Infection is predominantly associated with diarrhea and biliary tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, clinical manifestations and diagnosis of cryptosporidiosis. The treatment and prevention of cryptosporidial disease are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1670?source=see_link\">",
"     \"Treatment and prevention of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465130\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last few years molecular methods have enabled characterization and identification of species and genotypes within Cryptosporidium isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/2\">",
"     2",
"    </a>",
"    ]. There are about 20 species of Cryptosporidium, including species that infect mammals, birds, reptiles and fish [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/3\">",
"     3",
"    </a>",
"    ]. C. parvum (4 mcm diameter) is the main species responsible for clinical disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/4\">",
"     4",
"    </a>",
"    ]. C. parvum has been divided into two separate species: C. hominis (previously C. parvum genotype 1) and C. parvum (previously C. parvum genotype 2). C. hominis apparently infects mainly humans, while C. parvum is frequently found in a number of other animals as well as in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The host range for many species seems to be quite variable, and C. felis, C. muris, C. canis, C. suis, and C. meleagridis have also been identified in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/1,3,7\">",
"     1,3,7",
"    </a>",
"    ]. Additional heterogeneity within species may lead to variations in infectivity and clinical expression in different hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium was first identified as a cause of gastrointestinal disease in humans in 1976, and is now recognized globally as an important cause of diarrhea in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/10\">",
"     10",
"    </a>",
"    ]. Cryptosporidium species have been identified in every continent except Antarctica [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryptosporidium has been described as the etiologic agent in three main epidemiologic scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sporadic, often water-related outbreaks of self-limited diarrhea in immunocompetent hosts",
"     </li>",
"     <li>",
"      Chronic, life-threatening illness in immunocompromised patients, particularly those with HIV infection",
"     </li>",
"     <li>",
"      Diarrhea and malnutrition in young children in developing countries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged disease is increased in patients with cellular and humoral immune deficiencies, including HIV, organ transplantation, immunosuppressive drugs, IgA deficiency, and hypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the number of cases of cryptosporidiosis has been declining among HIV patients, largely because of immune reconstitution with highly active antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryptosporidium infection is more common in countries that have increased crowding and poor sanitary conditions. In endemic areas, the incidence increases during rainy periods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It is also more frequent in children less than two years old, although outbreaks occur worldwide in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The prevalence is increased in dairy farmers, which is probably because C. parvum causes diarrhea in cattle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, cryptosporidiosis incidence remained relatively stable from 2008 to 2010, following a greater than threefold increase from 2004 to 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;Whether this is due to changing epidemiology or increased availability and application of diagnostic assays is unclear. Although cryptosporidiosis affects persons in all age groups, cases are most frequently reported in children aged one to nine years in the United States. Cryptosporidium is present in 1 to 3 percent of immunocompetent patients with diarrhea in industrialized countries and 7 to 10 percent in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Seroprevalence rates are higher, being approximately 25 to 60 percent in the United States and 65 to 95 percent in some developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population-based laboratory surveillance data from Canada have shown Cryptosporidium sp infection to occur at an overall rate of 6.0 per 100,000 populations per year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/26\">",
"     26",
"    </a>",
"    ]. The incidence was significantly higher in children than in adults (17.8 per 100,000 per year occurring among those aged &lt;20 years of age, compared to 1.25 per 100,000 per year for adults &ge;20 years of age [RR 14.29; 95% CI 9.77-21.11; p&lt;0.0001]).",
"   </p>",
"   <p>",
"    Cryptosporidiosis is a notifiable disease in the European Union, and surveillance data in Europe for 2005 showed 7960 cryptosporidiosis cases reported from 16 countries. The crude incidence rate was 1.9 cases per 100,000 overall, with considerable differences in the rates of cryptosporidiosis among countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence is much higher in patients with HIV infection. In HIV-infected subjects in the United States and Europe, 8 to 30 percent and in developing countries 15 to 50 percent excreted Cryptosporidium oocysts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/28-32\">",
"     28-32",
"    </a>",
"    ], making it one of the most common enteropathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecally passed Cryptosporidium oocysts are immediately infectious to those who ingest them. Transmission of cryptosporidiosis occurs via spread from an infected person or animal, or from a fecally contaminated environment such as a food or water source [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Cryptosporidiosis outbreaks have been associated with drinking water supplies, animal contact, travel, swimming pools, and recreational water facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/35\">",
"     35",
"    </a>",
"    ]. C. hominis infections are generally associated with foreign travel and in day-care associated cases, whereas C. parvum is associated with farm animal contact [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ingestion of only a few oocysts (10 to 50) can lead to severe disease and persistent infection, particularly in immunodeficient patients. The ID50 for healthy people without serological evidence of previous cryptosporidiosis has been estimated at 132 oocysts for C parvum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/37\">",
"     37",
"    </a>",
"    ] and 10 to 83 oocysts for C hominis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/38\">",
"     38",
"    </a>",
"    ]; infected individuals can excrete up to a billion oocysts per infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/39\">",
"     39",
"    </a>",
"    ]. Previous exposure and immunologic health also influence host susceptibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Contaminated water",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major source of infection is contaminated drinking or swimming water, which causes community outbreaks and travelers' diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/40\">",
"     40",
"    </a>",
"    ]. Cryptosporidium was present in 2.8 percent of 795 international travelers with diarrhea in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/23\">",
"     23",
"    </a>",
"    ]. Cryptosporidium oocysts are present in 65 to 97 percent of surface waters and are difficult to eradicate since oocysts are resistant to many disinfectants, are not effectively removed by many filtration systems, and can survive in the environment for months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. As a result, oocysts can be intermittently detected in tap water [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, swimming pools, natural ponds, and other recreational water sources are significant sources of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. A novel outbreak of Cryptosporidiosis was described among firefighters responding to a fire in a barn housing calves [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous waterborne outbreaks have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/49\">",
"     49",
"    </a>",
"    ]. The largest occurred in 1993, when 403,000 residents of Milwaukee developed gastrointestinal symptoms after their drinking water became contaminated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The extent of this outbreak may actually have been underappreciated; antibody determinations to two C. parvum antigens were made in children 6 months to 12 years of age who had routine lead screening performed during March to May of 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/52\">",
"     52",
"    </a>",
"    ]. The prevalence of antibodies during a five-week period rose from 15 to 82 percent and 17 to 87 percent in two southern zip codes in the city, which were close to the implicated water treatment plant. Outbreaks associated with apple cider contaminated by Cryptosporidia oocysts have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. An outbreak associated with a local waterpark involving more than 350 cases was reported from Illinois in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Foodborne transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foodborne outbreaks are less common than waterborne outbreaks but are reported, usually in the setting of contaminated cafeteria food [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In one outbreak associated with consumption of food in a university cafeteria linked a C. parvum genotype 1 (now called C. hominis) isolate to an infected food handler who prepared raw produce [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/58\">",
"     58",
"    </a>",
"    ]. Eighty-eight students and four employees became ill; C. hominis was isolated from 16 of 23 ill students (70 percent) and two of four employees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Person-to-person",
"    </span>",
"    &nbsp;&mdash;&nbsp;Person-to-person transmission is common particularly among household members, sexual partners, children in daycare centers and their caretakers, and healthcare workers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In one study, 19 percent of household contacts of index cases of cryptosporidiosis developed acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/61\">",
"     61",
"    </a>",
"    ]. In another report, 27 percent of asymptomatic children attending a day care center in New York excreted oocysts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Respiratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 1156 children in Uganda who presented with diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/63\">",
"     63",
"    </a>",
"    ], 926 fecal samples were screened, 116 (13 percent) of which were positive for cryptosporidium. Among the patients who had evidence of fecal infection, 48 also had testing of sputum samples; 17 (35 percent) were positive for cryptosporidium. The vast majority of the children with respiratory cryptosporidiosis were HIV-seronegative (94 percent). The authors suggested that transmission could arise if oocysts are aerosolized during coughing; however, whether or not respiratory transmission actually occurs is yet unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of Cryptosporidium is not well understood. The organisms cause a secretory diarrhea that can be associated with malabsorption. It is likely that the intracellular nature of the infection interferes with intestinal absorption and secretion. The organisms can spread via the intestinal lumen to involve the biliary system, where they can cause stricturing and cholangitis. No specific toxin has been identified, although one study of young children in Haiti demonstrated the increased presence of systemic and intestinal proinflammatory cytokines (eg, tumor necrosis factor and interleukin-8) compared to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"     \"AIDS cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryptosporidia are found within epithelial cells and are associated with distortion of the villus architecture. Inflammatory changes may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/65\">",
"     65",
"    </a>",
"    ]. Progressive morphological and functional abnormalities of the small intestine occur as parasite numbers increase, although intensity of infection and inflammation does not correlate well with the severity of clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/66\">",
"     66",
"    </a>",
"    ]. Whether differences in the organism's virulence or the level of host immunity primarily account for the variable course of infection in different people is not well understood.",
"   </p>",
"   <p>",
"    The immune response associated with cryptosporidiosis involves cellular and humoral components. The T-lymphocyte cellular responses are important in controlling infection, as evidenced by the increased disease severity in HIV-infected patients with CD4 counts less than 100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Specific IgM, IgG,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgA responses develop during infection. Epidemiologic evidence for protective immunity to Cryptosporidium has been suggested by the observation that residents in areas where Cryptosporidium is endemic have milder symptoms with subsequent infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/14,67,68\">",
"     14,67,68",
"    </a>",
"    ]. However, the development of antibodies is not necessarily associated with clearance of infection, as illustrated in studies of HIV-infected patients, who developed serum and intestinal antibodies but failed to clear the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The production of IFN-gamma is involved in the resolution of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/71-74\">",
"     71-74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of Cryptosporidium can be completed within a single host. Oocysts are ingested, undergo excystation in the small bowel, and release four banana-shaped motile sporozoites that attach to the epithelial cell wall. The sporozoites mature asexually into meronts, which release merozoites intraluminally. These can reinvade host cells, resulting in autoinfection, or can undergo sexual maturation to form new oocytes which can excyst within the host gastrointestinal tract or can pass out into the environment. Oocysts are infectious and can remain viable for many months at a wide range of temperatures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium can cause an asymptomatic infection, a mild diarrheal illness, or severe enteritis with or without biliary tract involvement. Asymptomatic infection can occur in immunocompetent and immunodeficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/67,75\">",
"     67,75",
"    </a>",
"    ]. As many as 30 percent of childhood infections have been asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/24,62\">",
"     24,62",
"    </a>",
"    ]. Infection in elderly patients can lead to severe volume depletion in association with high case-fatality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period is usually 7 to 10 days (range 3 to 28 days). The number of oocysts ingested appears to be related to the time to and duration of infection, but not the severity of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who develop diarrhea frequently have associated malaise, nausea and anorexia, crampy abdominal pain, and low-grade fever. The diarrhea may be acute or chronic, transient, intermittent or continuous, and scant or voluminous with up to 25",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    of watery stool. Fecal blood or leukocytes are rare unless there is coinfection with another enteric pathogen. Patients with chronic diarrhea can develop profound weight loss.",
"   </p>",
"   <p>",
"    The illness usually resolves without therapy in 10 to 14 days in immunologically healthy people, although it can persist longer or relapse after initial improvement. Excretion of oocysts after resolution of clinical symptoms can continue for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/77\">",
"     77",
"    </a>",
"    ]. There is some evidence in nonimmunocompromised infants that Cryptosporidia infection can lead to persistent diarrhea and have a lasting adverse affect on nutritional status and growth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/14,78\">",
"     14,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In immunocompromised hosts (particularly those with T-cell immunodeficiency), the illness is more frequently protracted and severe, and can lead to significant wasting, particularly when the CD4 count is &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    There is also evidence that specific species or subtype families are associated with different clinical manifestations. For example, in a cross-sectional study of 230 HIV-infected patients in Peru, infection with C. hominis was associated with diarrhea alone while infection with C. parvum was associated with diarrhea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/79\">",
"     79",
"    </a>",
"    ]. The American Gastroenterological Association (AGA) technical review for malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/80\">",
"     80",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A number of other clinical manifestations of cryptosporidiosis in AIDS patients have been described, including cholecystitis, cholangitis, hepatitis, pancreatitis, and respiratory tract involvement. Biliary tract involvement affects 10 to 30 percent of patients with AIDS and can result in acalculous cholecystitis, sclerosing cholangitis, and pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Symptoms include right upper quadrant pain and fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"     \"AIDS cholangiopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=see_link\">",
"     \"Acalculous cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary involvement has been described, but it is unclear whether the organism is a true pathogen or merely colonizes the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Nonspecific respiratory symptoms including cough have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Disseminated cryptosporidiosis has not been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of laboratory abnormalities depends upon the severity and duration of infection.",
"   </p>",
"   <p>",
"    The serum alkaline phosphatase may be elevated in patients with biliary tract involvement. In such patients, ultrasound and CT imaging may show an enlarged gallbladder with a thickened wall and dilated intra- and extrahepatic biliary ducts. Diagnosis of biliary involvement is confirmed by histology or by examination of bile for oocysts, since stool specimens may or may not be positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"     \"AIDS cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe, protracted disease can have evidence of malabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cryptosporidiosis is made by microscopic identification of the oocysts in stool or tissue. The organisms may also be present in duodenal aspirates, bile secretions, biopsy specimens from affected gastrointestinal tissue, or respiratory secretions.",
"   </p>",
"   <p>",
"    Specific details regarding microscopy and other diagnostic methods are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium species cannot be cultivated in vitro. As a result, the diagnosis is primarily based on microscopic identification. The laboratory should be alerted to the potential diagnosis and specific stains for the organisms should be requested, since routine examination for ova and parasites usually does not detect cryptosporidia spores. Specimens can be examined fresh or formalin-fixed, by light or phase-contrast microscopy. Modified acid-fast stains are usually used, although the organisms also can be seen using hematoxylin and eosin, Giemsa, or malachite green staining. With the modified acid-fast stain, the oocysts stain red or pink and are usually 4 to 6 mcm in diameter. Light microscopy is unable to distinguish between genetically distinct parasites.",
"   </p>",
"   <p>",
"    The accuracy of the acid-fast stain has not been well established but depends in part upon the number of stool specimens examined, since the number of oocysts shed in feces is not constant. In one report, examination of a single stool specimen identified only 30 percent of intestinal Cryptosporidia infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of specimens required to conclusively exclude the diagnosis has not been studied, but in chronic infections, examining up to three specimens is reasonable. Additionally, examination of unformed specimens and concentrated specimens increase the diagnostic yield. Fecal specimens usually lack leukocytes and erythrocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidial enteritis can be diagnosed from hematoxylin and eosin staining; cryptosporidium appears basophilic and occurs either alone or in clusters on the brush border of the mucosal surface. Because infection can be patchy, biopsy specimens may be less sensitive than stool examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies and enzyme immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies against the oocyst wall and antigen capture ELISA tests have been used in fluorescent assays (eg, Meridian Merifluor assay and the TechLab Crypto IF kit) to detect Cryptosporidium in fecal specimens or in tissue specimens. These techniques increase the sensitivity compared to routine light microscopy and are easy to perform [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/88-91\">",
"     88-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enzyme immunoassay kits include the Alexon ProSpect Assay, the Seradyn Color Vue and the Meridian Premier Cryptosporidium, which have been evaluated in a number of studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ProSpect T kit had a sensitivity of 100 percent and specificity of 99 percent when compared to the modified acid-fast stain [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Meridian Premier and the ProSpect T kits had sensitivities of 98 and 99 percent, respectively, and specificities of 100 for both when compared to the Meridian Merifluor assay as the reference method [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ProSpecT and Color Vue had sensitivities of 96 and 76 percent, and specificities of 98 and 100 percent, respectively, when using the Merifluor stain as the reference method [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The acid-fast stain and EIA had sensitivities of 94 and 100 percent, and specificities of 76 and 100 percent, respectively, compared to direct immunofluorescence [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advantages of the ELISA tests are that they are easy to use, are not affected by preservatives, and do not require the degree of technical skill needed for microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/96\">",
"     96",
"    </a>",
"    ]. However, a major disadvantage is their high cost. Furthermore, faulty ProSpecT kits have been associated with false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although diagnosis of cryptosporidiosis is generally based on microscopy, this method offers no information on the infecting species, which can be helpful in epidemiologic investigations. Some specialized research laboratories use PCR testing, which is more sensitive than microscopy and has the ability to differentiate between Cryptosporidium genotypes, thereby having a potential use in detecting the source of outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A commercially available PCR-ELISA-based method also allows for detection and genotyping of cryptosporidium in biological samples [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13961/abstract/100\">",
"     100",
"    </a>",
"    ]. Compared to microscopy, one study of this hybrid assay in 33 stool samples demonstrated a sensitivity and specificity of 97 and 100 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic detection using IFA assays or ELISA tests are available, but generally are used only as an epidemiologic tool, because antibody persistence limits the usefulness in diagnosis of acute infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/24/6530?source=see_link\">",
"       \"Patient information: Cryptosporidiosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465372\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryptosporidium is an intracellular protozoan that is one of the most common parasitic enteric pathogens in humans. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptosporidium has been associated with gastrointestinal disease in sporadic self-limited outbreaks among immunocompetent hosts and chronic illness in immunosuppressed patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission of cryptosporidiosis occurs via spread from an infected person or animal, or from a fecally contaminated environment, such as a food or water source. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptosporidiosis is associated with a secretory diarrhea that can be associated with malabsorption. It is likely that the intracellular nature of the parasite interferes with intestinal absorption and secretion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptosporidium can cause asymptomatic infection, a mild diarrheal illness, or severe enteritis with or without biliary tract involvement. In immunocompetent hosts, the illness usually spontaneously resolves without therapy, while among immunosuppressed host cryptosporidiosis can be a chronic debilitating illness with wasting and persistent diarrhea. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cryptosporidiosis is made through the use of enzyme immunoassay or by microscopic identification of the oocysts in stool or tissue. The organisms may also be present in duodenal aspirates, bile secretions, biopsy specimens from the gastrointestinal tract, or respiratory secretions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/1\">",
"      Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N Engl J Med 2002; 346:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/2\">",
"      Robinson G, Elwin K, Chalmers RM. Unusual Cryptosporidium genotypes in human cases of diarrhea. Emerg Infect Dis 2008; 14:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/3\">",
"      Xiao L, Fayer R, Ryan U, Upton SJ. Cryptosporidium taxonomy: recent advances and implications for public health. Clin Microbiol Rev 2004; 17:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/4\">",
"      Fayer R, Ungar BL. Cryptosporidium spp. and cryptosporidiosis. Microbiol Rev 1986; 50:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/5\">",
"      Peng MM, Xiao L, Freeman AR, et al. Genetic polymorphism among Cryptosporidium parvum isolates: evidence of two distinct human transmission cycles. Emerg Infect Dis 1997; 3:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/6\">",
"      Morgan-Ryan UM, Fall A, Ward LA, et al. Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens. J Eukaryot Microbiol 2002; 49:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/7\">",
"      Cacci&ograve; SM. Molecular epidemiology of human cryptosporidiosis. Parassitologia 2005; 47:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/8\">",
"      Clark DP. New insights into human cryptosporidiosis. Clin Microbiol Rev 1999; 12:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/9\">",
"      Tanriverdi S, Markovics A, Arslan MO, et al. Emergence of distinct genotypes of Cryptosporidium parvum in structured host populations. Appl Environ Microbiol 2006; 72:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/10\">",
"      Yoder JS, Wallace RM, Collier SA, et al. Cryptosporidiosis surveillance--United States, 2009-2010. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/11\">",
"      O'connor RM, Shaffie R, Kang G, Ward HD. Cryptosporidiosis in patients with HIV/AIDS. AIDS 2011; 25:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/12\">",
"      Mor SM, Tzipori S. Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge. Clin Infect Dis 2008; 47:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/13\">",
"      Le Moing V, Bissuel F, Costagliola D, et al. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS 1998; 12:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/14\">",
"      Newman RD, Sears CL, Moore SR, et al. Longitudinal study of Cryptosporidium infection in children in northeastern Brazil. J Infect Dis 1999; 180:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/15\">",
"      Huang DB, White AC. An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am 2006; 35:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/16\">",
"      Soave R, Armstrong D. Cryptosporidium and cryptosporidiosis. Rev Infect Dis 1986; 8:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/17\">",
"      Mannheimer SB, Soave R. Protozoal infections in patients with AIDS. Cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis. Infect Dis Clin North Am 1994; 8:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/18\">",
"      Lengerich EJ, Addiss DG, Marx JJ, et al. Increased exposure to cryptosporidia among dairy farmers in Wisconsin. J Infect Dis 1993; 167:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases--United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/20\">",
"      Kuhls TL, Mosier DA, Crawford DL, Griffis J. Seroprevalence of cryptosporidial antibodies during infancy, childhood, and adolescence. Clin Infect Dis 1994; 18:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/21\">",
"      Current WL, Garcia LS. Cryptosporidiosis. Clin Microbiol Rev 1991; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/22\">",
"      Casemore DP. Epidemiological aspects of human cryptosporidiosis. Epidemiol Infect 1990; 104:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/23\">",
"      Jelinek T, Lotze M, Eichenlaub S, et al. Prevalence of infection with Cryptosporidium parvum and Cyclospora cayetanensis among international travellers. Gut 1997; 41:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/24\">",
"      Ungar BL, Gilman RH, Lanata CF, Perez-Schael I. Seroepidemiology of Cryptosporidium infection in two Latin American populations. J Infect Dis 1988; 157:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/25\">",
"      Ungar BL, Mulligan M, Nutman TB. Serologic evidence of Cryptosporidium infection in US volunteers before and during Peace Corps service in Africa. Arch Intern Med 1989; 149:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/26\">",
"      Laupland KB, Church DL. Population-based laboratory surveillance for Giardia sp. and Cryptosporidium sp. infections in a large Canadian health region. BMC Infect Dis 2005; 5:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/27\">",
"      Semenza JC, Nichols G. Cryptosporidiosis surveillance and water-borne outbreaks in Europe. Euro Surveill 2007; 12:E13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/28\">",
"      Sewankambo N, Mugerwa RD, Goodgame R, et al. Enteropathic AIDS in Uganda. An endoscopic, histological and microbiological study. AIDS 1987; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/29\">",
"      Colebunders R, Lusakumuni K, Nelson AM, et al. Persistent diarrhoea in Zairian AIDS patients: an endoscopic and histological study. Gut 1988; 29:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/30\">",
"      Conlon CP, Pinching AJ, Perera CU, et al. HIV-related enteropathy in Zambia: a clinical, microbiological, and histological study. Am J Trop Med Hyg 1990; 42:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/31\">",
"      Laughon BE, Druckman DA, Vernon A, et al. Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology 1988; 94:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/32\">",
"      Tarimo DS, Killewo JZ, Minjas JN, Msamanga GI. Prevalence of intestinal parasites in adult patients with enteropathic AIDS in north-eastern Tanzania. East Afr Med J 1996; 73:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/33\">",
"      Framm SR, Soave R. Agents of diarrhea. Med Clin North Am 1997; 81:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/34\">",
"      Yoder JS, Beach MJ, Centers for Disease Control and Prevention (CDC). Cryptosporidiosis surveillance--United States, 2003-2005. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Communitywide cryptosporidiosis outbreak--Utah, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/36\">",
"      Davies AP, Chalmers RM. Cryptosporidiosis. BMJ 2009; 339:b4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/37\">",
"      DuPont HL, Chappell CL, Sterling CR, et al. The infectivity of Cryptosporidium parvum in healthy volunteers. N Engl J Med 1995; 332:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/38\">",
"      Chappell CL, Okhuysen PC, Langer-Curry R, et al. Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg 2006; 75:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/39\">",
"      Chappell CL, Okhuysen PC, Sterling CR, DuPont HL. Cryptosporidium parvum: intensity of infection and oocyst excretion patterns in healthy volunteers. J Infect Dis 1996; 173:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/40\">",
"      Jokipii L, Pohjola S, Jokipii AM. Cryptosporidiosis associated with traveling and giardiasis. Gastroenterology 1985; 89:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/41\">",
"      LeChevallier MW, Norton WD, Lee RG. Occurrence of Giardia and Cryptosporidium spp. in surface water supplies. Appl Environ Microbiol 1991; 57:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/42\">",
"      Juranek DD. Cryptosporidiosis: sources of infection and guidelines for prevention. Clin Infect Dis 1995; 21 Suppl 1:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/43\">",
"      LeChevallier MW, Norton WD, Lee RG. Giardia and Cryptosporidium spp. in filtered drinking water supplies. Appl Environ Microbiol 1991; 57:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/44\">",
"      McAnulty JM, Fleming DW, Gonzalez AH. A community-wide outbreak of cryptosporidiosis associated with swimming at a wave pool. JAMA 1994; 272:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/45\">",
"      Barwick RS, Levy DA, Craun GF, et al. Surveillance for waterborne-disease outbreaks--United States, 1997-1998. MMWR CDC Surveill Summ 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Cryptosporidiosis outbreaks associated with recreational water use--five states, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of cryptosporidiosis associated with a splash park - Idaho, 2007. MMWR Morb Mortal Wkly Rep 2009; 58:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of cryptosporidiosis associated with a firefighting response - Indiana and Michigan, June 2011. MMWR Morb Mortal Wkly Rep 2012; 61:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/49\">",
"      Fricker CR, Crabb JH. Water-borne cryptosporidiosis: detection methods and treatment options. Adv Parasitol 1998; 40:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/50\">",
"      Levy DA, Bens MS, Craun GF, et al. Surveillance for waterborne-disease outbreaks--United States, 1995-1996. MMWR CDC Surveill Summ 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/51\">",
"      MacKenzie WR, Schell WL, Blair KA, et al. Massive outbreak of waterborne cryptosporidium infection in Milwaukee, Wisconsin: recurrence of illness and risk of secondary transmission. Clin Infect Dis 1995; 21:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/52\">",
"      McDonald AC, Mac Kenzie WR, Addiss DG, et al. Cryptosporidium parvum-specific antibody responses among children residing in Milwaukee during the 1993 waterborne outbreak. J Infect Dis 2001; 183:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/53\">",
"      Millard PS, Gensheimer KF, Addiss DG, et al. An outbreak of cryptosporidiosis from fresh-pressed apple cider. JAMA 1994; 272:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/54\">",
"      From the Centers for Disease Control and Prevention. Outbreaks of Escherichia coli O157:H7 infection and cryptosporidiosis associated with drinking unpasteurized apple cider--Connecticut and New York, October 1996. JAMA 1997; 277:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/55\">",
"      Causer LM, Handzel T, Welch P, et al. An outbreak of Cryptosporidium hominis infection at an Illinois recreational waterpark. Epidemiol Infect 2006; 134:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/56\">",
"      P&ouml;nka A, Kotilainen H, Rimhanen-Finne R, et al. A foodborne outbreak due to Cryptosporidium parvum in Helsinki, November 2008. Euro Surveill 2009; 14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/57\">",
"      Ethelberg S, Lisby M, Vestergaard LS, et al. A foodborne outbreak of Cryptosporidium hominis infection. Epidemiol Infect 2009; 137:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/58\">",
"      Quiroz ES, Bern C, MacArthur JR, et al. An outbreak of cryptosporidiosis linked to a foodhandler. J Infect Dis 2000; 181:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/59\">",
"      Current WL. Cryptosporidium parvum: household transmission. Ann Intern Med 1994; 120:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/60\">",
"      Musher DM, Musher BL. Contagious acute gastrointestinal infections. N Engl J Med 2004; 351:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/61\">",
"      Newman RD, Zu SX, Wuhib T, et al. Household epidemiology of Cryptosporidium parvum infection in an urban community in northeast Brazil. Ann Intern Med 1994; 120:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/62\">",
"      Crawford FG, Vermund SH, Ma JY, Deckelbaum RJ. Asymptomatic cryptosporidiosis in a New York City day care center. Pediatr Infect Dis J 1988; 7:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/63\">",
"      Mor SM, Tumwine JK, Ndeezi G, et al. Respiratory cryptosporidiosis in HIV-seronegative children in Uganda: potential for respiratory transmission. Clin Infect Dis 2010; 50:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/64\">",
"      Kirkpatrick BD, Noel F, Rouzier PD, et al. Childhood cryptosporidiosis is associated with a persistent systemic inflammatory response. Clin Infect Dis 2006; 43:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/65\">",
"      Heyworth MF. Parasitic diseases in immunocompromised hosts. Cryptosporidiosis, isosporiasis, and strongyloidiasis. Gastroenterol Clin North Am 1996; 25:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/66\">",
"      Genta RM, Chappell CL, White AC Jr, et al. Duodenal morphology and intensity of infection in AIDS-related intestinal cryptosporidiosis. Gastroenterology 1993; 105:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/67\">",
"      Petersen C. Cryptosporidium and the food supply. Lancet 1995; 345:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/68\">",
"      Okhuysen PC, Chappell CL, Sterling CR, et al. Susceptibility and serologic response of healthy adults to reinfection with Cryptosporidium parvum. Infect Immun 1998; 66:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/69\">",
"      Benhamou Y, Kapel N, Hoang C, et al. Inefficacy of intestinal secretory immune response to Cryptosporidium in acquired immunodeficiency syndrome. Gastroenterology 1995; 108:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/70\">",
"      Cozon G, Biron F, Jeannin M, et al. Secretory IgA antibodies to Cryptosporidium parvum in AIDS patients with chronic cryptosporidiosis. J Infect Dis 1994; 169:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/71\">",
"      Rehg JE. Effect of interferon-gamma in experimental Cryptosporidium parvum infection. J Infect Dis 1996; 174:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/72\">",
"      Culshaw RJ, Bancroft GJ, McDonald V. Gut intraepithelial lymphocytes induce immunity against Cryptosporidium infection through a mechanism involving gamma interferon production. Infect Immun 1997; 65:3074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/73\">",
"      Gomez Morales MA, Ausiello CM, Guarino A, et al. Severe, protracted intestinal cryptosporidiosis associated with interferon gamma deficiency: pediatric case report. Clin Infect Dis 1996; 22:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/74\">",
"      Tilley M, McDonald V, Bancroft GJ. Resolution of cryptosporidial infection in mice correlates with parasite-specific lymphocyte proliferation associated with both Th1 and Th2 cytokine secretion. Parasite Immunol 1995; 17:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/75\">",
"      Janoff EN, Limas C, Gebhard RL, Penley KA. Cryptosporidial carriage without symptoms in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/76\">",
"      Mor SM, DeMaria A Jr, Griffiths JK, Naumova EN. Cryptosporidiosis in the elderly population of the United States. Clin Infect Dis 2009; 48:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/77\">",
"      Jokipii L, Jokipii AM. Timing of symptoms and oocyst excretion in human cryptosporidiosis. N Engl J Med 1986; 315:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/78\">",
"      Checkley W, Epstein LD, Gilman RH, et al. Effects of Cryptosporidium parvum infection in Peruvian children: growth faltering and subsequent catch-up growth. Am J Epidemiol 1998; 148:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/79\">",
"      Cama VA, Ross JM, Crawford S, et al. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J Infect Dis 2007; 196:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/80\">",
"      American Gastroenterological Association medical position statement: guidelines for the management of malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Gastroenterology 1996; 111:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/81\">",
"      Gross TL, Wheat J, Bartlett M, O'Connor KW. AIDS and multiple system involvement with cryptosporidium. Am J Gastroenterol 1986; 81:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/82\">",
"      Soave R, Johnson WD Jr. Cryptosporidium and Isospora belli infections. J Infect Dis 1988; 157:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/83\">",
"      Moore JA, Frenkel JK. Respiratory and enteric cryptosporidiosis in humans. Arch Pathol Lab Med 1991; 115:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/84\">",
"      Travis WD, Schmidt K, MacLowry JD, et al. Respiratory cryptosporidiosis in a patient with malignant lymphoma. Report of a case and review of the literature. Arch Pathol Lab Med 1990; 114:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/85\">",
"      Meynard JL, Meyohas MC, Binet D, et al. Pulmonary cryptosporidiosis in the acquired immunodeficiency syndrome. Infection 1996; 24:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/86\">",
"      Clavel A, Arnal AC, S&aacute;nchez EC, et al. Respiratory cryptosporidiosis: case series and review of the literature. Infection 1996; 24:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/87\">",
"      Blanshard C, Jackson AM, Shanson DC, et al. Cryptosporidiosis in HIV-seropositive patients. Q J Med 1992; 85:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/88\">",
"      Weber R, Bryan RT, Bishop HS, et al. Threshold of detection of Cryptosporidium oocysts in human stool specimens: evidence for low sensitivity of current diagnostic methods. J Clin Microbiol 1991; 29:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/89\">",
"      Garcia LS, Brewer TC, Bruckner DA. Fluorescence detection of Cryptosporidium oocysts in human fecal specimens by using monoclonal antibodies. J Clin Microbiol 1987; 25:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/90\">",
"      Kehl KS, Cicirello H, Havens PL. Comparison of four different methods for detection of Cryptosporidium species. J Clin Microbiol 1995; 33:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/91\">",
"      Arrowood MJ, Sterling CR. Comparison of conventional staining methods and monoclonal antibody-based methods for Cryptosporidium oocyst detection. J Clin Microbiol 1989; 27:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/92\">",
"      Parisi MT, Tierno PM Jr. Evaluation of new rapid commercial enzyme immunoassay for detection of Cryptosporidium oocysts in untreated stool specimens. J Clin Microbiol 1995; 33:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/93\">",
"      Garcia LS, Shimizu RY. Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J Clin Microbiol 1997; 35:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/94\">",
"      Aarnaes SL, Blanding J, Speier S, et al. Comparison of the ProSpecT and Color Vue enzyme-linked immunoassays for the detection of Cryptosporidium in stool specimens. Diagn Microbiol Infect Dis 1994; 19:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/95\">",
"      Siddons CA, Chapman PA, Rush BA. Evaluation of an enzyme immunoassay kit for detecting cryptosporidium in faeces and environmental samples. J Clin Pathol 1992; 45:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/96\">",
"      Dagan R, Fraser D, El-On J, et al. Evaluation of an enzyme immunoassay for the detection of Cryptosporidium spp. in stool specimens from infants and young children in field studies. Am J Trop Med Hyg 1995; 52:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/97\">",
"      Centers for Disease Control and Prevention (CDC). False-positive laboratory tests for Cryptosporidium involving an enzyme-linked immunosorbent assay--United States, November 1997-March 1998. MMWR Morb Mortal Wkly Rep 1999; 48:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/98\">",
"      Doing KM, Hamm JL, Jellison JA, et al. False-positive results obtained with the Alexon ProSpecT Cryptosporidium enzyme immunoassay. J Clin Microbiol 1999; 37:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/99\">",
"      Morgan UM, Pallant L, Dwyer BW, et al. Comparison of PCR and microscopy for detection of Cryptosporidium parvum in human fecal specimens: clinical trial. J Clin Microbiol 1998; 36:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13961/abstract/100\">",
"      Savin C, Sarfati C, Menotti J, et al. Assessment of cryptodiag for diagnosis of cryptosporidiosis and genotyping Cryptosporidium species. J Clin Microbiol 2008; 46:2590.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5733 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13961=[""].join("\n");
var outline_f13_40_13961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13465372\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13465130\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Contaminated water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Foodborne transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Person-to-person",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Respiratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Monoclonal antibodies and enzyme immunoassays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13465372\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=related_link\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/24/6530?source=related_link\">",
"      Patient information: Cryptosporidiosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1670?source=related_link\">",
"      Treatment and prevention of cryptosporidiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13962="Electrodiagnostic evaluation of the neuromuscular junction";
var content_f13_40_13962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrodiagnostic evaluation of the neuromuscular junction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13962/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13962/contributors\">",
"     David H Weinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13962/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/40/13962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/40/13962/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/40/13962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H35316733\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive nerve stimulation (RNS) and single fiber electromyography (SFEMG) are important confirmatory tests for the diagnosis of disorders of the nicotinic neuromuscular junction, particularly for myasthenia gravis, Lambert-Eaton myasthenic syndrome, and botulism. This topic will review the basic principles of neuromuscular transmission and electrodiagnostic testing with RNS and SFEMG.",
"   </p>",
"   <p>",
"    Other clinical aspects of neuromuscular junction disorders are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"     \"Botulism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468250\">",
"    <span class=\"h1\">",
"     THE NEUROMUSCULAR JUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nicotinic neuromuscular junction is a complex, specialized structure incorporating the distal axon terminal and the muscle membrane that allows for the unidirectional chemical communication between peripheral nerve and muscle. It consists of the presynaptic nerve terminal, the synaptic cleft, and the postsynaptic endplate region on the muscle fiber. Acetylcholine serves as the neurotransmitter for voluntary striated muscle. The sections that follow provide a simplified summary of the morphology and neurophysiology of the neuromuscular junction that permits an adequate understanding of the electrodiagnostic testing principles (",
"    <a class=\"graphic graphic_figure graphicRef62694 \" href=\"UTD.htm?18/25/18838\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35316795\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presynaptic region of the nicotinic neuromuscular junction consists of a specialized terminal nerve structure surrounded by Schwann cells. The presynaptic region includes voltage-gated calcium channels embedded in the nerve membrane, numerous mitochondria, and acetylcholine-containing synaptic vesicles. Each vesicle contains 5000 to 10,000 molecules of acetylcholine, known as a quantum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The populations of vesicles behave as if they are divided roughly into three pools [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The primary pool for immediate release",
"     </li>",
"     <li>",
"      The secondary or mobilization storage pool",
"     </li>",
"     <li>",
"      The reserve storage pool",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary pool is located in the vicinity of the \"active zones\" in the presynaptic nerve terminal and consists of approximately 1000 vesicles that are available for immediate release. The secondary pool consists of approximately 10,000 vesicles that can be mobilized for release within a few seconds. The reserve pool consists of approximately 100,000 to 300,000 vesicles that must be transported from the axon or cell body to replenish the other stores prior to becoming available for release.",
"   </p>",
"   <p>",
"    The synaptic cleft is the roughly 50 nm space between the nerve terminal and the muscle membrane. Acetylcholinesterase, the enzyme responsible for the degradation of acetylcholine, is released into this area.",
"   </p>",
"   <p>",
"    The postsynaptic membrane is a specialized structure within the muscle fiber membrane consisting of complex junctional folds that increase the surface area approximately 10-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/3\">",
"     3",
"    </a>",
"    ]. Numerous nicotinic acetylcholine receptors are embedded in the membrane at the crests of the folds [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/4\">",
"     4",
"    </a>",
"    ]. The acetylcholine receptors are complex structures containing four subunits surrounding an ion channel (",
"    <a class=\"graphic graphic_figure graphicRef78580 \" href=\"UTD.htm?32/27/33200\">",
"     figure 2",
"    </a>",
"    ). When the two acetylcholine binding sites are filled, there is a conformational change in the receptor structure that allows for an increase in sodium conductance and thus a local change in the muscle membrane potential, as described in the next section below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468257\">",
"    <span class=\"h2\">",
"     Physiology of acetylcholine release",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nerve action potential propagates down the motor axon to the presynaptic nerve terminal. The presynaptic voltage-gated calcium channels are depolarized, allowing the flow of calcium ions into the presynaptic terminal region [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/5\">",
"     5",
"    </a>",
"    ]. In the presence of calcium, the acetylcholine-containing vesicles of the primary pool combine with the terminal membrane at the active zones, releasing their contents into the synaptic cleft. The presynaptic voltage-gated potassium channels serve to terminate calcium entry, and thus halt the release of acetylcholine. The acetylcholine diffuses across the synaptic cleft and combines with the postsynaptic acetylcholine receptors, generating a localized, graded, non-propagating, depolarizing current with no refractory period known as the endplate potential (EPP). When the EPP reaches threshold, an all-or-none depolarization of the postsynaptic muscle membrane occurs, inducing a muscle fiber action potential and ultimately a muscle fiber contraction. Normally, about 10 to 20 percent of the primary pool or 100 to 200 quanta of acetylcholine are released at a given neuromuscular junction in response to an action potential [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], creating an EPP that is several-fold greater than the threshold to depolarize the muscle fiber [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Under normal circumstances, this considerable safety factor ensures that a depolarization of the distal nerve segments will induce reliably a contraction of the innervated muscle fiber.",
"   </p>",
"   <p>",
"    The probability of acetylcholine release is primarily dependent on two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The amount of intracellular calcium",
"     </li>",
"     <li>",
"      The number of acetylcholine vesicles in the primary pool at the terminal nerve region",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It takes approximately one to two seconds for the primary pool of acetylcholine vesicles to be replenished. Furthermore, it takes approximately 100 ms to return calcium concentrations to their pre-depolarization equilibrium. Therefore, rates of repetitive nerve stimulation in the 1 to 5 Hz range or weak voluntary muscle contractions result in the depletion of available acetylcholine vesicles without significantly altering the calcium concentration. This process results in a smaller number of quanta released with each subsequent nerve impulse. At high rates of stimulation (10 to 50 Hz) or following high-intensity voluntary muscle contractions, there is a sustained, significant increase in the intracellular calcium concentration because the influx of new calcium ions occurs before the previously introduced calcium has diffused back out of the presynaptic terminal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, there is a less important increase in the size of the immediately available acetylcholine pool due to augmentation from the secondary storage pool that results in an increase in quantal release following subsequent nerve stimulations.",
"   </p>",
"   <p>",
"    In normal muscle, these maneuvers have little impact on function, as the safety factor inherent in the neuromuscular junction transmission assures a reliable muscle fiber contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. The compound muscle action potential (CMAP) is essentially unchanged due to the large safety factor that promotes and maintains near maximal muscle fiber activation with supramaximal nerve stimulation despite fluctuations in the EPP.",
"   </p>",
"   <p>",
"    With a neuromuscular junction disorder of the postsynaptic membrane such as myasthenia gravis, the number of acetylcholine receptors is reduced and this in turn reduces the safety factor for muscle fiber activation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    ). In this situation, some muscle fibers fail to reach threshold due to the decreased presynaptic acetylcholine release that normally occurs at slow rates of repetitive stimulation, thereby leading to a decrease in the CMAP amplitude, a phenomenon known as the decremental response (",
"    <a class=\"graphic graphic_waveform graphicRef53515 \" href=\"UTD.htm?7/17/7441\">",
"     waveform 1",
"    </a>",
"    ). In contrast, the modest increase in the presynaptic release of acetylcholine that occurs at high rates of stimulation or with maximal intensity voluntary muscle contractions will usually have a minimal effect on the CMAP amplitude in the great majority of patients with myasthenia gravis, since the safety factor for transmission is usually adequate for contraction of all the muscle fibers even before the increased amounts of acetylcholine become available. In the most severe cases of myasthenia gravis, the baseline CMAP amplitude can be reduced at rest due to failure of action potential generation in some fraction of neuromuscular junctions because of incomplete muscle fiber depolarization from the reduced EPPs (ie, reduced safety factor). A modest increase in CMAP amplitude, known as the incremental response, can therefore be seen in this setting as the increased acetylcholine release with tetanic stimulation increases the EPPs in most muscle fibers beyond threshold.",
"   </p>",
"   <p>",
"    In disorders of the presynaptic terminal, such as Lambert-Eaton myasthenic syndrome (LEMS), the number of released vesicles is markedly reduced at baseline (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'Pathophysiology'",
"    </a>",
"    ). Therefore, the pattern of evoked response amplitudes is different from that seen in myasthenia gravis. In most cases of LEMS, the reduced acetylcholine released in response to stimulation results in reduced EPPs and a correspondingly reduced CMAP amplitude. High frequency stimulation can markedly increase the amount of available presynaptic intracellular calcium, which in turn can augment the number of released quanta of acetylcholine and thus enlarge the size of the resultant CMAP amplitude, consistent with an incremental response. The changes can be quite dramatic with CMAP amplitude increases of several hundredfold (",
"    <a class=\"graphic graphic_waveform graphicRef58848 \" href=\"UTD.htm?31/36/32322\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/11\">",
"     11",
"    </a>",
"    ]. Following a weak voluntary contraction or at low rates of repetitive stimulation (1 to 5 Hz), small decremental responses can be seen in presynaptic neuromuscular junction disorders due to the reduction in the size of the available acetylcholine vesicle pool with an unaltered calcium concentration (",
"    <a class=\"graphic graphic_waveform graphicRef74605 \" href=\"UTD.htm?5/32/5647\">",
"     waveform 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468264\">",
"    <span class=\"h1\">",
"     ELECTRODIAGNOSTIC PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinical signs and laboratory abnormalities contribute to the diagnosis of disorders of the neuromuscular junction. Repetitive nerve stimulation (RNS) and, at times, single fiber electromyography (SFEMG) are key confirmatory tests in the diagnostic armamentarium. (See",
"    <a class=\"local\" href=\"#H9468271\">",
"     'Repetitive nerve stimulation (RNS)'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9468341\">",
"     'Single fiber electromyography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A complete electrodiagnostic study including needle EMG is usually necessary for the diagnosis of neuromuscular junction disorders, including conventional sensory and motor nerve conduction studies and late responses (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link\">",
"     \"Nerve conduction studies: Late responses\"",
"    </a>",
"    ). Under most circumstances, these studies are normal in postsynaptic neuromuscular junction disorders, such as myasthenia gravis. Presynaptic neuromuscular junction disorders such as the Lambert-Eaton myasthenic syndrome often have a pattern of low compound muscle action potential amplitudes with normal motor latencies and normal sensory nerve action potentials. It is only with RNS or SFEMG that the true nature of the disorder is demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468271\">",
"    <span class=\"h1\">",
"     REPETITIVE NERVE STIMULATION (RNS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive nerve stimulation represents a modification of conventional motor nerve conduction studies. The interval between repeated motor nerve stimulations is varied to manipulate the neuromuscular physiology described above (see",
"    <a class=\"local\" href=\"#H9468257\">",
"     'Physiology of acetylcholine release'",
"    </a>",
"    above). Slow RNS is designed to maximally stress the neuromuscular junction safety factor. Since it takes approximately one to two seconds to replete the primary pool of presynaptic acetylcholine vesicles, slow rates of repetitive stimulation (1 to 5 Hz) deplete the number of available quanta for release with subsequent depolarizations. The percent of the remaining quanta released with the next stimulation will be determined by the presynaptic calcium concentration. Repetitive stimulation rates of 1 to 5 Hz allows for the re-equilibration of the presynaptic calcium concentration between stimulations so with the smaller primary pool, a smaller number of quanta will be released with each subsequent stimulation for at least the first five or six stimuli in a train. In the normal neuromuscular junction, this reduced amount of acetylcholine is still adequate to reliably depolarize the muscle fiber. However, in pathologic states where the safety factor for neuromuscular junction transmission is considerably reduced, some fibers will fail to depolarize in the later stimuli of a train and the compound muscle action potential amplitude will drop, which is referred to as a decrement.",
"   </p>",
"   <p>",
"    The presence of this decremental response on RNS has been the neurophysiologic hallmark of myasthenia gravis. Suspicion of myasthenia gravis remains the major indication for the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Electrophysiologic confirmation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468278\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique of RNS incorporates the surface stimulation and surface recording procedures used in routine motor nerve conduction studies (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of nerve conduction studies\", section on 'Methodology'",
"    </a>",
"    ). The compound muscle action potential (CMAP) obtained after single supramaximal stimulation represents the summation of the electrical activity from the individual muscle fibers of the entire muscle. The negative peak area (or alternatively the amplitude) is a reflection of the number of muscle fibers activated.",
"   </p>",
"   <p>",
"    Before delivering the RNS train, the joint is immobilized if possible. As an example, taping the fingers together or applying a hand brace can prevent finger movement, and thus movement artifacts, when stimulating the ulnar nerve. Some muscles are not amenable to immobilization, such as the facial or trapezius muscles. The stimulator is taped in position and held to prevent movement of the stimulating electrode, which leads to a submaximal stimulation and a reduction of the CMAP amplitude or area. This problem is one of the major causes of inaccurate data. (See",
"    <a class=\"local\" href=\"#H9468292\">",
"     'Artifacts and pitfalls of slow RNS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468285\">",
"    <span class=\"h2\">",
"     Slow RNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With slow RNS, a train of five to nine stimuli are delivered to the peripheral nerve and the resultant compound muscle action potentials are sequentially recorded (",
"    <a class=\"graphic graphic_waveform graphicRef70430 \" href=\"UTD.htm?30/16/30991\">",
"     waveform 4",
"    </a>",
"    ). A slow rate (1 to 5 Hz) causes depletion of the immediately available acetylcholine pool without increasing presynaptic calcium. This procedure reduces the neuromuscular junction transmission safety factor and is usually used to study patients suspected of having a postsynaptic neuromuscular junction disorder such as myasthenia gravis. The sensitivity of the procedure is further enhanced by retesting the muscle after a period of tetanic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/12\">",
"     12",
"    </a>",
"    ]. Electrical high frequency (tetanic) stimulation is extremely uncomfortable for the necessary 45 to 60 seconds but the same effect is obtained in the cooperative patient by one minute of maximal isometric exercise specifically in the muscle being tested. Although initially inducing facilitation (post-tetanic potentiation) by an increase in the presynaptic calcium and increased mobilization of the acetylcholine pool, this effect wanes after two to four minutes, and the depletion of presynaptic acetylcholine reduces the neuromuscular junction safety factor, increasing the decrement in a subsequent train of five to nine stimulations (post-tetanic exhaustion). While several different protocols have been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], we suggest RNS testing with trains of five to nine potentials before exercise and after one minute of maximal isometric activation at one-half, one, two, and four minute intervals. A typical series of RNS stimuli trains is demonstrated for both a normal patient (",
"    <a class=\"graphic graphic_waveform graphicRef80939 \" href=\"UTD.htm?22/5/22614\">",
"     waveform 5",
"    </a>",
"    ) and a patient with myasthenia gravis (",
"    <a class=\"graphic graphic_waveform graphicRef57066 \" href=\"UTD.htm?12/12/12488\">",
"     waveform 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The degree of decrement is usually expressed as the percent of the decrease in amplitude (A) or area of the lowest response (usually the fourth or fifth) relative to the first potential:",
"   </p>",
"   <p>",
"    Percent decrement = (A 1",
"    <sup>",
"     st",
"    </sup>",
"    response &ndash; A 4",
"    <sup>",
"     th",
"    </sup>",
"    or 5",
"    <sup>",
"     th",
"    </sup>",
"    response) &divide; A 1",
"    <sup>",
"     st",
"    </sup>",
"    response",
"   </p>",
"   <p>",
"    A reproducible decrement of &gt;10 percent is considered abnormal in most muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. A notable exception is the tibialis anterior, where a decrement of &gt;20 percent is recommended as the abnormal cut-off value [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/17\">",
"     17",
"    </a>",
"    ]. If there is any question of the quality of the data as described in the next section, a 20 percent decrement is more conservative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468292\">",
"    <span class=\"h3\">",
"     Artifacts and pitfalls of slow RNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of misinterpreted slow RNS data relate to a series of common artifacts. Each must be carefully assessed before a final conclusion is reached.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stimulus intensity must be supramaximal for each stimulation. Most commonly, the initial stimulus intensity is supramaximal, but if the stimulator moves during the course of testing, it can deliver a submaximal stimulus and a pseudodecrement may occur. Alternatively, the resulting waveforms may have considerable wave-to-wave variability in a seemingly random pattern (",
"      <a class=\"graphic graphic_waveform graphicRef81617 \" href=\"UTD.htm?30/48/31503\">",
"       waveform 7",
"      </a>",
"      )",
"      <strong>",
"      </strong>",
"      in contrast to the gradual decline in amplitude and area typical of a biologically significant decrement (",
"      <a class=\"graphic graphic_waveform graphicRef53515 \" href=\"UTD.htm?7/17/7441\">",
"       waveform 1",
"      </a>",
"      ). It is easy to understand how the decrement in the figure showing the resulting waveforms could be reported as significantly abnormal, 45 percent (",
"      <a class=\"graphic graphic_waveform graphicRef81617 \" href=\"UTD.htm?30/48/31503\">",
"       waveform 7",
"      </a>",
"      ), when in reality the problem is entirely technical. To avoid this artifact, we suggest taping the stimulator in place and holding it throughout the course of testing, even between trains of stimuli, to prevent movement.",
"     </li>",
"     <li>",
"      Patient movement or electrode contamination alters the interface between skin and recording electrode and between the electrode and the signal generator (the muscle). This may induce instability in the baseline of the compound muscle action potentials. Significant baseline variability impairs the accurate determination of the amplitude and often invalidates the results. The baseline for each waveform should be identical and create a level floor for the determination of amplitude (",
"      <a class=\"graphic graphic_waveform graphicRef70430 \" href=\"UTD.htm?30/16/30991\">",
"       waveform 4",
"      </a>",
"      ). Therefore when possible, the limb being studied should be immobilized to minimize movement of the recording electrode. In general, the more distal the muscle, the more easily it is immobilized.",
"     </li>",
"     <li>",
"      Acetylcholinesterase inhibitors should be discontinued prior to study as they can theoretically reduce abnormalities causing a false negative result [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/13\">",
"       13",
"      </a>",
"      ]. Four hours is probably adequate, but we suggest stopping acetylcholinesterase inhibitors 12 or more hours before the RNS study.",
"     </li>",
"     <li>",
"      As is true for all nerve conduction studies, the control of temperature is critical. Reduced temperature increases the safety factor of neuromuscular transmission and thus reduces the decrement, resulting in a false negative result [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The careful evaluation of all waveforms will help prevent inappropriate diagnoses based upon artifact. The physiologic abnormalities in myasthenia gravis tend to occur smoothly among potentials in a series without abrupt or inconsistent fluctuations in the individual waves (",
"    <a class=\"graphic graphic_waveform graphicRef53515 \" href=\"UTD.htm?7/17/7441\">",
"     waveform 1",
"    </a>",
"    ). The maximal decrement is usually present between the first and either the fourth or fifth potential in a series. In the sixth to ninth potentials (",
"    <a class=\"graphic graphic_waveform graphicRef53515 \" href=\"UTD.htm?7/17/7441\">",
"     waveform 1",
"    </a>",
"    ), there is either a mild increase in",
"    <span class=\"nowrap\">",
"     amplitude/area",
"    </span>",
"    or a leveling off, most likely due to the eventual repletion of the acetylcholine primary pool. This pattern is characteristic of myasthenia gravis and if it is not present, the data must be viewed with skepticism.",
"   </p>",
"   <p>",
"    The final test for the accuracy of a decrement is its repair following brief high-intensity isometric exercise. This can be done after a single RNS train demonstrates a decrement or after the occurrence of post-tetanic exhaustion where 15 seconds of a maximal isometric contraction followed by a train of five supramaximal stimuli will demonstrate the resolution of the decrement by increasing the presynaptic calcium concentration and thus the quanta release (",
"    <a class=\"graphic graphic_waveform graphicRef57066 \" href=\"UTD.htm?12/12/12488\">",
"     waveform 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468299\">",
"    <span class=\"h3\">",
"     Nerve selection for slow RNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of nerves for study should be based upon the accessibility of a nerve for study and the distribution of muscle weakness. The likelihood of a positive result increases if a clinically affected nerve is studied, but some nerves are more easily evaluated with RNS than others. The ulnar nerve is most commonly tested, with recordings made from the adductor digiti minimi muscle because of the ease of immobilization and stimulation. However, the probability of an abnormal study is higher in more proximal muscles. One study suggested that recording over the extensor indicis proprius muscle, innervated by the radial nerve, is technically straightforward with greater sensitivity compared with the adductor digiti minimi [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/19\">",
"     19",
"    </a>",
"    ]. Any shoulder or leg muscle amenable to study would be the next recommended location if the selected muscle was clinically weak, particularly the axillary nerve (deltoid muscle recording) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/20\">",
"     20",
"    </a>",
"    ] and the peroneal nerve (tibialis anterior). If not, the spinal accessory nerve recording over the trapezius muscle is particularly uncomplicated and would be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although technically more difficult, the highest yield with RNS is typically obtained by studying a facial muscle. Thus, RNS of a facial muscle should be performed if the study of more accessible muscles is not diagnostic. The orbicularis oculi muscle is the facial muscle most often examined. The trigeminal nerve (masseter) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/22\">",
"     22",
"    </a>",
"    ] and other segments of the facial nerve (nasalis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/23,24\">",
"     23,24",
"    </a>",
"    ],",
"    <strong>",
"    </strong>",
"    orbicularis oris) are also useful at times.",
"   </p>",
"   <p>",
"    The importance of respiratory muscle involvement in myasthenia gravis led to investigations of phrenic nerve RNS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Patients with isolated oropharyngeal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diaphragmatic involvement can be particularly difficult diagnostic problems [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/28\">",
"     28",
"    </a>",
"    ]. In one phrenic nerve RNS report, the investigators stressed the importance of having the patient hold their breath during the stimulus train [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/25\">",
"     25",
"    </a>",
"    ], but this can be difficult for some individuals with diaphragmatic weakness. We have had difficulty obtaining reproducible data utilizing these techniques, but they represent the only electrophysiologic procedures available for the evaluation of the respiratory system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468306\">",
"    <span class=\"h3\">",
"     Slow RNS protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected myasthenia gravis, slow RNS is performed at 2 or 3 Hz using trains of nine stimuli at rest. If a decrement of &ge;20 percent is present, 10 seconds of maximal isometric exercise is performed to see whether the decrement repairs. If it does not, another 10 seconds of exercise is recommended. No further RNS testing of that nerve is necessary if the decrement is &gt;20 percent, repairs with exercise, and contains the other physiologic characteristics of decrement (see",
"    <a class=\"local\" href=\"#H9468292\">",
"     'Artifacts and pitfalls of slow RNS'",
"    </a>",
"    above). If not, testing for postexercise exhaustion is performed with one minute of maximal isometric exercise, followed by trains of nine stimuli every minute for at least four minutes and at times six to eight minutes if an ambiguous result is seen. Concentric needle examination of several muscles is also suggested at a minimum, including any muscle with an abnormal RNS, since any illness with reinnervation and several different types of muscle disease can have a decrement on slow RNS, as discussed in the next section below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468313\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the great majority of cases, slow RNS is performed to evaluate the possibility of myasthenia gravis. The same principles of interpretation apply for other postsynaptic neuromuscular junction disorders, with some notable exceptions described below. The demonstration of significant decrement in two or more muscles is preferred, but not required, for the diagnosis of myasthenia gravis in the right clinical setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of RNS in the diagnosis of myasthenia gravis varies widely among the published studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/14,29,30\">",
"     14,29,30",
"    </a>",
"    ]. The sensitivity is increased by studying multiple nerves, studying nerves in the distribution of weakened muscles, studying nerves to proximal muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/24,31\">",
"     24,31",
"    </a>",
"    ], and by testing after high frequency (tetanic) stimulation or after maximal isometric exercise. Repetitive nerve stimulation to the ulnar nerve recording at the adductor digiti minimi is the easiest to perform, but in patients with pure ocular myasthenia or mild generalized disease, the sensitivity is low [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, the yield in the adductor digiti minimi is much higher in patients with severe generalized weakness, especially when intrinsic hand muscles weakness is present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/14,15,24\">",
"     14,15,24",
"    </a>",
"    ]. Among patients with generalized myasthenia gravis, facial RNS was more likely to be abnormal in the subgroup of patients who were seropositive for muscle specific tyrosine&nbsp;kinase (MuSK) antibodies than for patients who seropositive for acetylcholine receptor antibodies positive or seronegative for both MuSK and acetylcholine receptor antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myasthenia gravis is not the only etiology associated with a decremental response, especially if the decrement increases through the nine or more stimuli in a train. The differential diagnosis is not usually clinically difficult, but conventional nerve conduction studies and electromyography are usually necessary. Conditions that have been noted to induce decremental responses include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lambert-Eaton myasthenic syndrome",
"     </li>",
"     <li>",
"      Radiculopathy",
"     </li>",
"     <li>",
"      Motor neuron disease",
"     </li>",
"     <li>",
"      Peripheral neuropathy",
"     </li>",
"     <li>",
"      Polymyositis",
"     </li>",
"     <li>",
"      Some myopathies (McArdle disease, paramyotonia congenita, hyperkalemic periodic paralysis, etc.)",
"     </li>",
"     <li>",
"      Medication effects (especially d-penicillamine, aminoglycosides and nondepolarizing neuromuscular blocking agents)",
"     </li>",
"     <li>",
"      Botulism",
"     </li>",
"     <li>",
"      Organophosphate poisoning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, several methods were used in an attempt to increase the sensitivity of the procedure, including muscle warming, limb ischemia and curare. However, exercise is the only provocative procedure commonly employed in modern clinical practice. A study that explored the influence of temperature made a compelling case for the use of limb warming combined with exercise in some situations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a patient with suspected myasthenia gravis who has normal or equivocal RNS studies, single fiber electromyography is suggested if the diagnosis is uncertain. (See",
"    <a class=\"local\" href=\"#H9468341\">",
"     'Single fiber electromyography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468320\">",
"    <span class=\"h2\">",
"     Rapid RNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In disorders of the presynaptic terminal of the neuromuscular junction, where the number of released vesicles is markedly reduced, high frequency (tetanic) stimulation can markedly increase the release of acetylcholine and thus the size of the compound muscle action potential (CMAP). The clinical correlate is a corresponding increase in muscle power. Therefore, in disorders of impaired presynaptic acetylcholine release, the defining neurophysiologic pattern is a reduced CMAP amplitude in rested muscle that significantly increases with tetanic stimulation. The reduced baseline CMAP amplitude typically involves the great majority of motor nerves, even recording over strong muscles, and the absolute value is usually well below the normal range. The most frequently encountered clinical disorder of presynaptic function is Lambert-Eaton myasthenic syndrome (LEMS).",
"   </p>",
"   <p>",
"    As discussed previously, tetanic stimulation is most easily accomplished by voluntary maximal isometric muscle contractions, although RNS at 10 to 50 Hz can be employed in obtunded patients. The typical clinical protocol for suspected LEMS is 15 seconds of maximal isometric contraction of the target muscle, preceded and followed by a supramaximal CMAP (",
"    <a class=\"graphic graphic_waveform graphicRef58519 \" href=\"UTD.htm?39/18/40236\">",
"     waveform 8",
"    </a>",
"    ). The alternative procedure is high frequency electrical repetitive stimulation (20 to 50 Hz) for 1 to 10 seconds (",
"    <a class=\"graphic graphic_waveform graphicRef58848 \" href=\"UTD.htm?31/36/32322\">",
"     waveform 2",
"    </a>",
"    ), which is consistently reported to be uncomfortable. Amplitude increases of 100 percent are traditionally considered to be diagnostic of LEMS, but a compelling case has been made for the more liberal value of 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/11\">",
"     11",
"    </a>",
"    ]. Although mild increments can be seen from facilitation and pseudofacilitation, values at this level are clearly abnormal and exclude normal phenomena as well as disorders of peripheral nerve, postsynaptic neuromuscular junction, or muscle. At slow rates of RNS, decremental responses are also often present in presynaptic neuromuscular junction disorders due to the progressive reduction of quantum release from a progressive decline in the size of the available acetylcholine vesicle pool and the static calcium concentration (",
"    <a class=\"graphic graphic_waveform graphicRef74605 \" href=\"UTD.htm?5/32/5647\">",
"     waveform 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Botulism is another presynaptic neuromuscular disorder. Botulinum toxin interferes with multiple proteins involved in the release of acetylcholine and is unrelated to the presynaptic calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/34\">",
"     34",
"    </a>",
"    ]. Compound motor action potentials and RNS are often normal early in the course or have relatively mild reductions in CMAP amplitude [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/35\">",
"     35",
"    </a>",
"    ]. The sensitivity of the study is improved by testing proximal or weak muscles where the CMAP amplitude is more likely to be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. High frequency RNS can either be normal or demonstrate relatively modest increments, which are consistently less than 100 percent. This is further complicated by the common presence of pseudofacilitation (increases in amplitude without corresponding increases in area) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/35\">",
"     35",
"    </a>",
"    ]. Increments are more likely in type B botulism then in type A botulism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/34,36-40\">",
"     34,36-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468334\">",
"    <span class=\"h3\">",
"     Rapid RNS protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected LEMS, the abnormalities are usually evident in all muscles, so the adductor digiti minimi (ulnar nerve) is chosen for study. The supramaximal CMAP baseline is recorded, followed by a slow RNS train of five stimuli at 2 to 3 Hz. Next, 10 seconds of maximal isometric exercise is performed, if the patient is cooperative, and the CMAP repeated. For those patients unable to activate the muscle voluntarily, a high frequency RNS is delivered at 20 Hz for two to three seconds, after preparing the awake patient for the significant expected discomfort. If unclear, a second trial at another readily accessible muscle is recommended, with a preference for a weak muscle if possible. The procedure for suspected botulism is similar. However, as described above, the abnormalities are often more subtle with botulism than with LEMS and the examination of a weak muscle is more important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468341\">",
"    <span class=\"h1\">",
"     SINGLE FIBER ELECTROMYOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional monopolar or concentric needle electrodes record potentials that represent the summated compilation of individual muscle fibers firing in near synchrony. Single fiber electromyography (SFEMG) is performed with a specially configured electrode (",
"    <a class=\"graphic graphic_figure graphicRef71362 \" href=\"UTD.htm?10/19/10544\">",
"     figure 3",
"    </a>",
"    ) that allows the recording of a small number of individual muscle fiber potentials within the same motor unit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/41\">",
"     41",
"    </a>",
"    ]. Although this technique has several applications, the primary purpose is the electrophysiologic evaluation of the neuromuscular junction and the determination of &ldquo;jitter&rdquo;, which represents the variability of the interval between stimulation and depolarization of a single muscle fiber with stimulated SFEMG (",
"    <a class=\"graphic graphic_figure graphicRef63609 \" href=\"UTD.htm?29/10/29857\">",
"     figure 4",
"    </a>",
"    ), or between two single muscle fibers from the same motor unit with conventional SFEMG (",
"    <a class=\"graphic graphic_figure graphicRef62043 \" href=\"UTD.htm?13/16/13569\">",
"     figure 5",
"    </a>",
"    ). As described below, SFEMG is the most sensitive electrodiagnostic procedure for the determination of myasthenia gravis. (See",
"    <a class=\"local\" href=\"#H9468391\">",
"     'Utility of SFEMG'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468348\">",
"    <span class=\"h2\">",
"     Jitter",
"    </span>",
"    &nbsp;&mdash;&nbsp;When single muscle fibers from the same motor unit are activated or stimulated repetitively, there is a very small variability in the latency of each response. This is due primarily to changes in the amplitude and slope of the end plate potential on the postsynaptic membrane; the contributions from the peripheral nerve or muscle fiber components of the motor unit are negligible. This variability in the latency is termed jitter. To measure jitter in the clinical setting, the recording electrode is positioned to record two or more muscle fibers simultaneously using the techniques described below. In the absence of a disorder of the peripheral motor nerve, any variability in the interpotential latency difference, referred to as the interpotential interval (IPI), would be due to changes in the time of neuromuscular junction transmission.",
"   </p>",
"   <p>",
"    The conventional method of expressing jitter is as the mean value of consecutive differences (MCD) rather than the mean IPI. This calculation compensates for small changes in the electrode position during the study.",
"   </p>",
"   <p>",
"    MCD = ([IPI",
"    <sub>",
"     1",
"    </sub>",
"    &ndash; IPI",
"    <sub>",
"     2",
"    </sub>",
"    ] + . . . . . . . . . . + [IPI",
"    <sub>",
"     n&ndash;1",
"    </sub>",
"    &ndash; IPI",
"    <sub>",
"     n",
"    </sub>",
"    ]) &divide; (n &ndash; 1)",
"   </p>",
"   <p>",
"    When the neuromuscular junction safety factor is reduced, there will be times when the end plate potential may be inadequate to depolarize the muscle fiber and its failure to contract is called blocking. The clinical correlation of a significant degree of blocking is muscle weakness. Muscles with increased jitter but little or no blocking usually have normal strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468355\">",
"    <span class=\"h2\">",
"     Needle electrode",
"    </span>",
"    &nbsp;&mdash;&nbsp;A special concentric needle electrode is usually used for SFEMG recordings. A small recording surface is present 3 mm from the tip of the electrode on the side of the shaft (",
"    <a class=\"graphic graphic_figure graphicRef71362 \" href=\"UTD.htm?10/19/10544\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/41\">",
"     41",
"    </a>",
"    ]. This allows for a selective extracellular recording field adjacent to a small number of muscle fibers. There is an exponential drop of the recorded motor fiber amplitude with increasing distance from the recording site. This is a critical characteristic since it minimizes the contamination from adjacent muscle fibers. The active recording surface of the SFEMG electrode is 25 to 30 &mu;m with a functional recording field of approximately 300 &mu;m from the uptake area and a 200 &mu;m interelectrode distance. In comparison, a conventional concentric needle electrode has an exposed surface of 150 by 600 &mu;m with a recording radius of about 1 mm. Preliminary studies comparing the specialized single fiber EMG electrode with conventional concentric or monopolar recording electrodes in the diagnosis of myasthenia gravis have yielded similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468362\">",
"    <span class=\"h2\">",
"     Single fiber potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single fiber potential is dominated by high frequency components. This allows the low frequency filter to be set high, minimizing the volume-conducted components of more distant motor units. The biphasic spike has a rise time range of about 75 to 200 &mu;s and duration of about 1 ms. The amplitude varies from 200 &mu;V to 10 mV but it is usually in the 1 to 5 mV range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468369\">",
"    <span class=\"h2\">",
"     Recording procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to isolate a stable pair of single fiber potentials from the same motor unit requires practice and patience. Use of a triggering device and delay are necessary and are included in the automated programs of the modern digital electromyography machines.",
"   </p>",
"   <p>",
"    Recording the single fiber potentials requires that the muscle be activated in a controlled manner. Traditionally, this has been accomplished with a sustained weak voluntary contraction. There are obvious restraints to the use of this procedure in patients who have difficulty performing the necessary contraction or who are unable to cooperate. Stimulated SFEMG has gained acceptance as an accurate alternative that is usually quicker and easier for the patient, but offers some novel technical considerations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With voluntary contraction SFEMG, the patient weakly activates the relevant muscle, most often the extensor digiti communis, and the recording electrode is inserted. The needle is slowly rotated or advanced to maximize the muscle fiber potentials with the trigger set on the initial positivity of the action potential. The key is making small movements of the recording electrode and rotating the shaft until two or more suitable time-locked potentials are present. A single fiber potential will have an identical repeating waveform since it depolarizes in an all-or-none manner while a waveform with a varying configuration is likely a summated potential of two or more single fiber potentials and is excluded.",
"     </li>",
"     <li>",
"      Stimulated SFEMG is performed by stimulating distal nerve twigs, often intramuscular, with a needle electrode and recording the individual muscle fiber depolarizations with the same recording techniques and recording electrode as described above when utilizing voluntary activation (",
"      <a class=\"graphic graphic_figure graphicRef63609 \" href=\"UTD.htm?29/10/29857\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stimulated SFEMG is technically more difficult than the conventional voluntary procedure. As only one muscle fiber is studied at a time, the stimulus-to-response interval is measured rather than an interpotential interval. Multiple fibers can be recorded at a time but each involves a separate analysis. Any waveform peak meeting the appropriate criteria can be used, often allowing for the evaluation of numerous fibers in a single tracing. The normal mean MCD in stimulated SFEMG is about two-thirds the value for voluntary activation, since the jitter is occurring in only a single fiber instead of both fibers of a pair. The top normal mean MCD for the extensor digiti communis (stimulated) is 25 &mu;s.",
"   </p>",
"   <p>",
"    Stimulated SFEMG is useful in many clinical situations, and is particularly appropriate for the study of facial muscles since steady prolonged voluntary activation of these muscles is difficult. Other applications vary with the clinical setting.",
"   </p>",
"   <p>",
"    In evaluating the results of a SFEMG study, it must be remembered that jitter is altered by many factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature",
"     </li>",
"     <li>",
"      Firing rate",
"     </li>",
"     <li>",
"      Neuromuscular blocking agents",
"     </li>",
"     <li>",
"      Acetylcholinesterase inhibitors",
"     </li>",
"     <li>",
"      Ischemia",
"     </li>",
"     <li>",
"      Reinnervating illnesses",
"     </li>",
"     <li>",
"      Neuromuscular junction disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients on cholinesterase inhibitors still have abnormal tests, but the sensitivity is reduced and we recommend the medications be stopped 12 to 24 hours prior to the study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468376\">",
"    <span class=\"h2\">",
"     Criteria for abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jitter varies considerably between different muscles. Standard values have been established for many muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]; we generally use the SFEMG reference values published in 1994 by the Ad Hoc Committee of the AAEM Single Fiber Special Interest Group [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best studied muscle for SFEMG is the extensor digiti communis, which is well suited to the difficult process of minimal voluntary activation. Three pieces of data are usually considered in the interpretation of a study:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The jitter, expressed as the mean value of consecutive differences (MCD) (see",
"      <a class=\"local\" href=\"#H9468348\">",
"       'Jitter'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The percent of pairs whose jitter exceeds the upper limit of normal for the muscle under study",
"     </li>",
"     <li>",
"      The percent of blocked fibers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since blocking represents the most severe form of neuromuscular junction dysfunction, it is rarely seen without a clear increase in jitter. For the extensor digiti communis muscle, jitter (mean MCD) &gt;35 &micro;s is generally considered abnormal, as is &gt;10 percent of pairs with MCD values &gt;55 &micro;s or any fiber blocking. The same values for stimulated SFEMG of the extensor digiti communis are mean MCD &gt;25 &micro;s or &gt;10 percent of pairs with MCD values &gt;40 &micro;s [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/48\">",
"     48",
"    </a>",
"    ]. Values for the orbicularis oculi muscle are 20 &micro;s and 30 &micro;s respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Jitter values remain fairly stable until roughly 60 years of age when the normal values in some muscles need to be adjusted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468391\">",
"    <span class=\"h2\">",
"     Utility of SFEMG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single fiber electromyography is the most sensitive electrodiagnostic procedure for the determination of myasthenia gravis. It is more sensitive than RNS because neuromuscular junction abnormalities that do not induce muscle fiber blocking (decrement) can still demonstrate important increases in jitter. Consequently, there are often significant jitter abnormalities in muscles without weakness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pattern similar to RNS, the sensitivity of SFEMG is directly related to the severity of myasthenia. As an example, one report found that SFEMG of the extensor digiti communis muscle was abnormal in 60 percent of patients with ocular myasthenia gravis and 89 percent with generalized myasthenia gravis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/50\">",
"       50",
"      </a>",
"      ]. These values increased to 97 percent and 99 percent respectively if SFEMG of",
"      <strong>",
"       any",
"      </strong>",
"      of three tested muscle was used as the criteria (extensor digitorum communis, frontalis or orbicularis oculi) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/50\">",
"       50",
"      </a>",
"      ]. Other studies have reported similar values [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/51-53\">",
"       51-53",
"      </a>",
"      ]. The yield has been consistently highest in weak muscles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      facial muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/54\">",
"       54",
"      </a>",
"      ]. Even in pure ocular myasthenia gravis, SFEMG in the extensor digiti communis (an unaffected muscle) is abnormal at the time of presentation in the majority of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some have suggested the subgroup of patients with MuSK antibody-positive myasthenia gravis may be less likely to have abnormal SFEMG in the extensor digiti communis muscle than patients with acetylcholine receptor antibody positive myasthenia gravis or other patients with seronegative myasthenia gravis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/57-59\">",
"       57-59",
"      </a>",
"      ], but this was not confirmed by others [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/32,60\">",
"       32,60",
"      </a>",
"      ]. All three groups have had approximately the same frequency of abnormalities with SFEMG in the orbicularis oculi muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/32,54,57\">",
"       32,54,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Voluntary SFEMG may have a greater sensitivity for the diagnosis of myasthenia gravis than stimulated SFEMG in the extensor digiti communis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/61\">",
"       61",
"      </a>",
"      ]. However, methodologic problems limit the value of this data and further investigation is necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two reports, SFEMG of the extensor digiti communis in patients with ocular myasthenia gravis did not predict progression to generalized myasthenia gravis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/56,62\">",
"       56,62",
"      </a>",
"      ], although in the one prospective study, those patients with a normal SFEMG were less likely to subsequently develop generalized myasthenia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although there is a tendency for increased jitter with increasing stimulation rates in some patients with myasthenia gravis, this is not a consistent or predictable finding and it is not useful as a diagnostic test [",
"      <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/50,55,63\">",
"       50,55,63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Like myasthenia gravis, LEMS has a reduced safety factor for neuromuscular junction transmission. Jitter is therefore increased in this condition, often with concomitant blocking. In addition, both jitter and blocking are characteristically improved at higher stimulation rates in patients with LEMS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. However, the converse is seen often enough that the absence of an inverse rate effect does not exclude the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/63,67\">",
"     63,67",
"    </a>",
"    ]. Furthermore, an inverse rate effect on jitter and blocking with higher stimulation rates can also be seen in myasthenia gravis and thus its presence does not exclude myasthenia gravis with or without LEMS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SFEMG has also proven to be useful in suspected cases of botulism where conventional NCS and RNS studies are normal or only mildly abnormal. In one outbreak of food borne botulism, SFEMG correctly diagnosed all of seven cases while rapid RNS was not diagnostic in any [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/35,68\">",
"     35,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260351284\">",
"    <span class=\"h1\">",
"     CLINICAL CONTEXT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive nerve stimulation and SFEMG are important confirmatory tests in the diagnosis of disorders of neuromuscular transmission, particularly for myasthenia gravis, Lambert-Eaton myasthenic syndrome, and botulism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468406\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of myasthenia gravis is reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link&amp;anchor=H20#H20\">",
"     \"Ocular myasthenia gravis\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical diagnosis of myasthenia gravis should be confirmed, if possible, by immunologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrodiagnostic testing (",
"    <a class=\"graphic graphic_table graphicRef77349 \" href=\"UTD.htm?18/3/18491\">",
"     table 1",
"    </a>",
"    ). Demonstration of positive acetylcholine receptor antibody or MuSK antibody assays provides the laboratory confirmation of myasthenia gravis. Electrodiagnostic studies are an important supplement to the immunologic studies and may also provide confirmation of the diagnosis of myasthenia. For the diagnosis of generalized myasthenia gravis, RNS and SFEMG have sensitivities of approximately 75 percent and 95 percent, respectively, when multiple muscles are studied [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/50\">",
"     50",
"    </a>",
"    ]. However, SFEMG is more technically demanding and less widely available than RNS. Thus, when serologic testing is nondiagnostic, we perform RNS studies first, followed by SFEMG if the diagnosis is still uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468413\">",
"    <span class=\"h2\">",
"     Lambert-Eaton myasthenic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) is reviewed briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of LEMS is usually made on clinical grounds and confirmed by the presence of antibodies to voltage-gated calcium channel (VGCC)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by electrodiagnostic studies. A high titer",
"    <span class=\"nowrap\">",
"     P/Q-type",
"    </span>",
"    VGCC antibody result is strongly suggestive of LEMS in the appropriate clinical setting. However,",
"    <span class=\"nowrap\">",
"     P/Q-type",
"    </span>",
"    VGCC antibodies are present in a variety of clinical situations where LEMS is not present. Thus, the diagnosis of LEMS is confirmed on RNS by a reproducible postexercise increase in compound muscle action potential amplitude of at least 100 percent compared with pre-exercise baseline value. The high sensitivity and specificity of rapid RNS for the diagnosis of LEMS typically precludes the need for SFEMG, but the latter can be helpful in difficult cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9468420\">",
"    <span class=\"h2\">",
"     Botulism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of botulism is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"     \"Botulism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link&amp;anchor=H14#H14\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Infant botulism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of any of the four types of botulism &ndash; infant, foodborne, wound, and adult enteric &ndash; can at times be confirmed with appropriate assays for botulinum toxin or with C. botulinum cultures, but these tests are time-consuming and have suboptimal sensitivity. Thus, a presumptive diagnosis should be made based upon the clinical presentation and electrophysiologic findings while the potentially confirmatory stool studies are pending.",
"   </p>",
"   <p>",
"    Botulism in the adult is the neuromuscular junction disorder that is most likely to have normal conventional nerve conduction and RNS studies. As mentioned above, the size of the increment typically is smaller in botulism than in LEMS (see",
"    <a class=\"local\" href=\"#H9468334\">",
"     'Rapid RNS protocol'",
"    </a>",
"    above), and is consistently less that 100 percent, but the yield is increased by examining weak muscles. In the few systematic studies comparing RNS and SFEMG, the latter procedure is more sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/40/13962/abstract/35,68\">",
"     35,68",
"    </a>",
"    ]. SFEMG abnormalities allowed for the correct identification of botulism in patients with negative botulinum toxin assays, normal conventional nerve conduction studies and normal RNS. In infantile botulism, rapid RNS studies are usually abnormal but there is also a high false positive rate in normal infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link&amp;anchor=H14#H14\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Infant botulism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260351271\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nicotinic neuromuscular junction is a complex, specialized structure incorporating the distal axon terminal and the muscle membrane that allows for the unidirectional chemical communication between peripheral nerve and muscle. It consists of the presynaptic nerve terminal, the synaptic cleft, and the postsynaptic endplate region on the muscle fiber. Acetylcholine serves as the neurotransmitter for voluntary striated muscle (",
"      <a class=\"graphic graphic_figure graphicRef62694 \" href=\"UTD.htm?18/25/18838\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9468250\">",
"       'The neuromuscular junction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many clinical signs and laboratory abnormalities contribute to the diagnosis of disorders of the neuromuscular junction. Repetitive nerve stimulation (RNS) and single fiber electromyography (SFEMG) are key confirmatory tests in the diagnostic armamentarium. (See",
"      <a class=\"local\" href=\"#H9468264\">",
"       'Electrodiagnostic procedures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H260351284\">",
"       'Clinical context'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive nerve stimulation represents a modification of conventional motor nerve conduction studies. The interval between repeated motor nerve stimulations is designed to maximally stress the neuromuscular junction safety factor. (See",
"      <a class=\"local\" href=\"#H9468271\">",
"       'Repetitive nerve stimulation (RNS)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Slow rates of RNS (1 to 5 Hz) deplete the number of quanta of acetylcholine available for release with subsequent depolarizations. In pathologic states where the safety factor for neuromuscular junction transmission is considerably reduced, some muscle fibers will fail to depolarize in the later stimuli of a train and the compound muscle action potential amplitude will drop, which is referred to as a decremental response (",
"      <a class=\"graphic graphic_waveform graphicRef53515 \" href=\"UTD.htm?7/17/7441\">",
"       waveform 1",
"      </a>",
"      ). A reproducible decrement of &gt;10 percent is considered abnormal in most muscles. (See",
"      <a class=\"local\" href=\"#H9468271\">",
"       'Repetitive nerve stimulation (RNS)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9468285\">",
"       'Slow RNS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In disorders of the presynaptic terminal of the neuromuscular junction, where the number of released vesicles is markedly reduced, voluntary maximal isometric muscle contraction or high frequency RNS can markedly increase the release of acetylcholine and thus enlarge the size of the resultant compound muscle action potential amplitude and area, which is referred to as an incremental response (",
"      <a class=\"graphic graphic_waveform graphicRef58848 \" href=\"UTD.htm?31/36/32322\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9468271\">",
"       'Repetitive nerve stimulation (RNS)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9468320\">",
"       'Rapid RNS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Single fiber electromyography (SFEMG) is performed with a specially configured electrode (",
"      <a class=\"graphic graphic_figure graphicRef71362 \" href=\"UTD.htm?10/19/10544\">",
"       figure 3",
"      </a>",
"      ) that allows the recording of a small number of individual muscle fiber potentials. The primary purpose is the evaluation of the neuromuscular junction by the determination of &ldquo;jitter&rdquo;, which represents the variability of the interval between the depolarization in two single muscle fibers from the same motor unit (or in the case of stimulated SFEMG, between the stimulation and depolarization of a single muscle fiber) (",
"      <a class=\"graphic graphic_figure graphicRef62043 \" href=\"UTD.htm?13/16/13569\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9468341\">",
"       'Single fiber electromyography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9468348\">",
"       'Jitter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myasthenia gravis is by far the most commonly suspected clinical disorder evaluated with these techniques. For the diagnosis of generalized myasthenia gravis, RNS and SFEMG have sensitivities of approximately 75 percent and 95 percent, respectively. However, SFEMG is more technically demanding and less widely available than RNS. (See",
"      <a class=\"local\" href=\"#H260351284\">",
"       'Clinical context'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/1\">",
"      Fletcher P, Forrester T. The effect of curare on the release of acetylcholine from mammalian motor nerve terminals and an estimate of quantum content. J Physiol 1975; 251:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/2\">",
"      Kuffler SW, Yoshikami D. The number of transmitter molecules in a quantum: an estimate from iontophoretic application of acetylcholine at the neuromuscular synapse. J Physiol 1975; 251:465.",
"     </a>",
"    </li>",
"    <li>",
"     Howard JF Jr. Neuromuscular transmission. In: Neuromuscular function and disease: Basic, clinical and electrodiagnostic aspects, 1st edition, Brown WF, Bolton CF, Aminoff MJ.  (Eds), W.B. Saunders Company, Philadelphia 2002. Vol 1, p.401.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/4\">",
"      Albuquerque EX, Barnard EA, Porter CW, Warnick JE. The density of acetylcholine receptors and their sensitivity in the postsynaptic membrane of muscle endplates. Proc Natl Acad Sci U S A 1974; 71:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/5\">",
"      Baker PF. Calcium and the control of neuro-secretion. Sci Prog 1977; 64:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/6\">",
"      FATT P, KATZ B. An analysis of the end-plate potential recorded with an intracellular electrode. J Physiol 1951; 115:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/7\">",
"      Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve 2006; 33:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/8\">",
"      DEL CASTILLO J, KATZ B. Quantal components of the end-plate potential. J Physiol 1954; 124:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/9\">",
"      Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol 2001; 64:393.",
"     </a>",
"    </li>",
"    <li>",
"     Preston DC, Shapiro BE. Repetitive nerve stimulation. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, 2nd edition, Butterworth-Heinemann, 2005. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/11\">",
"      Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, 2nd edition, Butterworth-Heinemann, 2005.",
"    </li>",
"    <li>",
"     Kimura J. Electrodiagnosis in diseases of nerve and muscle: Principles and practice, 3rd edition, Oxford University Press, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/14\">",
"      Oh SJ, Eslami N, Nishihira T, et al. Electrophysiological and clinical correlation in myasthenia gravis. Ann Neurol 1982; 12:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/15\">",
"      Sanders DB. Clinical neurophysiology of disorders of the neuromuscular junction. J Clin Neurophysiol 1993; 10:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/16\">",
"      Slomi�� A, Rosenfalck A, Buchthal F. Electrical and mechanical responses of normal and myasthenic muscle. Brain Res 1968; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/17\">",
"      Oh SJ, Head T, Fesenmeier J, Claussen G. Peroneal nerve repetitive nerve stimulation test: its value in diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Muscle Nerve 1995; 18:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/18\">",
"      Borenstein S, Desmedt JE. Local cooling in myasthenia. Improvement of neuromuscular failure. Arch Neurol 1975; 32:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/19\">",
"      Petretska A, Jarrar R, Rubin DI. Radial nerve repetitive stimulation in myasthenia gravis. Muscle Nerve 2006; 33:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/20\">",
"      Yiannikas C, Sheean GL, King PJ. The relative sensitivities of the axillary and accessory nerves in the diagnosis of myasthenia gravis. Muscle Nerve 1994; 17:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/21\">",
"      Schumm F, St&ouml;hr M. Accessory nerve stimulation in the assessment of myasthenia gravis. Muscle Nerve 1984; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/22\">",
"      Rubin DI, Harper CM, Auger RG. Trigeminal nerve repetitive stimulation in myasthenia gravis. Muscle Nerve 2004; 29:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/23\">",
"      Ruys-Van Oeyen AE, van Dijk JG. Repetitive nerve stimulation of the nasalis muscle: technique and normal values. Muscle Nerve 2002; 26:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/24\">",
"      Niks EH, Badrising UA, Verschuuren JJ, Van Dijk JG. Decremental response of the nasalis and hypothenar muscles in myasthenia gravis. Muscle Nerve 2003; 28:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/25\">",
"      Mier A, Brophy C, Moxham J, Green M. Repetitive stimulation of phrenic nerves in myasthenia gravis. Thorax 1992; 47:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/26\">",
"      Zifko U, Nicolle MW, Remtulla H, Bolton CF. Repetitive phrenic nerve stimulation study in normal subjects. J Clin Neurophysiol 1997; 14:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/27\">",
"      Zifko UA, Nicolle MW, Grisold W, Bolton CF. Repetitive phrenic nerve stimulation in myasthenia gravis. Neurology 1999; 53:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/28\">",
"      Maher J, Grand'Maison F, Nicolle MW, et al. Diagnostic difficulties in myasthenia gravis. Muscle Nerve 1998; 21:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/29\">",
"      Bever CT Jr, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983; 14:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/30\">",
"      Horowitz SH, Genkins G, Kornfeld P, Papatestas AE. Electrophysiologic diagnosis of myasthenia gravis and the regional curare test. Neurology 1976; 26:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/31\">",
"      Schady W, MacDermott N. On the choice of muscle in the electrophysiological assessment of myasthenia gravis. Electromyogr Clin Neurophysiol 1992; 32:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/32\">",
"      Oh SJ, Hatanaka Y, Hemmi S, et al. Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve 2006; 33:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/33\">",
"      Rutkove SB, Shefner JM, Wang AK, et al. High-temperature repetitive nerve stimulation in myasthenia gravis. Muscle Nerve 1998; 21:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/34\">",
"      Maselli RA, Ellis W, Mandler RN, et al. Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve 1997; 20:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/35\">",
"      Padua L, Aprile I, Monaco ML, et al. Neurophysiological assessment in the diagnosis of botulism: usefulness of single-fiber EMG. Muscle Nerve 1999; 22:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/36\">",
"      Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998; 21:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/37\">",
"      Maselli RA, Bakshi N. AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. Muscle Nerve 2000; 23:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/38\">",
"      Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism: a review. Muscle Nerve 1982; 5:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/39\">",
"      Cornblath DR, Sladky JT, Sumner AJ. Clinical electrophysiology of infantile botulism. Muscle Nerve 1983; 6:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/40\">",
"      Cherington M. Botulism. Ten-year experience. Arch Neurol 1974; 30:432.",
"     </a>",
"    </li>",
"    <li>",
"     St&aring;lberg E, Trontelj JV. Single fibre electromyography, The Miravalle Press, Woking, Surrey 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/42\">",
"      Benatar M, Hammad M, Doss-Riney H. Concentric-needle single-fiber electromyography for the diagnosis of myasthenia gravis. Muscle Nerve 2006; 34:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/43\">",
"      Farrugia ME, Weir AI, Cleary M, et al. Concentric and single fiber needle electrodes yield comparable jitter results in myasthenia gravis. Muscle Nerve 2009; 39:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/44\">",
"      Massey JM, Sanders DB, Howard JF Jr. The effect of cholinesterase inhibitors of SFEMG in myasthenia gravis. Muscle Nerve 1989; 12:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/45\">",
"      Single fiber EMG reference values: a collaborative effort. Ad Hoc Committee of the AAEM Special Interest Group on Single Fiber EMG. Muscle Nerve 1992; 15:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/46\">",
"      Bromberg MB, Scott DM. Single fiber EMG reference values: reformatted in tabular form. AD HOC Committee of the AAEM Single Fiber Special Interest Group. Muscle Nerve 1994; 17:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/47\">",
"      Balci K, Turgut N, Nurlu G. Normal values for single fiber EMG parameters of frontalis muscle in healthy subjects older than 70 years. Clin Neurophysiol 2005; 116:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/48\">",
"      Trontelj JV, Mihelin M, Fernandez JM, St&aring;lberg E. Axonal stimulation for end-plate jitter studies. J Neurol Neurosurg Psychiatry 1986; 49:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/49\">",
"      Trontelj JV, Khuraibet A, Mihelin M. The jitter in stimulated orbicularis oculi muscle: technique and normal values. J Neurol Neurosurg Psychiatry 1988; 51:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/50\">",
"      Sanders DB, St&aring;lberg EV. AAEM minimonograph #25: single-fiber electromyography. Muscle Nerve 1996; 19:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/51\">",
"      Sanders DB, Howard JF Jr, Johns TR. Single-fiber electromyography in myasthenia gravis. Neurology 1979; 29:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/52\">",
"      Oh SJ, Kim DE, Kuruoglu R, et al. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992; 15:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/53\">",
"      Oey PL, Wieneke GH, Hoogenraad TU, van Huffelen AC. Ocular myasthenia gravis: the diagnostic yield of repetitive nerve stimulation and stimulated single fiber EMG of orbicularis oculi muscle and infrared reflection oculography. Muscle Nerve 1993; 16:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/54\">",
"      Valls-Canals J, Povedano M, Montero J, Pradas J. Stimulated single-fiber EMG of the frontalis and orbicularis oculi muscles in ocular myasthenia gravis. Muscle Nerve 2003; 28:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/55\">",
"      Sanders DB, Howard JF Jr. AAEE minimonograph #25: Single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986; 9:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/56\">",
"      Weinberg DH, Rizzo JF 3rd, Hayes MT, et al. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 1999; 22:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/57\">",
"      Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005; 116:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/58\">",
"      Farrugia ME, Kennett RP, Newsom-Davis J, et al. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve 2006; 33:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/59\">",
"      Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann N Y Acad Sci 2008; 1132:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/60\">",
"      Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/61\">",
"      Murga L, S&aacute;nchez F, Men&eacute;ndez C, Castilla JM. Diagnostic yield of stimulation and voluntary single-fiber electromyography in myasthenia gravis. Muscle Nerve 1998; 21:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/62\">",
"      Rostedt A, Saders LL, Edards LJ, et al. Predictive value of single-fiber electromyography in the extensor digitorum communis muscle of patients with ocular myasthenia gravis: a retrospective study. J Clin Neuromuscul Dis 2000; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/63\">",
"      Sanders DB. The effect of firing rate on neuromuscular jitter in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1992; 15:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/64\">",
"      Schwartz MS, St&aring;lberg E. Myasthenic syndrome studied with single fiber electromyography. Arch Neurol 1975; 32:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/65\">",
"      Trontelj JV, St&aring;lberg E. Single motor end-plates in myasthenia gravis and LEMS at different firing rates. Muscle Nerve 1991; 14:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/66\">",
"      Chaudhry V, Watson DF, Bird SJ, Cornblath DR. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1991; 14:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/67\">",
"      Trontelj JV, St&aring;lberg E, Mihelin M, Khuraibet A. Jitter of the stimulated motor axon. Muscle Nerve 1992; 15:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/40/13962/abstract/68\">",
"      Girlanda P, Dattola R, Messina C. Single fibre EMG in 6 cases of botulism. Acta Neurol Scand 1983; 67:118.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14147 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13962=[""].join("\n");
var outline_f13_40_13962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H260351271\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35316733\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9468250\">",
"      THE NEUROMUSCULAR JUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35316795\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468257\">",
"      Physiology of acetylcholine release",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9468264\">",
"      ELECTRODIAGNOSTIC PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9468271\">",
"      REPETITIVE NERVE STIMULATION (RNS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468278\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468285\">",
"      Slow RNS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9468292\">",
"      - Artifacts and pitfalls of slow RNS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9468299\">",
"      - Nerve selection for slow RNS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9468306\">",
"      - Slow RNS protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9468313\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468320\">",
"      Rapid RNS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9468334\">",
"      - Rapid RNS protocol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9468341\">",
"      SINGLE FIBER ELECTROMYOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468348\">",
"      Jitter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468355\">",
"      Needle electrode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468362\">",
"      Single fiber potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468369\">",
"      Recording procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468376\">",
"      Criteria for abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468391\">",
"      Utility of SFEMG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260351284\">",
"      CLINICAL CONTEXT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468406\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468413\">",
"      Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9468420\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260351271\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14147\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14147|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/25/18838\" title=\"figure 1\">",
"      Normal neuromuscular junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/27/33200\" title=\"figure 2\">",
"      Model of the AChR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/19/10544\" title=\"figure 3\">",
"      Single fiber and concentric needle electrodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/10/29857\" title=\"figure 4\">",
"      Stimulated SFEMG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/16/13569\" title=\"figure 5\">",
"      SFEMG recording",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14147|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/3/18491\" title=\"table 1\">",
"      Sensitivity of tests for MG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14147|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/17/7441\" title=\"waveform 1\">",
"      Decremental response with RNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/36/32322\" title=\"waveform 2\">",
"      Incremental response with RNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/32/5647\" title=\"waveform 3\">",
"      Slow RNS in LEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?30/16/30991\" title=\"waveform 4\">",
"      RNS before excercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?22/5/22614\" title=\"waveform 5\">",
"      RNS pre and post exercise normal subject",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/12/12488\" title=\"waveform 6\">",
"      RNS in myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?30/48/31503\" title=\"waveform 7\">",
"      RNS variability due to artifact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/18/40236\" title=\"waveform 8\">",
"      Exercise testing in LEMS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=related_link\">",
"      Nerve conduction studies: Late responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31287?source=related_link\">",
"      Pathogenesis of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_40_13963="Risk after reducing smoking";
var content_f13_40_13963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lung cancer risk by smoking status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Smoking category",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Heavy smokers",
"       </td>",
"       <td class=\"subtitle2\">",
"        Reducers",
"       </td>",
"       <td class=\"subtitle2\">",
"        Light smokers",
"       </td>",
"       <td class=\"subtitle2\">",
"        Ex-smokers",
"       </td>",
"       <td class=\"subtitle2\">",
"        Never smokers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adjusted hazard ratio* (95% CI)",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        0.73 (0.54-0.98)",
"       </td>",
"       <td>",
"        0.44 (0.35-0.56)",
"       </td>",
"       <td>",
"        0.17 (0.13-0.23)",
"       </td>",
"       <td>",
"        0.09 (0.06-0.13)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Heavy smokers: &ge;15 cigarettes or equivalent tobacco per day.",
"    <br>",
"     Reducers: Heavy smokers who decreased by &ge;50 percent.",
"     <br>",
"      Light smokers: 1 to 14 cigarettes or equivalent tobacco per day.",
"      <div class=\"footnotes\">",
"       * Multivariate analysis adjusted for sex, cohort of origin, inhalation habits (yes/no), tobacco type (cigarettes, cigars/pipe/cheroots, mixed), and years as smokers (continuous).",
"      </div>",
"      <div class=\"reference\">",
"       Data from: Godtfredsen N, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005; 294:1505.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13963=[""].join("\n");
var outline_f13_40_13963=null;
var title_f13_40_13964="Spinal cord syndromes";
var content_f13_40_13964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spinal cord syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmental (transection) syndrome",
"       </td>",
"       <td>",
"        Loss of all sensory modalities, weakness below affected level; bladder dysfunction",
"       </td>",
"       <td>",
"        Trauma, hemorrhage, epidural abscess, transverse myelitis, epidural metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal cord syndrome",
"       </td>",
"       <td>",
"        Loss of proprioception, vibratory sensation; variable weakness and bladder dysfunction",
"       </td>",
"       <td>",
"        Tabes dorsalis, Friedreich ataxia, subacute combined degeneration, AIDS myelopathy, epidural metastases, cervical spondylotic myelopathy, multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventral cord syndrome (anterior spinal artery syndrome)",
"       </td>",
"       <td>",
"        Loss of pain and temperature sensation, weakness, bladder dysfunction",
"       </td>",
"       <td>",
"        Spinal cord infarction, disc herniation, radiation myelopathy, HTLV-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brown Sequard syndrome",
"       </td>",
"       <td>",
"        Ipsilateral weakness and loss of proprioception; contralateral loss of pain and temperature sensation",
"       </td>",
"       <td>",
"        Knife or bullet injury, multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central cord syndrome",
"       </td>",
"       <td>",
"        Segmental loss of pain and temperature, weakness often greater in the arms than legs",
"       </td>",
"       <td>",
"        Syringomyelia, intramedullary tumor, acute injury in cervical spondylotic myelopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pure motor syndrome",
"       </td>",
"       <td>",
"        Weakness without sensory disturbance",
"       </td>",
"       <td>",
"        Poliomyelitis, amyotrophic lateral sclerosis, HTLV-1, hereditary spastic paraplegia, lathyrism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conus medullaris syndrome",
"       </td>",
"       <td>",
"        Bladder and rectal dysfunction, saddle anesthesia",
"       </td>",
"       <td>",
"        Disc herniation, trauma, tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cauda equina syndrome",
"       </td>",
"       <td>",
"        Asymmetric multiradicular pain, leg weakness, and sensory loss; bladder dysfunction",
"       </td>",
"       <td>",
"        Disc herniation, arachnoiditis, tumor, lumbar spine stenosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13964=[""].join("\n");
var outline_f13_40_13964=null;
var title_f13_40_13965="Nondepolarizing NMBAs in ICU";
var content_f13_40_13965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nondepolarizing neuromuscular blocking agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Duration of action",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Onset (min)",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Elimination (% renal)",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Elimination (other)",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"       Half-life(min)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Normal",
"      </td>",
"      <td class=\"subtitle2\">",
"       Renal Failure",
"      </td>",
"      <td class=\"subtitle2\">",
"       Hepatic Failure",
"      </td>",
"      <td class=\"subtitle2\">",
"       Elderly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Atracurium",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       2.0-2.5",
"      </td>",
"      <td>",
"       &lt;10",
"      </td>",
"      <td>",
"       Ho, EH",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cisatracurium",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       3.0-6.0",
"      </td>",
"      <td>",
"       &lt;20",
"      </td>",
"      <td>",
"       Ho",
"      </td>",
"      <td>",
"       22-29",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Doxacurium",
"      </td>",
"      <td>",
"       L",
"      </td>",
"      <td>",
"       3.0-5.0",
"      </td>",
"      <td>",
"       60-90",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       85-100",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metocurine",
"      </td>",
"      <td>",
"       L",
"      </td>",
"      <td>",
"       2.0-3.0",
"      </td>",
"      <td>",
"       80-100",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       250-300",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mivacurium",
"      </td>",
"      <td>",
"       S",
"      </td>",
"      <td>",
"       1.5-2.5",
"      </td>",
"      <td>",
"       &lt;10",
"      </td>",
"      <td>",
"       EH",
"      </td>",
"      <td>",
"       2-5",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &uarr;*",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pancuronium",
"      </td>",
"      <td>",
"       L",
"      </td>",
"      <td>",
"       1.0-3.0",
"      </td>",
"      <td>",
"       60-80",
"      </td>",
"      <td>",
"       H",
"      </td>",
"      <td>",
"       100-130",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pipecuronium",
"      </td>",
"      <td>",
"       L",
"      </td>",
"      <td>",
"       1.5-3.0",
"      </td>",
"      <td>",
"       60-90",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       120-150",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rocuronium",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       1.0-1.5",
"      </td>",
"      <td>",
"       &lt;10",
"      </td>",
"      <td>",
"       H",
"      </td>",
"      <td>",
"       60-100",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tubocurarine",
"      </td>",
"      <td>",
"       L",
"      </td>",
"      <td>",
"       1.0-2.0",
"      </td>",
"      <td>",
"       40-60",
"      </td>",
"      <td>",
"       H",
"      </td>",
"      <td>",
"       160-180",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vecuronium",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       1.5-3.0",
"      </td>",
"      <td>",
"       10-20",
"      </td>",
"      <td>",
"       H",
"      </td>",
"      <td>",
"       80-90",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     S: short; I: intermediate; L:long; Ho: Hofmann elimination; EH: Ester hydrolysis; H: hepatic elimination; &uarr;: half-life increased; &darr;: half-lifedecreased; &harr;:no difference in half-life compared to normal patients.",
"     <br>",
"      * The half-life of mivacurium is increased in patients with chronicrenal and hepatic failure.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13965=[""].join("\n");
var outline_f13_40_13965=null;
var title_f13_40_13966="Reactive arthritis - nails";
var content_f13_40_13966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reactive arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 176px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subungual hyperkeratosis and onycholysis in reactive arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13966=[""].join("\n");
var outline_f13_40_13966=null;
var title_f13_40_13967="Chromoendoscopy";
var content_f13_40_13967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76175/chromoendoscopy_conv.mp4?title=Chromoendoscopy\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chromoendoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spray catheter used for chromendoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcia I Canto, MD, MHS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_40_13967=[""].join("\n");
var outline_f13_40_13967=null;
